US20110053865A1 - Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same - Google Patents

Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same Download PDF

Info

Publication number
US20110053865A1
US20110053865A1 US12/745,052 US74505208A US2011053865A1 US 20110053865 A1 US20110053865 A1 US 20110053865A1 US 74505208 A US74505208 A US 74505208A US 2011053865 A1 US2011053865 A1 US 2011053865A1
Authority
US
United States
Prior art keywords
amino acid
binding
sequences
subunit
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/745,052
Other languages
English (en)
Inventor
Michael John Scott Saunders
Christophe Blanchetot
Heidi Rommelaere
Jo Vercammen
Johannes Joseph Wilhelmus de Haard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablynx NV
Original Assignee
Ablynx NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx NV filed Critical Ablynx NV
Priority to US12/745,052 priority Critical patent/US20110053865A1/en
Assigned to ABLYNX N.V. reassignment ABLYNX N.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ROMMELAERE, HEIDI, VERCAMMEN, JO, BLANCHETOT, CHRISTOPHE, DE HAARD, JOHANNES JOSEPH WILHELMUS, SAUNDERS, MICHAEL JOHN SCOTT
Publication of US20110053865A1 publication Critical patent/US20110053865A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to amino acid sequences that are directed against (as defined herein) heterodimeric cytokines and/or their receptors, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively).
  • the invention also relates to nucleic acids encoding such amino acid sequences and polypeptides (also referred to herein as “nucleic acids of the invention” or “nucleotide sequences of the invention”); to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes mentioned herein.
  • Heterodimeric cytokines, their receptors and the pathways, signalling, biological mechanisms and physiological effect in which they and their receptors are involved are known from the prior art.
  • heterodimeric cytokines and their receptors are IL-12, IL-23 and IL-27, and their receptors IL-12R, IL-23R, and IL-27, respectively.
  • these cytokines are heterodimeric, consisting of two different subunits, i.e. IL12p40 and IL12p35 in case of IL-12, IL12p40 and IL23p19 (also called IL-30B) in case of IL-23, and EBI3 and IL27p28 in case of IL-27.
  • the receptors for these heterodimeric cytokines consist of multiple subunits, i.e.
  • IL12Rbeta1 and IL12Rbeta2 in case of IL-12R
  • IL12Rbeta1 and IL23R in case of IL-23R
  • WSX1 and gp130 in case of IL-27R.
  • IL12 remains the prototypical heterodimeric cytokine (composed of IL12p40 and IL12p35), it was not until relatively recently that other related heterodimers exist.
  • IL-23 and its subunit p19 were identified on the basis of a homology search for IL-6-family members. Their studies revealed that p19 dimerizes with IL12p40 and that this cytokine, known as IL23, uses IL12R ⁇ 1, but not IL12R ⁇ 2, as a component of its high-affinity receptor. Functional cloning identified the other subunit of the receptor for IL23, a subunit known as IL23R (text adapted from CA Hunter 2003). It was also found that IL-23 plays an important role in proliferation of The17 cells.
  • IL27 is another heterodimeric cytokine related to IL12 composed of EBI3 and IL27p28.
  • Epstein-Barr virus (EBV)-induced molecule 3 (EBI3) had been identified as an IL-12p40 homologue.
  • EBI3 Epstein-Barr virus-induced molecule 3
  • IL-27p28 the p28 subunit of IL-27 (IL-27p28) was discovered as a protein with homology to IL-12p35 and IL-6.
  • IL-35 a further heterodimeric cytokine belonging to the IL-12 family, called IL-35.
  • This heterodimeric cytokine is described as contributing to regulator T-cell function and is composed of the IL12p35 and EBI-3 subunits.
  • cytokine receptors Thirty-four known type I cytokine receptors have been described, and although the ligands are more difficult to identify, there are at least 27 that can be clustered into 5 distinct families (see Boulay et al 2003).
  • One of these groupings is composed of the ligands for a series of cytokine receptors that use gp130 (glycoprotein 130) or one of several gp130-related proteins. These include the receptors for IL6 and the receptors for the heterodimeric cytokines IL-12, IL-23 and IL-27 (Hunter, supra).
  • the IL12 receptor is a heterodimer of IL12Rbeta1 and IL12Rbeta2.
  • the IL23 receptor is a heterodimer of IL12Rbeta1 and IL23R.
  • IL12Rbeta1 is a used by both IL12 and IL-23 for signalling. Targeting this receptor will lead to a blockade of both IL-12 and IL-23 signaling.
  • the IL27 receptor is a hetero dimer composed of WSX1 (Identified on the basis of a homology search for gp130-like proteins) and gp130 which is a common element of the receptor for IL-6 (which comprises IL-6R ⁇ and gp130) and the receptor for IL27 (which comprises WSX1 and gp130), which is consistent with the close familial relationship of these cytokines.
  • heterodimeric cytokines and their receptors have some subunits in common., with for example IL12p40 being present in both IL-12 and IL-23, and for example IL-12Rbeta1 being present in both the (cognate) receptor for IL-12 as well as the (cognate) receptor for IL-23. Also, some of the other subunits present in the heterodimeric cytokines or the receptors, although not identical, are structurally and/or functionally similar, and on the basis of these similarities can be grouped as follows:
  • cytokines and their receptors are critical players in (the pathways) regulating all aspects of immune responses. This is also the case for the heterodimeric cytokines that belong to the interleukin-12 (IL12)-related family and for their receptors.
  • IL 12 the prototypical heterodimeric member of the IL-12 family—induces interferon- ⁇ (IFN- ⁇ ) production by NK, T cells, dendritic cells (DC), and macrophages.
  • IFN- ⁇ interferon- ⁇
  • IL-12 also promotes the differentiation of naive CD4 + T cells into T helper 1 (T H 1) cells that produce IFN- ⁇ and aid in cell-mediated immunity. Therefore the central role of IL12 in the generation of T H 1 cells (cell-mediated immune response) has long been appreciated.
  • mouse models established that IL12 is required for the development of protective innate and adaptive immune response to intracellular pathogens.
  • IL23 and IL27 are of the other heterodimeric cytokines from the IL-12 family—also regulate T H 1-cell response, albeit with distinct functions.
  • the ability of IL-23 to stimulate CD4 + T cells to produce IL-17 has a dominant role in the development and maintenance of autoimmune inflammation.
  • a principal function of IL-27 in viva is to limit the intensity and duration of innate and adaptive immune responses.
  • IL12p40 can be found as a monomers or homodimers which have antagonistic activities.
  • IL23 was shown to be responsible for the chronic inflammation observed in inflammatory bowel disease. This was confirmed by the fact that the IL23R gene was identified as being involved in inflammatory bowel disease. It has also been found that p19 knock out mice are resistant to collagen-induced arthritis and colitis, whereas comparable p35 knock out mice were found to be more susceptible to collagen-induced arthritis. Also, when p19 knock out mice were crossed with IL-10 knock out mice, the resulting offspring were resistant to colitis, whereas similar crosses of p19 knock out mice with IL-10 knock out mice resulted in offspring that was susceptible to colitis.
  • IL-12/p19 may be a more attractive target for the treatment of colitis, Crohn's diseases, IBD, multiple sclerosis, rheumatoid arthritis and some of the other diseases and disorders mentioned herein that IL-12/p35 or p40 (as a compound directed against p40 will probably modulate both IL-12 and IL-23).
  • one specific object of the invention is to provide amino acid sequences and polypeptides that are directed against p19, and in particular amino acid sequences and polypeptides that are specific for (as defined herein) p19 compared to both p35 and p40 and/or that are specific for (as defined herein) IL-23 compared to IL-12. Examples of such amino acid sequences and polypeptides will become clear from the description herein.
  • the amino acid sequences, polypeptides and compositions of the present invention can generally be used to modulate (as defined herein) the signalling that is mediated by heterodimeric cytokines and/or their receptors, to modulate (as defined herein) the biological pathways in which heterodimeric cytokines and/or their receptors are involved, and/or to modulate (as defined herein) the biological mechanisms, responses and effects associated with heterodimeric cytokines, their receptors, such signalling and/or these pathways (all the foregoing is also collectively referred to herein as “heterodimeric cytokine-mediated signalling”).
  • amino acid sequences, polypeptides and compositions of the present invention can generally be used to modulate the immune system and/or one or more specific immune responses in a subject to which one or more of the amino acid sequences, polypeptides and compositions of the present invention are administered (i.e. in therapeutically relevant amounts).
  • heterodimeric cytokines as used herein in its broadest sense generally includes any heterodimeric cytokine, i.e. a cytokine that comprises at least two, and more preferably only two, subunits.
  • heterodimeric cytokine encompasses heterodimeric cytokines that are associated with cell-mediated (T H 1) immunity, although the invention is its broadest sense is not limited thereto and also encompasses heterodimeric cytokines associated with humoral (T H 2) immunity.
  • the amino acid sequences and polypeptides of invention are directed against a heterodimeric cytokine that is chosen from heterodimeric cytokines that comprise a p40 subunit or p40-like subunit, such as a p40 subunit (present in for example IL-12 and IL-23) or Epstein-Barr virus (EBV)-induced molecule 3 (EB13, present in for example IL-27 and IL-35).
  • a p40 subunit present in for example IL-12 and IL-23
  • EBV Epstein-Barr virus
  • the amino acid sequences and polypeptides of invention are directed against a heterodimeric cytokine that is chosen from heterodimeric cytokines that comprise a p19 subunit or a p19-like subunit, such as a p19 subunit (present in for example IL-23), a p35 subunit (present in for example IL-12 and IL-35), or a p28 subunit (present in for example 1L-27) or a homolog thereof.
  • a heterodimeric cytokine that is chosen from heterodimeric cytokines that comprise a p19 subunit or a p19-like subunit, such as a p19 subunit (present in for example IL-23), a p35 subunit (present in for example IL-12 and IL-35), or a p28 subunit (present in for example 1L-27) or a homolog thereof.
  • amino acid sequences and polypeptides of invention may be directed against a heterodimeric cytokine that will comprise at least one p19 subunit or p19-like subunit and at least one p40 subunit or p40-like subunit.
  • amino acid sequences and polypeptides of invention are directed against a heterodimeric cytokine that is chosen from IL-12, IL-23, IL-27 and/or IL-35.
  • amino acid sequences and polypeptides of the invention are directed against IL-23 (i.e. against p40, p19 or both).
  • Such amino acid sequences and polypeptides of the invention (as well as compositions comprising the same), can be used for preventing and treating disorders associated with IL-23.
  • amino acid sequences and polypeptides of the invention are directed against IL-12 (i.e. against p40, p35 or both).
  • Such amino acid sequences and polypeptides of the invention may be as further described herein, and can be used for preventing and treating disorders associated with IL-12.
  • amino acid sequences, polypeptides and compositions can be used to modulate (as defined herein, and for example as an agonist or an antagonist) heterodimeric cytokines and their receptors; and/or the signaling, pathways, biological mechanisms and effects in which these are involved.
  • amino acid sequences and polypeptides that are antagonists of heterodimeric cytokines and their receptors can also be used to reduce or inhibit the agonistic effects of heterodimeric cytokines.
  • amino acid sequences such as the p19+ sequences, p19 ⁇ sequences, p40+ sequences, p40 ⁇ sequences, p35 sequences, IL-27 sequences, IL-12Rb1 sequences, IL-12Rb2 sequences and IL-23 sequences described herein
  • polypeptides such as the—for example multivalent, multispecific and/or biparatopic—constructs described herein that comprise at least one p19+ sequence, p19 ⁇ sequence, p40+ sequence, p40 ⁇ sequence, p35 sequence, IL-27 sequence, IL-12Rb1 sequence, IL-12Rb2 sequence and/or IL-23 sequence
  • compositions of the present invention can be used for the prevention and treatment (as defined herein) of diseases and disorders associated with heterodimeric cytokines and their receptors (and/or with the signaling, pathways, biological mechanisms and effects in which these are involved).
  • “diseases and disorders associated with heterodimeric cytokines and their receptors” can be defined as diseases and disorders that can be prevented and/or treated, respectively, by suitably administering to a subject in need thereof (i.e. having the disease or disorder or at least one symptom thereof and/or at risk of attracting or developing the disease or disorder) of either a polypeptide or composition of the invention (and in particular, of a pharmaceutically active amount thereof) and/or of a known active principle active against heterodimeric cytokines and/or their receptors or a biological pathway or mechanism in which heterodimeric cytokines and/or their receptors is involved (and in particular, of a pharmaceutically active amount thereof).
  • diseases and disorders associated with heterodimeric cytokines and their receptors will be clear to the skilled person based on the disclosure herein, and for example include the following diseases and disorders: inflammation and inflammatory disorders such as bowel diseases (colitis, Crohn'disease, IBD), infectious diseases, psioriasis, cancer, autoimmune diseases (such as MS), carcoidis, transplant rejection, cystic fibrosis, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, viral infection, common variable immunodeficiency, and the various diseases and disorders mentioned in the prior art cited herein. Based thereon, it will also be clear to the skilled person with heterodimeric cytokines (and/or receptors thereof) are involved in which specific diseases and disorders.
  • polypeptides and compositions of the present invention can be used for the prevention and treatment of diseases and disorders associated with heterodimeric cytokines and their receptors which are characterized by excessive and/or unwanted signalling mediated by heterodimeric cytokines and/or their receptors or by the pathway(s) in which heterodimeric cytokines and/or their receptors is involved.
  • diseases and disorders associated with heterodimeric cytokines and their receptors will again be clear to the skilled person based on the disclosure herein.
  • usually antagonists of heterodimeric cytokines and their receptors and/or with the signaling, pathways, biological mechanisms and effects in which these are involved will be used.
  • Agonists of heterodimeric cytokines and their receptors can be used to stimulate or enhance one or more immune response in a human or animal, for example for the prevention and/or treatment of diseases that are characterized by a weakened immune system or that may occur as a result of having a weakened immune system.
  • IL12p40 has also been shown to have an essential role in autoimmune inflammation as shown in disease model system as EAE (Experimental Allergic Encephalomyelitis) or CIA (Collagen-induced arthritis).
  • amino acid sequences and polypeptides of the invention can for example be used to prevent and/or to treat all diseases and disorders that are currently being prevented or treated with active principles that can modulate heterodimeric cytokines and/or their receptors-mediated signalling, such as those mentioned in the prior art cited above (for example, the monoclonal antibody CNTO 1275 that is described in WO 02/09748 and WO 06/069036; ABT-874, a monoclonal against p40 that is being developed by Abbott; as well as the small molecule Apilimod®, Syntha Pharmaceuticals).
  • polypeptides of the invention can be used to prevent and/or to treat all diseases and disorders for which treatment with such active principles is currently being developed, has been proposed, or will be proposed or developed in future.
  • the polypeptides of the present invention may be used for the prevention and treatment of other diseases and disorders than those for which these known active principles are being used or will be proposed or developed; and/or that the polypeptides of the present invention may provide new methods and regimens for treating the diseases and disorders described herein.
  • amino acid sequences of the invention may be in a so-called “monovalent” format (i.e. comprising or essentially consisting of a single antigen binding domain or binding unit) or in a “multivalent” format (i.e. comprising or essentially consisting of two or more binding domains or binding units—which may be the same or different—that are linked to each other, optionally via one or more suitable linkers).
  • monovalent i.e. comprising or essentially consisting of a single antigen binding domain or binding unit
  • multivalent i.e. comprising or essentially consisting of two or more binding domains or binding units—which may be the same or different—that are linked to each other, optionally via one or more suitable linkers.
  • such multivalent amino acid sequences and polypeptides of the invention may for example, without limitation, be multispecific (such as bispecific or trispecific) or multiparatopic (such as biparatopic) constructs (or be both multiparatopic and multispecific, such as a biparatopic construct against the p19 subunit that contains a further binding domain for binding to a serum protein, as exemplified herein); and may for example be constructs that comprise at least two binding domains or binding units that are each directed towards a different epitope on the same subunit of a heterodimeric cytokine, constructs that comprise at least two binding domains or binding units that each have a different biological function (for example one binding domain that can block or inhibit receptor-ligand interaction, and one binding domain that does not block or inhibit receptor-ligand interaction), or constructs that comprise at least two binding domains or binding units that are each directed towards a different subunit of a heterodimeric cytokine.
  • multispecific such as bispecific or trispecific
  • multiparatopic constructs or be both
  • constructs can generally be provided (and in particular, purposefully designed for a specific biological action) by suitably linking (optionally via suitable linkers) or combining two or more “monovalent” amino acid sequences of the invention (or by suitably linking or combining nucleotide sequences encoding such monovalent amino acid sequences to provide a nucleic acid that encodes the desired multivalent construct, and then suitably expressing said multivalent construct).
  • the invention not only makes available the monovalent and multivalent amino acid sequences and polypeptides described herein, but also provides—by making available the monovalent amino acid sequences and polypeptides described herein—the skilled person with a range of different binding domains and binding units that can be used as “building blocks” to provide a range of different multivalent, multispecific and/or multiparatopic (and in particular, biparatopic) constructs (which may have different binding affinities, avidities, specificities, potencies and/or efficacies), which through the use of suitable “building blocks” as described herein can be purposefully designed for use in different aspects of the invention (as further described herein).
  • the invention in a particular aspect provides a number of different amino acid sequences that each can be used as a single binding domain or binding unit, either as such (i.e. as a monovalent amino acid sequence as further described herein) or as part of (and/or as a “building block”) for, a multivalent, multispecific and/or multispecific construct, as further described herein.
  • amino acid sequences may for example be classified as follows:
  • Each of the p19+sequences, p19 ⁇ sequences, p40+sequences, p40 ⁇ sequence, p35 sequences, IL-27 sequences, IL-12Rb1 sequences, IL-12Rb2 sequences and IL-23R sequences may be as further described herein and each class of amino acid sequences of the invention forms a further aspect of the invention.
  • the invention also relates to the use of such p19+ sequences, p19 ⁇ sequences, p40+ sequences, p40 ⁇ sequences, p35 sequences, IL-27 sequences, IL-12Rb1 sequences, IL-12Rb2 sequences and IL-23R sequences (and/or of nucleotide sequences and/or nucleic acids encoding the same) as “building blocks” (i.e. as single antigen binding domains or units) in or for multivalent, multispecific and/or multiparatopic constructs, as further described herein.
  • amino acid sequences of the invention that are not capable of modulating, neutralizing, blocking and/or inhibiting the binding of a heterodimeric cytokine to its cognate receptor (such as the p19 ⁇ sequences or p40 ⁇ sequences) may still find use as binding domains and/or binding units in multivalent, multispecific and/or multiparatopic polypeptides of the invention, for example in order to provide/improve specificity and/or to provide/improve affinity and/or avidity. Examples thereof will become clear to the skilled person from the disclosure herein.
  • said construct, protein and/or polypeptide comprises said p35 sequence (one or more) and one or more further binding domains or binding units, and wherein at least one of said further binding domains or binding units is directed against a second subunit of the said heterodimeric cytokine different from p35 (such as p40 in IL-12);
  • any of the above aspects/uses comprises the use of a nucleotide sequence and/or nucleic acid that encodes a monovalent amino acid sequence in in providing, constructing, and/or as part of a nucleotide sequence and/or nucleic acid that encodes a multivalent, multispecific and/or multiparatopic constructs (such as a biparatopic construct)
  • said aspect/use optionally further comprises the use of the a nucleotide sequence and/or nucleic acid thus obtained in preparing (e.g. by suitable expression, as further described herein) the multivalent, multispecific and/or multiparatopic construct encoded by said nucleotide sequence and/or nucleic acid.
  • a (“multispecific”, as defined herein) polypeptide construct that is directed against (as defined herein) a heterodimeric protein, polypeptide, ligand or receptor (or other “target”) that comprises:
  • a (“multispecific”, as defined herein) polypeptide construct that is directed against (as defined herein) a first heterodimeric protein, polypeptide, ligand or receptor that comprises:
  • polypeptide construct that is directed against (as defined herein) a heterodimeric protein, polypeptide, ligand or receptor (or other “target”) that comprises:
  • polypeptide construct that is directed against (as defined herein) a heterodimeric protein that is a ligand for a receptor and that comprises:
  • polypeptide construct that is directed against (as defined herein) a heterodimeric protein that is a ligand for a receptor and that comprises:
  • polypeptide construct that is directed against (as defined herein) a heterodimeric protein, polypeptide, ligand or receptor that comprises:
  • the first and second binding domain may be as generally described herein (for example, in terms of affinity, specificity etc. for the subunit against which they are directed) for the amino acid sequences of the invention in general.
  • the first, second and optionally further binding domains or binding units present in said constructs are preferably such that they form or are capable of forming (optionally after suitable folding) a single antigen binding domain or antigen binding unit, and may for example be amino acid sequences that comprise an immunoglobulin fold, amino acid sequences that are comprises of four framework regions and three CDR's, and may in particular be domain antibodies, single domain antibodies, VHH's, “dAb's” or Nanobodies (all as further described herein), or suitable fragments thereof.
  • Suitable heterodimeric “targets” for the above multispecific (and in particular, bispecific) and multiparatopic (and in particular biparatopic) constructs will be clear to the skilled person based on the disclosure herein; as will be the advantages of the use of the above constructs against such targets.
  • the heterodimeric protein, polypeptide, ligand or receptor may be a heterodimeric protein that is a ligand for a heterodimeric receptor, and may in particular be a heterodimeric cytokine (for example, IL-12, IL-23, IL-27 or IL-35).
  • the heterodimeric protein, polypeptide, ligand or receptor may be a heterodimeric ligand that is a receptor for a heterodimeric ligand, and may in particular be a receptor for a heterodimeric cytokine (for example, a receptor for IL-12, IL-23, IL-27 or IL-35).
  • said heterodimeric protein, ligand or polypeptide may be a heterodimeric cytokine or a (heterodimeric) receptor for a cytokine (and in particular for a heterodimeric cytokine).
  • a construct as referred to under j) above may act as an agonist for the signalling that is mediated by the cognate receptor for IL-12 (in which case, the construct is expected to be specific for the signalling that is mediated by the cognate receptor for IL-12 compared to the signalling that is mediated by the cognate receptor for IL-23 mediated signalling, or may essentially not even be capable of acting as agonist for the signalling that is mediated by the cognate receptor for IL-23); and/or (ii) may be capable of modulating, neutralizing, blocking and/or inhibiting the binding of a IL-12 to its cognate receptor and/or may otherwise be capable of preventing, modulating, neutralizing, blocking and/or inhibiting the receptor-mediated signalling that, without the presence of said construct, would be triggered by binding of IL-12 to its cognate receptor (i.e.
  • IL-12 act as an antagonist for IL-12 and/or for the signalling that is mediated by the cognate receptor for IL-12), and as such be specific for the cognate receptor for IL-12 compared to the cognate receptor for IL-23 (and/or bind with higher avidity and/or specificity to the cognate receptor for IL-12 compared to the cognate receptor for IL-23).
  • a construct as referred to under k) above may act as an agonist for the signalling that is mediated by the cognate receptor for IL-23 (in which case, the construct is expected to be specific for the signalling that is mediated by the cognate receptor for IL-23 compared to the signalling that is mediated by the cognate receptor for IL-12 mediated signalling, or may essentially not even be capable of acting as agonist for the signalling that is mediated by the cognate receptor for IL-12); and/or (ii) may be capable of modulating, neutralizing, blocking and/or inhibiting the binding of a IL-23 to its cognate receptor and/or may otherwise be capable of preventing, modulating, neutralizing, blocking and/or inhibiting the receptor-mediated signalling that, without the presence of said construct, would be triggered by binding of IL-23 to its cognate receptor (i.e.
  • IL-23 act as an antagonist for IL-23 and/or for the signalling that is mediated by the cognate receptor for IL-23), and as such be specific for the cognate receptor for IL-23 compared to the cognate receptor for IL-12 (and/or bind with higher avidity and/or specificity to the cognate receptor for IL-23 compared to the cognate receptor for IL-12).
  • amino acid sequences that are directed against (as defined herein) heterodimeric cytokines and/or their receptors, in particular against heterodimeric cytokines and/or their receptors from a warm-blooded animal, more in particular against heterodimeric cytokines and/or their receptors from a mammal, and especially against human heterodimeric cytokines and/or their receptors; and to provide proteins and polypeptides comprising or essentially consisting of at least one such amino acid sequence.
  • the invention provides amino acid sequences that are directed against (as defined herein) and/or can specifically bind (as defined herein) to heterodimeric cytokines and/or their receptors; as well as compounds and constructs, and in particular proteins and polypeptides, that comprise at least one such amino acid sequence.
  • Said amino acid sequence preferably form and/or essentially consist of a single (antigen) binding domain or binding unit, and/or are capable of forming and/or of functioning as a single (antigen) binding domain or binding unit (optionally after suitable folding), either as such and/or as part of a protein or polypeptide of the invention as further described herein.
  • the invention provides amino acid sequences (such as the p19+ sequences, p19 ⁇ sequences, p40+ sequences, p40 ⁇ sequences, p35 sequences, IL-27 sequences, IL-12Rb1 sequences, IL-12Rb2 sequences and IL-23 sequences described herein) that can bind to heterodimeric cytokines and/or their receptors with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value, as further described herein) that is as defined herein; as well as compounds and constructs, and in particular proteins and polypeptides, that comprise at least one such amino acid sequence.
  • amino acid sequences such as the p19+ sequences, p19 ⁇ sequences, p40+ sequences, p40 ⁇ sequences, p35 sequences, IL-27 sequence
  • amino acid sequences and polypeptides of the invention are preferably such that they:
  • a monovalent amino acid sequence of the invention is preferably such that it will bind to heterodimeric cytokines and/or their receptors with an affinity less than 500 nM, preferably less than 200 nM, more preferably less than 10 nM, such as less than 500 pM.
  • an amino acid sequence of the invention will usually contain within its amino acid sequence one or more amino acid residues or one or more stretches of amino acid residues (i.e. with each “stretch” comprising two or amino acid residues that are adjacent to each other or in close proximity to each other, i.e. in the primary or tertiary structure of the amino acid sequence) via which the amino acid sequence of the invention can bind to heterodimeric cytokines and/or their receptors, which amino acid residues or stretches of amino acid residues thus form the “site” for binding to heterodimeric cytokines and/or their receptors (also referred to herein as the “antigen binding site”).
  • amino acid sequences provided by the invention are preferably in essentially isolated form (as defined herein), or form part of a protein or polypeptide of the invention (as defined herein), which may comprise or essentially consist of one or more amino acid sequences of the invention and which may optionally further comprise one or more further amino acid sequences (all optionally linked via one or more suitable linkers).
  • the one or more amino acid sequences of the invention may be used as a binding unit in such a protein or polypeptide, which may optionally contain one or more further amino acid sequences that can serve as a binding unit (i.e.
  • a monovalent, multivalent or multispecific polypeptide of the invention against one or more other targets than heterodimeric cytokines and/or their receptors), so as to provide a monovalent, multivalent or multispecific polypeptide of the invention, respectively, all as described herein.
  • a protein or polypeptide may also be in essentially isolated form (as defined herein).
  • amino acid sequences such as the p19+ sequences, p19 ⁇ sequences, p40+ sequences, p40 ⁇ sequences, p35 sequences, IL-27 sequences, IL-12Rb1 sequences, IL-12Rb2 sequences and IL-23 sequences described herein
  • polypeptides such as the—for example multivalent, multispecific and/or biparatopic—constructs described herein that comprise at least one p19+ sequence, p19 ⁇ sequence, p40+ sequence, p40 ⁇ sequence, p35 sequence, IL-27 sequence, IL-12Rb1 sequence, IL-12Rb2 sequence and/or IL-23 sequence
  • of the invention as such preferably essentially consist of a single amino acid chain that is not linked via disulphide bridges to any other amino acid sequence or chain (but that may or may not contain one or more intramolecular disulphide bridges.
  • Nanobodies may sometimes contain a disulphide bridge between CDR3 and CDR1 or FR2).
  • one or more amino acid sequences of the invention may be linked to each other and/or to other amino acid sequences (e.g. via disulphide bridges) to provide peptide constructs that may also be useful in the invention (for example Fab′ fragments, F(ab′) 2 fragments, ScFv constructs, “diabodies” and other multispecific constructs.
  • Fab′ fragments, F(ab′) 2 fragments, ScFv constructs, “diabodies” and other multispecific constructs for example Fab′ fragments, F(ab′) 2 fragments, ScFv constructs, “diabodies” and other multispecific constructs.
  • amino acid sequence of the invention when intended for administration to a subject (for example for therapeutic and/or diagnostic purposes as described herein), it is preferably either an amino acid sequence that does not occur naturally in said subject; or, when it does occur naturally in said subject, in essentially isolated form (as defined herein).
  • amino acid sequences of the invention are preferably directed against human heterodimeric cytokines and/or their receptors; whereas for veterinary purposes, the amino acid sequences and polypeptides of the invention are preferably directed against heterodimeric cytokines and/or their receptors from the species to be treated, or at at least cross-reactive with heterodimeric cytokines and/or their receptors from the species to be treated.
  • amino acid sequence of the invention may optionally, and in addition to the at least one binding site for binding against heterodimeric cytokines and/or their receptors, contain one or more further binding sites for binding against other antigens, proteins or targets.
  • the efficacy of the amino acid sequences and polypeptides of the invention, and of compositions comprising the same, can be tested using any suitable in vitro assay, cell-based assay, in vivo assay and/or animal model known per se, or any combination thereof, depending on the specific disease or disorder involved.
  • Suitable assays and animal models will be clear to the skilled person, and for example include in vitro assays such as Biacore (see for example Example 12, 20 or 23), Alpha-screen (see for example Example 14, Example 20 or Example22), FLIPR, ELISA (see for example Example 10) and competitive ELISA (see for example Example 11), cell-based assays such as proliferation of activated PBMCs (for measuring modulation of IL-12 mediated signalling,) IL17 production of activated spleen cells (for measuring modulation of IL-23 mediated signalling, see for example Aggarwal, Journal of Biological Chemistry, 278, 3, 2003, 1910-1914); and assays for measuring differentiation of THE1 and/or inhibition of THE17 cells (for for measuring modulation of IL-23 mediated signalling), and various animal models for inflammatory diseases and disorders, such as models for autoimmune inflammation such as EAE (Experimental Allergic Encephalomyelitis), CIA (Collagen-induced arthritis), IL12-induced neopterin release, and
  • the skilled person will generally be able to select a suitable in vitro assay, cellular assay or animal model to test the amino acid sequences and polypeptides of the invention to a heterodimeric cytokine or a receptor thereof, for their capacity to modulate heterodimeric cytokines and their receptors, and/or the signaling, pathways, biological mechanisms and effects in which these are involved; and for their therapeutic and/or prophylactic effect in respect of one or more diseases and disorders that are associate with a heterodimeric cytokine and/or a receptors thereof.
  • amino acid sequences and polypeptides that are directed against heterodimeric cytokines and/or their receptors from a first species of warm-blooded animal may or may not show cross-reactivity with heterodimeric cytokines and/or their receptors from one or more other species of warm-blooded animal.
  • amino acid sequences and polypeptides directed against human heterodimeric cytokines and/or their receptors may or may not show cross reactivity with heterodimeric cytokines and/or their receptors from one or more other species of primates (such as, without limitation, monkeys from the genus Macaca (such as, and in particular, cynomologus monkeys ( Macaca fascicularis ) and/or rhesus monkeys ( Macaca mulatta )) and baboon ( Papio ursinus )) and/or with heterodimeric cytokines and/or their receptors from one or more species of animals that are often used in animal models for diseases (for example mouse, rat, rabbit, pig or dog), and in particular in animal models for diseases and disorders associated with heterodimeric cytokines and/or their receptors (such as the species and animal models mentioned herein).
  • primates such as, without limitation, monkeys from the genus Macaca (such as, and in particular,
  • amino acid sequences and polypeptides of the invention that are cross-reactive with heterodimeric cytokines and/or their receptors from multiple species of mammal will usually be advantageous for use in veterinary applications, since it will allow the same amino acid sequence or polypeptide to be used across multiple species.
  • amino acid sequences and polypeptides directed against heterodimeric cytokines and/or their receptors from one species of animal can be used in the treatment of another species of animal, as long as the use of the amino acid sequences and/or polypeptides provide the desired effects in the species to be treated.
  • the present invention is in its broadest sense also not particularly limited to or defined by a specific antigenic determinant, epitope, part, domain, subunit or confirmation (where applicable) of heterodimeric cytokines and/or their receptors against which the amino acid sequences and polypeptides of the invention are directed.
  • the amino acid sequences and polypeptides are (at least) directed against an interaction site (as defined herein) on the heterodimeric cytokine or the receptor.
  • a polypeptide of the invention may contain two or more amino acid sequences of the invention that are directed against their intended (cognate) cognate target (such as a heterodimeric cytokine, a receptor for the same, or a subunit of either). Generally, such polypeptides will bind to said said target with increased avidity compared to a single amino acid sequence of the invention.
  • Such a polypeptide may for example comprise two amino acid sequences of the invention that are directed against the same antigenic determinant, epitope, part, domain, subunit or confirmation (where applicable) of said target (which may or may not be an interaction site); or comprise at least one “first” amino acid sequence of the invention that is directed against a first same antigenic determinant, epitope, part, domain, subunit or confirmation (where applicable) of said target (which may or may not be an interaction site); and at least one “second” amino acid sequence of the invention that is directed against a second antigenic determinant, epitope, part, domain, subunit or confirmation (where applicable) different from the first (and which again may or may not be an interaction site).
  • at least one amino acid sequence of the invention is directed against an interaction site (as defined herein), although the invention in its broadest sense is not limited thereto.
  • the amino acid sequences and polypeptides may be such that they compete with the cognate binding partner (e.g. the ligand, receptor or other binding partner, as applicable) for binding to the target, and/or such that they (fully or partially) neutralize binding of the binding partner to the target.
  • the cognate binding partner e.g. the ligand, receptor or other binding partner, as applicable
  • an amino acid sequence of the invention can bind to two or more antigenic determinants, epitopes, parts, domains, subunits or confirmations of heterodimeric cytokines and/or their receptors.
  • the antigenic determinants, epitopes, parts, domains or subunits of heterodimeric cytokines and/or their receptors to which the amino acid sequences and/or polypeptides of the invention bind may be essentially the same (for example, if heterodimeric cytokines and/or their receptors contains repeated structural motifs or occurs in a multimeric form) or may be different (and in the latter case, the amino acid sequences and polypeptides of the invention may bind to such different antigenic determinants, epitopes, parts, domains, subunits of heterodimeric cytokines and/or their receptors with an affinity and/or specificity which may be the same or different).
  • amino acid sequences and polypeptides of the invention may bind to either one of these confirmation, or may bind to both these confirmations (i.e. with an affinity and/or specificity which may be the same or different).
  • amino acid sequences and polypeptides of the invention may bind to a conformation of heterodimeric cytokines and/or their receptors in which it is bound to a pertinent ligand, may bind to a conformation of heterodimeric cytokines and/or their receptors in which it not bound to a pertinent ligand, or may bind to both such conformations (again with an affinity and/or specificity which may be the same or different).
  • amino acid sequences and polypeptides of the invention will generally bind to all naturally occurring or synthetic analogs, variants, mutants, alleles, parts and fragments of heterodimeric cytokines and/or their receptors; or at least to those analogs, variants, mutants, alleles, parts and fragments of heterodimeric cytokines and/or their receptors that contain one or more antigenic determinants or epitopes that are essentially the same as the antigenic determinant(s) or epitope(s) to which the amino acid sequences and polypeptides of the invention bind in heterodimeric cytokines and/or their receptors (e.g. in wild-type heterodimeric cytokines and/or their receptors).
  • the amino acid sequences and polypeptides of the invention may bind to such analogs, variants, mutants, alleles, parts and fragments with an affinity and/or specificity that are the same as, or that are different from (i.e. higher than or lower than), the affinity and specificity with which the amino acid sequences of the invention bind to (wild-type) heterodimeric cytokines and/or their receptors. It is also included within the scope of the invention that the amino acid sequences and polypeptides of the invention bind to some analogs, variants, mutants, alleles, parts and fragments of heterodimeric cytokines and/or their receptors, but not to others.
  • the amino acid sequences, polypeptides and compositions of the present invention can generally be used to modulate (as defined herein) the signalling that is mediated by heterodimeric cytokines and/or their receptors, to modulate (as defined herein) the biological pathways in which heterodimeric cytokines and/or their receptors are involved, and/or to modulate (as defined herein) the biological mechanisms, responses and effects associated with heterodimeric cytokines, their receptors, such signalling and/or these pathways (all the foregoing is also collectively referred to herein as “heterodimeric cytokine-mediated signalling”).
  • amino acid sequences, polypeptides and compositions of the present invention can generally be used to modulate the immune system and/or one or more specific immune responses in a subject to which one or more of the amino acid sequences, polypeptides and compositions of the present invention are administered (i.e. in therapeutically relevant amounts).
  • heterodimeric cytokines as used herein in its broadest sense generally includes any heterodimeric cytokine, i.e. a cytokine that comprises at least two, and more preferably only two, subunits.
  • heterodimeric cytokine encompasses heterodimeric cytokines that are associated with cell-mediated (T H 1) immunity, although the invention is its broadest sense is not limited thereto and also encompasses heterodimeric cytokines associated with humoral (T H 2) immunity.
  • the amino acid sequences and polypeptides of invention are directed against a heterodimeric cytokine that is chosen from heterodimeric cytokines that comprise a p40 subunit or p40-like subunit, such as a p40 subunit (present in for example IL-12 and IL-23) or Epstein-Barr virus (EBV)-induced molecule 3 (EBI3, present in for example IL-27 and IL-35).
  • a p40 subunit present in for example IL-12 and IL-23
  • EBV Epstein-Barr virus
  • the amino acid sequences and polypeptides of invention are directed against a heterodimeric cytokine that is chosen from heterodimeric cytokines that comprise a p19 subunit or a p19-like subunit, such as a p19 subunit (present in for example IL-23), a p35 subunit (present in for example IL-12 and IL-35), or a p28 subunit (present in for example IL-27) or a homolog thereof.
  • a heterodimeric cytokine that is chosen from heterodimeric cytokines that comprise a p19 subunit or a p19-like subunit, such as a p19 subunit (present in for example IL-23), a p35 subunit (present in for example IL-12 and IL-35), or a p28 subunit (present in for example IL-27) or a homolog thereof.
  • amino acid sequences and polypeptides of invention may be directed against a heterodimeric cytokine that will comprise at least one p19 subunit or p19-like subunit and at least one p40 subunit or p40-like subunit.
  • amino acid sequences and polypeptides of invention are directed against a heterodimeric cytokine that is chosen from IL-12, IL-23, IL-27 and/or IL-35.
  • amino acid sequences and polypeptides of the invention are directed against IL-23 (i.e. against p40, p19 or both).
  • Such amino acid sequences and polypeptides of the invention may be as further described herein and can be used for preventing and treating disorders associated with IL-23, the IL-23 receptor and/or IL-23 mediated signalling.
  • amino acid sequences and polypeptides of the invention that are directed against IL-23 may have advantages for therapeutic use over the amino acid sequences and polypeptides of the invention that are directed against IL-12.
  • amino acid sequences and polypeptides of the invention that are directed against p19 may have advantages for therapeutic use over the amino acid sequences and polypeptides of the invention that are directed against p35 or p40.
  • the invention provides amino acid sequences and polypeptides that are directed against at least one subunit of a heterodimeric cytokine (as defined herein). These amino acid sequences and/or polypeptides may be as further described herein.
  • the invention provides “bispecific” (as defined herein) polypeptides that are directed against both subunits of a heterodimeric cytokine. These polypeptides may be as further described herein.
  • the invention provides “biparatopic” (as defined herein) polypeptides that are directed against one subunit of a heterodimeric cytokine. These polypeptides may be as further described herein.
  • the invention provides amino acid sequences and polypeptides that are directed against at least one subunit of a heterodimeric cytokine, wherein said heterodimeric cytokine is associated with cell-mediated (T H 1) immunity.
  • the invention provides amino acid sequences and polypeptides that are directed against at least one subunit of a heterodimeric cytokine, wherein said heterodimeric cytokine is chosen from heterodimeric cytokines that comprise a p40 subunit or p40-like subunit, such as a p40 subunit (present in for example IL-12 and IL-23) or Epstein-Barr virus (EBV)-induced molecule 3 (EBI3, present in for example IL-27 and IL-35).
  • a p40 subunit present in for example IL-12 and IL-23
  • EBV Epstein-Barr virus
  • the invention provides amino acid sequences and polypeptides that are directed against a p40 subunit or a p40-like subunit, such as against one of the following subunits: p40 and/or EBI3, or a mutant, variant, allele or homolog of each of the foregoing.
  • the invention provides amino acid sequences and polypeptides that are directed against at least one subunit of a heterodimeric cytokine, wherein said heterodimeric cytokine is chosen from heterodimeric cytokines that comprise a p19 subunit or p19-like subunit, such as a p19 subunit (present in for example IL-23), a p35 subunit (present in for example IL-12 and IL-35), a p28 subunit (present in for example IL-27), or a mutant, variant, allele or homolog of each of the foregoing.
  • a p19 subunit present in for example IL-23
  • a p35 subunit present in for example IL-12 and IL-35
  • a p28 subunit present in for example IL-27
  • amino acid sequences and/or polypeptides may be as further described herein.
  • the invention provides amino acid sequences and polypeptides that are directed against a p19 subunit or p19-like subunit, such as against one of the following subunits: p19, p35 and/or p28, or a mutant, variant, allele or homolog of each of the foregoing.
  • amino acid sequences and/or polypeptides may be as further described herein.
  • the invention provides amino acid sequences and polypeptides that are directed against at least one subunit of one of the following heterodimeric cytokines: IL-12, IL-23, IL-27 and/or IL-35. These amino acid sequences and/or polypeptides may be as further described herein.
  • the invention provides amino acid sequences and polypeptides that are directed against IL-12 or at least one subunit of IL-12, which amino acid sequences and/or polypeptides may be as further described herein.
  • the invention provides amino acid sequences and polypeptides that are directed against IL-23 or at least one subunit of IL-23, which amino acid sequences and/or polypeptides may be as further described herein.
  • the invention provides amino acid sequences and polypeptides that are directed against IL-27 or at least one subunit of IL-27, which amino acid sequences and/or polypeptides may be as further described herein.
  • the invention provides amino acid sequences and polypeptides that are directed against IL-35 or at least one subunit of IL-35, which amino acid sequences and/or polypeptides may be as further described herein.
  • such a polypeptide against IL-12, IL-23, IL-27 or IL-35 may comprise or essentially consist of a single amino acid sequence of the invention (such as a Nanobody) that is directed against IL-12, IL-23, IL-27 or IL-35, respectively, and in particular against an interaction site (as defined herein) on IL-12, IL-23, IL-27 or IL-35.
  • a single amino acid sequence of the invention such as a Nanobody
  • polypeptide comprises two or more amino acid sequences of the invention (optionally linked to each other via one or more suitable linkers, as described herein) that are directed against IL-12, IL-23, IL-27 or IL-35 respectively
  • these amino acid sequences may be directed against the same epitope, antigenic determinant, part, domain or stretch of amino acid residues on IL-12, IL-23, IL-27 or IL-35, respectively, or against different epitopes, antigenic determinants, parts, domains or stretches of amino acid residues on IL-12, IL-23, IL-27 or IL-35.
  • such a polypeptide may comprise one or more amino acid sequences of the invention that are directed against an interaction site (as defined herein, and in particular the receptor binding site) on IL-12, IL-23, IL-27 or IL-35, respectively, and one or more amino acid sequences of the invention that are directed against a site, epitope, antigenic determinant, part, domain or stretch of amino acid residues on IL-12, IL-23, IL-27 or IL-35, respectively, that is not an interaction site.
  • an interaction site as defined herein, and in particular the receptor binding site
  • Such a polypeptide may also comprise one or more amino acid sequences of the invention that are directed against an interaction site (as defined herein, and in particular the receptor binding site) on IL-12, IL-23, IL-27 or IL-35, respectively, and one or more amino acid sequences that are directed against a different interaction site (as defined herein) on IL-12, IL-23, IL-27 or IL-35, respectively. It is also possible that such a polypeptide comprises two or more amino acid sequences of the invention that are directed against the same interaction site (as defined herein, and in particular the receptor binding site) on IL-12, IL-23, IL-27 or IL-35, respectively.
  • such a polypeptide may comprise one or more amino acid sequences of the invention (such as one or more Nanobodies) that can modulate binding of IL-12, IL-23, IL-27 or IL-35, respectively, to its receptor; and/or one or more amino acid sequences of the invention (such as one or more Nanobodies) that do not modulate (and in particular inhibit) binding of IL-12, IL-23, IL-27 or IL-35, respectively, to its receptor.
  • one or more amino acid sequences of the invention such as one or more Nanobodies
  • one or more Nanobodies that do not modulate (and in particular inhibit) binding of IL-12, IL-23, IL-27 or IL-35, respectively, to its receptor.
  • such a polypeptide may comprise one amino acid sequence of the invention (such as a Nanobodies) that can modulate binding of IL-12, IL-23, IL-27 or IL-35, respectively, to its receptor and one amino acid sequence of the invention (such as a Nanobody) that does not modulate binding of IL-12, IL-23, IL-27 or IL-35, respectively, to its receptor.
  • one amino acid sequence of the invention such as a Nanobodies
  • a Nanobody that does not modulate binding of IL-12, IL-23, IL-27 or IL-35, respectively, to its receptor.
  • the invention provides amino acid sequences and polypeptides that are directed against p19 (also referred to herein as “p19 sequences”).
  • p19 sequences Such amino acid sequences and/or polypeptides may be as further described herein (for example, such amino acid sequences may be may be “p19+ sequences” or “p19 ⁇ sequences”).
  • such a polypeptide may be a polypeptide that contains one or more amino acid sequences against p19, such as one or more Nanobodies against p19. It is expected that such a polypeptide of the invention will be selective for IL-23 and other heterodimeric cytokines that contain p19 compared to IL-12, IL-27 and/or IL-35.
  • the invention provides amino acid sequences and polypeptides that are directed against p35.
  • amino acid sequences and/or polypeptides may be as further described herein.
  • such a polypeptide may be a polypeptide that contains one or more amino acid sequences against p35, such as one or more Nanobodies against p3 5. It is expected that such a polypeptide of the invention will be selective for IL-12 and/or IL-35 and other heterodimeric cytokines that contain p40 compared to IL-12 and/or IL-27.
  • the invention provides amino acid sequences and polypeptides that are directed against p28.
  • amino acid sequences and/or polypeptides may be as further described herein.
  • such a polypeptide may be a polypeptide that contains one or more amino acid sequences against p28, such as one or more Nanobodies against p28. It is expected that such a polypeptide of the invention will be selective for IL-27 and other heterodimeric cytokines that contain p28 compared to IL-12, IL-23 and/or IL-35.
  • the invention provides amino acid sequences and polypeptides that are directed against p40.
  • amino acid sequences and/or polypeptides may be as further described herein (for example, such amino acid sequences may be may be “p40+ sequences” or “p40+sequences”).
  • such a polypeptide may be a polypeptide that contains one or more amino acid sequences against p40, such as one or more Nanobodies against p40. It is expected that such a polypeptide of the invention will be selective for IL-12 and/or IL-23 and other heterodimeric cytokines that contain p40 compared to IL-27 and/or IL-35.
  • the invention provides amino acid sequences and polypeptides that are directed against EBI3.
  • amino acid sequences and/or polypeptides may be as further described herein.
  • such a polypeptide may be a polypeptide that contains one or more amino acid sequences against EBI3, such as one or more Nanobodies against EBI3. It is expected that such a polypeptide of the invention will be selective for IL-27 and/or IL-23 and other heterodimeric cytokines that contain EBI3 compared to IL-12 and/or IL-23.
  • such a polypeptide against p19, p35, p28, p40 or EBI3, respectively may comprise or essentially consist of a single amino acid sequence of the invention (such as a Nanobody) that is directed against p19, p35, p28, p40 or EBI3, respectively, and in particular against an interaction site (as defined herein) on p19, p35, p28, p40 or EBI3.
  • a single amino acid sequence of the invention such as a Nanobody
  • polypeptide comprises two or more amino acid sequences of the invention (optionally linked to each other via one or more suitable linkers, as described herein) that are directed against p19, p35, p28, p40 or EBI3, respectively
  • these amino acid sequences may be directed against the same epitope, antigenic determinant, part, domain or stretch of amino acid residues on p19, p35, p28, p40 or EBI3, respectively, or against different epitopes, antigenic determinants, parts, domains or stretches of amino acid residues on p19, p35, p28, p40 or EBI3.
  • such a polypeptide may comprise one or more amino acid sequences of the invention that are directed against an interaction site (as defined herein, and in particular a site that is involved in binding of the heterodimeric cytokine in which said subunit is present to its receptor) on p19, p35, p28, p40 or EBI3, respectively, and one or more amino acid sequences of the invention that are directed against a site, epitope, antigenic determinant, part, domain or stretch of amino acid residues on p19, p35, p28, p40 or EBI3, respectively, that is not an interaction site.
  • an interaction site as defined herein, and in particular a site that is involved in binding of the heterodimeric cytokine in which said subunit is present to its receptor
  • EBI3 amino acid sequences of the invention that are directed against a site, epitope, antigenic determinant, part, domain or stretch of amino acid residues on p19, p35, p28, p40 or EBI
  • Such a polypeptide may also comprise one or more amino acid sequences of the invention that are directed against an interaction site (as defined herein, and in particular the receptor binding site) on p19, p35, p28, p40 or EBI3, respectively, and one or more amino acid sequences that are directed against a different interaction site (as defined herein) on p19, p35, p28, p40 or EBI3, respectively.
  • such a polypeptide comprises two or more amino acid sequences of the invention that are directed against the same interaction site (as defined herein, and in particular a site that is involved in binding of the heterodimeric cytokine in which said subunit is present to its receptor) on p19, p35, p28, p40 or EBI3, respectively.
  • such a polypeptide may comprise one or more amino acid sequences of the invention (such as one or more Nanobodies) that are directed against p19, p35, p28, p40 or EBI3, respectively, and that can modulate (and in particular inhibit) binding of the heterodimeric cytokine in which said subunit is present to its receptor; and/or one or more amino acid sequences of the invention (such as one or more Nanobodies) that are directed against p19, p35, p28, p40 or EBI3, respectively, but that are not capable of modulate binding of the heterodimeric cytokine in which said subunit is present to its receptor.
  • one or more amino acid sequences of the invention such as one or more Nanobodies
  • the invention provides amino acid sequences and (in particular) polypeptides that are directed against two different subunits that occur in heterodimeric cytokines.
  • the invention provides amino acid sequences and (in particular) polypeptides that are directed against two different subunits that occur in heterodimeric cytokines (and in particular in heterodimeric cytokines from the IL-12 family, such as in IL-12, IL-23, IL-27 and IL-35).
  • such an amino acid sequence or polypeptide may be directed (a) against p19 or a p19-like subunit, such as against p19, p35 or p28; and against at least one other subunit that occurs in a heterodimeric cytokine (such as in IL-12, IL-23, IL-27 and IL-35); or (b) against p40 or a p40-like subunit, such as against p40 or EBI-3 and against at least one other subunit that occurs in a heterodimeric cytokine (such as in IL-12, IL-23, IL-27 and IL-35).
  • the invention provides amino acid sequences and (in particular) polypeptides that are directed against (i) at least one p19 or p19-like subunit, such as against p19, p35 or p28; and (ii) at least one p40 or p40-like subunit, such as against p40 or EBI-3.
  • Such an amino acid sequence or polypeptide of the invention may for example also be an amino acid sequence or polypeptide of the invention that is directed towards the interface of two subunits that occur in a heterodimeric cytokine, such as towards the p19/p40 interface in IL-23, against the p35/p40 interface in IL-12, against the p28/EBI3 interface in IL-27, or against the p35/EBI3 interface in IL-35.
  • such a polypeptide of the invention may be a “bispecific” and in particular “biparatopic” polypeptide of the invention (as further described herein) that comprises at least one amino acid sequence of the invention (such as a Nanobody) that is directed against at least one p19 or p19-like subunit (such as against p19, p35 or p28), and at least one amino acid sequence of the invention (such as a Nanobody) that is directed against at least one p40 or p40-like subunit (such as against p40 or EBI-3).
  • a “bispecific” and in particular “biparatopic” polypeptide of the invention that comprises at least one amino acid sequence of the invention (such as a Nanobody) that is directed against at least one p19 or p19-like subunit (such as against p19, p35 or p28), and at least one amino acid sequence of the invention (such as a Nanobody) that is directed against at least one p40 or p40-like sub
  • the invention provides:
  • polypeptide may comprise:
  • the invention provides amino acid sequences and polypeptides that are directed against two or more subunits of heterodimeric cytokines.
  • the invention comprises multispecific proteins and polypeptides (as described herein) that comprise at least one binding unit against a first subunit of a heterodimeric cytokine and at least one binding unit against a second subunit of a heterodimeric cytokine that is different from said first subunit.
  • the invention comprises such multispecific proteins and polypeptides which comprise at least one binding unit against a first subunit of a heterodimeric cytokine and at least one binding unit against a second subunit of a heterodimeric cytokine that is different from said first subunit, in which said first and second subunit form part of the same heterodimeric cytokine (in other words, such multi specific proteins or polypeptides are “biparatopic” with respect to said heterodimeric cytokine, in that they are capable of binding to two different epitopes on said heterodimeric cytokine.
  • a protein or polypeptide as described herein may for example be biparatopic in respect of one of the subunits mentioned herein, i.e. comprise at least one binding unit against a first epitope on said subunit and at least one binding unit against a second epitope on said subunit).
  • multispecific proteins and polypeptides are multispecific proteins and polypeptides that are directed against p35 and p40 (which are both present in IL-12, so that such a multivalent protein or polypeptide is expected to be specific for IL-12), against p 19 and p40 (both present in IL-23), or against p28 and EBI3 (both present in IL-27).
  • the invention comprises such multispecific proteins and polypeptides which comprise at least one binding unit against a first subunit of a heterodimeric cytokine and at least one binding unit against a second subunit of a heterodimeric cytokine that is different from said first subunit, in which said first and second subunit are chosen from p19, p35, p28, p40 and/or EBI3; and/or mutants, variants, alleles or homologs of each of the foregoing.
  • such multispecific proteins and polypeptides may comprise at least one binding unit which is directed against a p19-like subunit such as p19, p35 or p 28 and at least one binding unit that is directed against a p40-like subunit such as p40 or EBI3 (it should also be noted that the invention even more generally relates to any multispecific protein and polypeptide which comprises at least one binding unit that is directed against a heterodimeric cytokine or a subunit thereof—such as p19, p35, p28, p40 and/or EBI3—and at least one further binding unit that is directed against any other (e.g. non-heterodimeric cytokine) desired target, antigenic determinant or epitope).
  • a p19-like subunit such as p19, p35 or p 28
  • p40-like subunit such as p40 or EBI3
  • an amino acid sequence or polypeptide as described herein may be directed against the interface between the two subunits that form a heterodimeric cytokine (usually the interface between a p19-like subunit and a p40-like subunit).
  • a heterodimeric cytokine usually the interface between a p19-like subunit and a p40-like subunit.
  • amino acid sequences and polypeptides described herein may be directed against the p35/p40 interface of IL-12, against the p19/p40 interface of IL-23, or against the p28/EBI-3 interface of IL-28.
  • amino acid sequences and polypeptides described herein may be directed against a single heterodimeric cytokine (or against a single subunit of a heterodimeric cytokine), but may also be directed against multiple heterodimeric cytokines (or against multiple subunits thereof, that either form part of the same heterodimeric cytokine or even of different heterodimeric cytokines).
  • amino acid sequences and polypeptides described herein are specific for (as defined herein) IL-23, compared to IL-12, IL-27 and IL-35.
  • amino acid sequences and polypeptides described herein are specific for (as defined herein) IL-12, compared to IL-23, IL-27 and IL-35.
  • amino acid sequences and polypeptides described herein are specific for (as defined herein) IL-27, compared to IL-12, IL-23 and IL-35.
  • amino acid sequences and polypeptides described herein are specific for (as defined herein) IL-35, compared to IL-12, IL-23 and IL-27.
  • amino acid sequences and polypeptides described herein are specific for (as defined herein) the p19 subunit, compared to the p35 or p28 subunits. Such amino acid sequences and polypeptides are expected to be specific for IL-23 (i.e. compared to IL-12, IL-27 and IL-35).
  • amino acid sequences and polypeptides described herein are specific for (as defined herein) the p28 subunit, compared to the p35 or p19 subunits.
  • Such amino acid sequences and polypeptides are expected to be specific for IL-27 (i.e. compared to IL-12, IL-23 and IL-35).
  • amino acid sequences and polypeptides described herein are specific for (as defined herein) the p35 subunit, compared to the p28 or p19 subunits. Such amino acid sequences and polypeptides are expected to be specific for IL-12 and IL-35 (i.e. compared to IL-23 and IL-27).
  • amino acid sequences and polypeptides described herein are specific for (as defined herein) the p40 subunit, compared to EBI-3. Such amino acid sequences and polypeptides are expected to be specific for IL-12 and IL-23 (i.e. compared to IL-27 and IL-35).
  • amino acid sequences and polypeptides described herein are specific for (as defined herein) the EBI-3 subunit, compared to the p40 subunit. Such amino acid sequences and polypeptides are expected to be specific for IL-27 and IL-35 (i.e. compared to IL-12 and IL-23).
  • amino acid sequences and polypeptides described herein are specific for both the p19 and p40 subunits (compared to other subunits), and in particular directed against (as defined herein, i.e. capable of specifically binding to) the p19 and p40 subunits, but not directed against (i.e. not capable of specifically binding to) any of the subunits p35, p28 and/or EBI3 (or, according to an even more specific aspect, not directed to any p19-like subunit other than p19 and not directed to any p40-like subunit other than p40).
  • Such amino acid sequences (which may for example span the p19/p40 interface in IL-23 as described herein) or polypeptides (which may for example be bispecific polypeptides with at least one binding unit directed against p19 and at least one binding unit directed against p40) are expected to be specific for IL-23 compared to IL-27, and are expected to bind with higher avidity (and preferably also selectivity) to IL-23 compared to IL-12.
  • amino acid sequences and polypeptides described herein are specific for both the p35 and p40 subunits (compared to other subunits), and in particular directed against (as defined herein, i.e. capable of specifically binding to) the p35 and p40 subunits, but not directed against (i.e. not capable of specifically binding to) any of the subunits p19, p28 and/or EBI3 (or, according to an even more specific aspect, not directed to any p19-like subunit other than p35 and not directed to any p40-like subunit other than p40).
  • Such amino acid sequences (which may for example span the p35/p40 interface in IL-12 as described herein) or polypeptides (which may for example be bispecific polypeptides with at least one binding unit directed against p35 and at least one binding unit directed against p40) are expected to be specific for IL-12 compared to IL-27, and are expected to bind with higher avidity (and preferably also selectivity) to IL-12 compared to IL-23.
  • amino acid sequences and polypeptides described herein are specific for both the p28 and EBI-3 subunits (compared to other subunits), and in particular directed against (as defined herein, i.e. capable of specifically binding to) the p28 subunit and EBI-3, but not directed against (i.e. not capable of specifically binding to) any of the subunits p19, p35 and/or p40 (or, according to an even more specific aspect, not directed to any p19-like subunit other than p28 and not directed to any p40-like subunit other than EBI-3).
  • amino acid sequences which may for example span the p28/EBI-3 interface in IL-27 as described herein
  • polypeptides which may for example be bispecific polypeptides with at least one binding unit directed against p28 and at least one binding unit directed against EBI3 are expected to be specific for IL-27 compared to IL-12 and IL-23.
  • the invention also provides amino acid sequences and polypeptides that are directed against receptors for heterodimeric cytokines, in particular for receptors of the heterodimeric cytokines described herein.
  • the invention provides amino acid sequences and polypeptides that are directed against receptors for heterodimeric cytokines, wherein said receptors are receptors for heterodimeric cytokines that are associated with cell-mediated (T H 1) immunity.
  • the invention provides amino acid sequences and polypeptides that are directed against receptors for heterodimeric cytokines, wherein said receptors are receptors for heterodimeric cytokines that contain one or more p19-like subunits, and/or that contain one or more p40-like subunits, and in particular contain one or more of the following subunits: p19, p35, p28, p40 and/or EBI3; or a mutant, variant, allele or homolog of each of the foregoing.
  • the invention provides amino acid sequences and polypeptides that are directed against receptors for heterodimeric cytokines, wherein said receptors are receptors for heterodimeric cytokines that at least contain the p19 subunit.
  • the invention provides amino acid sequences and polypeptides that are directed against receptors for heterodimeric cytokines, wherein said receptors are receptors for heterodimeric cytokines that at least contain the p35 subunit.
  • the invention provides amino acid sequences and polypeptides that are directed against receptors for heterodimeric cytokines, wherein said receptors are receptors for heterodimeric cytokines that at least contain the p28 subunit.
  • the invention provides amino acid sequences and polypeptides that are directed against receptors for heterodimeric cytokines, wherein said receptors are receptors for heterodimeric cytokines that at least contain the p40 subunit.
  • the invention provides amino acid sequences and polypeptides that are directed against receptors for heterodimeric cytokines, wherein said receptors are receptors for heterodimeric cytokines that at least contain EBI3.
  • the invention provides amino acid sequences and polypeptides that are directed against a receptor for IL-12, IL-23, IL-27 and/or IL-35, respectively, and preferably against a high-affinity receptor for IL-12, IL-23, IL-27 and/or IL-35, respectively.
  • the invention provides amino acid sequences and polypeptides that are directed against a receptor for IL-12, and preferably against a high-affinity receptor for IL-12, or against at least one subunit thereof. More preferably, such amino acid sequences and polypeptides are specific for (as defined herein) the (cognate) receptor of IL-12 compared the (cognate) receptor of IL-23R and/or the (cognate) receptor of IL-27.
  • the invention provides amino acid sequences and polypeptides that are directed against a receptor for IL-23, and preferably against a high-affinity receptor for IL-23, or against at least one subunit thereof. More preferably, such amino acid sequences and polypeptides are specific for (as defined herein) the (cognate) receptor of IL-23 compared to the (cognate) receptor of IL-12 and/or the (cognate) receptor of IL-27.
  • the invention provides amino acid sequences and polypeptides that are directed against a receptor for IL-27, and preferably against a high-affinity receptor for IL-27, or against at least one subunit thereof. More preferably, such amino acid sequences and polypeptides are specific for (as defined herein) the (cognate) receptor of IL-27 compared to the (cognate) receptor of IL-12 and the (cognate) receptor of IL-23.
  • the invention provides amino acid sequences and polypeptides that are directed against a receptor for IL-35, and preferably against a high-affinity receptor for IL-35, or against at least one subunit thereof.
  • the invention provides amino acid sequences and polypeptides that are directed against at least one subunit of a receptor for IL-12, IL-23, IL-27 and/or IL-35, and that preferably are directed against a subunit of a high-affinity receptor for IL-12, IL-23, IL-27 and/or IL-35.
  • Such amino acid sequences and polypeptides of the invention may for example be directed against a IL-23-like subunit of such a receptor, against a gp130-like subunit of such a receptor, or both (e.g. in the case of bispecific/biparatopic polypeptides of the invention).
  • such amino acid sequences and polypeptides are directed against a IL-23-like subunit of such a receptor such as IL-12Rbeta-2, IL-23R and WSX-1 (with amino acid sequences and polypeptides against gp-130 like subunits such as the IL-12Rbeta-1 subunit or against gp130, although not excluded from the scope of the invention, being less preferred).
  • the invention provides amino acid sequences and polypeptides that are directed against at least one subunit of a receptor for IL-12, preferably against a high-affinity receptor for IL-12.
  • said amino acid sequences and polypeptides are directed against the IL-12Rbeta-2 subunit.
  • such amino acid sequences and polypeptides are specific for (as defined herein) the IL-12Rbeta-2 subunit compared to the IL-23R subunit and the WSX-1 subunit. It is expected that such amino acid sequences and polypeptides will be specific for the (cognate) receptor of IL-12 compared to the (cognate) receptor of IL-23 and/or the (cognate) receptor of IL-27.
  • the invention provides amino acid sequences and polypeptides that are directed against at least one subunit of a receptor for IL-23, and preferably against a high-affinity receptor for IL-23.
  • said amino acid sequences and polypeptides are directed against the IL-23R subunit.
  • such amino acid sequences and polypeptides are specific for (as defined herein) the IL-23R subunit compared to the IL-12Rbeta-2 subunit and the WSX-1 subunit. It is expected that such amino acid sequences and polypeptides will be specific for the (cognate) receptor of IL-23 compared to the (cognate) receptor of IL-12 and/or the (cognate) receptor of IL-27.
  • the invention provides amino acid sequences and polypeptides that are directed against at least one subunit of a receptor for IL-27, and preferably against a high-affinity receptor for IL-27.
  • said amino acid sequences and polypeptides are directed against the WSX-1 subunit.
  • such amino acid sequences and polypeptides are specific for (as defined herein) the WSX-1 subunit IL-23R subunit compared to the IL-12Rbeta-2 subunit and the IL-23R subunit. It is expected that such amino acid sequences and polypeptides will be specific for the (cognate) receptor of IL-27 compared to the (cognate) receptor of IL-12 and/or the (cognate) receptor of IL-23.
  • the invention also provides amino acid sequences and polypeptides that are directed against IL-12Rbeta-1.
  • amino acid sequences and polypeptides are specific for (as defined herein) IL-12Rbeta-1 compared to gp130.
  • the invention also provides amino acid sequences and polypeptides that are directed against gp130.
  • amino acid sequences and polypeptides are specific for (as defined herein) gp130 compared to IL-12Rbeta-1.
  • amino acid sequences and polypeptides may all be as further described herein.
  • the invention provides bispecific polypeptides that are directed against a first subunit of a receptor for a heterodimeric cytokine, and against a second subunit of a receptor for a heterodimeric cytokine different from said first subunit.
  • such a bispecific polypeptide of the invention may comprise at least one amino acid sequence of the invention (such as a Nanobody) that is directed against a gp130-like subunit (such as the gp130 or IL-12beta-1 subunit, or variants, mutants, alleles or homologs thereof), and at least one amino acid sequence of the invention (such as a Nanobody) that is directed against an IL-23 like subunit (such as IL-12Rbeta-2, IL-23, or WSX-1).
  • a bispecific polypeptide is such that it is directed against a gp130-like subunit and an IL-23 like subunit that form part of the same receptor.
  • Such bispecific polypeptides may for example trigger, facilitate and/or enhance activation and/or association of the receptor (or more generally receptor-mediated signalling), for example by mimicking the effects of ligand binding; and thus act as an agonist for the receptor, its ligand and/or the relevant heterodimeric cytokine-mediated signalling (in this respect, it should also be noted that in another aspect, the invention comprises polypeptides of the invention that comprise one or more, such as two, three or four, amino acid sequences of the invention that are directed against a single cytokine receptor chain so as to induce dimerisation or oligomerization and leading to activation of the receptor).
  • bispecific polypeptides may for example block, inhibit or reduce binding of the ligand to the receptor, or block, inhibit or reduce activation and/or association of the receptor after binding of the ligand, and/or more generally act as an agonist for the receptor, its ligand and/or the relevant heterodimeric cytokine-mediated signalling
  • the invention provides:
  • amino acid sequences and polypeptides may all be as further described herein.
  • a polypeptide of the invention may be a bispecific polypeptide that comprises at least one amino acid sequence of the invention that is directed against a heterodimeric cytokine (or against at least one subunit thereof), and at least one amino acid sequence of the invention that is directed against a receptor for a heterodimeric cytokine (or against at least one subunit thereof).
  • a polypeptide of the invention may comprise at least amino acid sequence of the invention that is directed against a heterodimeric cytokine (or at least one subunit thereof), and at least one amino acid sequence of the invention that is directed against a receptor for said heterodimeric cytokine (or at least one subunit thereof), i.e. against the cognate receptor for said heterodimeric cytokine.
  • bispecific polypeptides may act as agonists of heterodimeric cytokines, their receptors, and heterodimeric cytokine-mediated signalling, i.e. by promoting or facilitating binding of the heterodimeric cytokine to its receptor, and/or by stabilizing the ligand/receptor complex upon binding of the heterodimeric cytokine to its receptor.
  • bispecific polypeptides preferably comprise amino acid sequences that do not neutralize binding of the heterodimeric cytokine to the receptor.
  • bispecific polypeptides may also be designed to act as an antagonists, i.e. link the cytokine to the receptor without activating it, act as a dominant negative regulator since the receptor is then occupied and inactive).
  • Bispecific polypeptides as described herein can also be linked to a Fc portion as described in Applicant's copending application entitled “Immunoglobulin constructs”, which has the same filing date as this application, Dec. 4, 2007.
  • a bispecific polypeptide that is directed against a heterodimeric cytokine and against a receptor that is not the cognate receptor for said heterodimeric cytokine may also be used to modulate the signalling that is mediated by the cytokine against which it is directed and (in particular) by the receptor against which it is directed.
  • a bispecific anti-IL12p35 and anti-IL23R polypeptide of the invention could link IL12 to the IL23 receptor and trigger a IL23 signal.
  • the above bispecific polypeptides may comprise:
  • amino acid sequences and polypeptides may all be as further described herein.
  • an amino acid sequence or polypeptide of the invention When an amino acid sequence or polypeptide of the invention is directed against a heterodimeric cytokine, it may modulate (as defined herein) heterodimeric cytokine-mediated signalling (as defined herein) in several different ways. For example, and although the invention in its broadest sense is not limited to any specific explanation, hypothesis or mechanism, it may be that such an amino acid sequence or polypeptide, upon binding to the heterodimeric cytokine (or to at least one subunit thereof):
  • an amino acid sequence or polypeptide of the invention that is directed against a heterodimeric cytokine is such that, upon binding to the heterodimeric cytokine, it prevents, reduces or inhibits binding of said heterodimeric cytokine to its receptor or to at least one subunit thereof (i.e.
  • a suitable assay such as one of the assays mentioned herein and/or used in the Experimental Part.
  • an amino acid sequence or polypeptide of the invention that is directed against a heterodimeric cytokine is such that, upon binding to the heterodimeric cytokine and following binding of the heterodimeric cytokine to its receptor (or to at least one subunit of the receptor), it prevents, reduces or inhibits activation and/or association of its receptor (i.e.
  • the telomere length is compared to the association of the receptor mediated by the heterodimeric cytokine without the presence of the amino acid sequence or polypeptide, and by at least 1%, such as by at least 5%, for example by at least 10%, at least 30%, at least 50%, at least 70% and up to 90% or more, as determined by a suitable assay, such as one of the assays mentioned herein and/or used in the Experimental Part).
  • an amino acid sequence or polypeptide of the invention that is directed against a heterodimeric cytokine is such that, upon binding to the heterodimeric cytokine, it prevents, reduces or inhibits the signalling of the receptor that is triggered by the heterodimeric cytokine-mediated association of the receptor (i.e.
  • a suitable assay such as one of the assays mentioned herein and/or used in the Experimental Part.
  • an amino acid sequence or polypeptide of the invention that is directed against a heterodimeric cytokine is such that, upon binding to the heterodimeric cytokine, it prevents, reduces or inhibits the heterodimeric cytokine-mediated signalling (as defined herein) associated with said heterodimeric cytokine and/or with its receptor (i.e.
  • the heterodimeric cytokine-mediated signalling mediated by the heterodimeric cytokines without the presence of the amino acid sequence or polypeptide and by at least 1%, such as by at least 5%, for example by at least 10%, at least 30%, at least 50%, at least 70% and up to 90% or more, as determined by a suitable assay, such as one of the assays mentioned herein and/or used in the Experimental Part).
  • amino acid sequences and polypeptides may all be as further described herein.
  • an amino acid sequence such as the p19+ sequences, p19 ⁇ sequences, p40+ sequences, p40 ⁇ sequences, p35 sequences, IL-27 sequences, IL-12Rb1 sequences, IL-12Rb2 sequences and IL-23 sequences described herein
  • polypeptide such as the—for example multivalent, multispecific and/or biparatopic—constructs described herein that comprise at least one p19+ sequence, p19 ⁇ sequence, p40+ sequence, p40 ⁇ sequence, p35 sequence, IL-27 sequence, IL-12Rb1 sequence, IL-12Rb2 sequence and/or IL-23 sequence
  • it may modulate (as defined herein) heterodimeric cytokine-mediated signalling (as defined herein) in several different ways.
  • the invention in its broadest sense is not limited to any specific explanation, hypothesis or mechanism, it may be that
  • an amino acid sequence or polypeptide of the invention that is directed against a receptor for a heterodimeric cytokine is such that, upon binding to the receptor (e.g. to at least one subunit thereof), it prevents, reduces or inhibits binding of its ligand to said receptor or to at least one subunit thereof (i.e.
  • a suitable assay such as one of the assays mentioned herein and/or used in the Experimental Part.
  • an amino acid sequence or polypeptide of the invention that is directed against a receptor for a heterodimeric cytokine is such that, upon binding to the receptor (e.g. to at least one subunit thereof), allows the ligand to bind to the receptor, but prevents, reduces or inhibits the signalling that is (or normally would be) triggered by binding of the ligand to the receptor or to at least one subunit thereof (i.e.
  • a suitable assay such as one of the assays mentioned herein and/or used in the Experimental Part.
  • an amino acid sequence or polypeptide of the invention that is directed against a receptor for a heterodimeric cytokine is such that, upon binding to the receptor (or to at least one subunit thereof), it prevents, reduces or inhibits activation and/or association of the receptor, and in particular ligand-mediated association of the receptor (i.e.
  • a suitable assay such as one of the assays mentioned herein and/or used in the Experimental Part.
  • an amino acid sequence or polypeptide of the invention that is directed against a receptor for a heterodimeric cytokine is such that, upon binding to the receptor, it prevents, reduces or inhibits the signalling that is triggered by ligand-mediated association of the receptor (i.e. compared to the signalling following binding of the ligand to the receptor without the presence of the amino acid sequence or polypeptide, and by at least 1%, such as by at least 5%, for example by at least 10%, at least 30%, at least 50%, at least 70% and up to 90% or more, as determined by a suitable assay, such as one of the assays mentioned herein and/or used in the Experimental Part).
  • an amino acid sequence or polypeptide of the invention that is directed against a receptor for heterodimeric cytokine is such that, upon binding to the receptor, it prevents, reduces or inhibits heterodimeric cytokine-mediated signalling (as defined herein) associated with said receptor and/or with its ligand (i.e.
  • cytokine-mediated signalling without the presence of the amino acid sequence or polypeptide, and by at least 1%, such as by at least 5%, for example by at least 10%, at least 30%, at least 50%, at least 70% and up to 90% or more, as determined by a suitable assay, such as one of the assays mentioned herein and/or used in the Experimental Part).
  • amino acid sequences and polypeptides may all be as further described herein.
  • the above amino acid sequences and polypeptides of the invention will generally act as antagonists of heterodimeric cytokine-mediated signalling (by which is generally meant herein the signalling associated with the heterodimeric cytokine and/or with the receptor for the heterodimeric cytokine, and in particular the signalling that is caused by binding of a heterodimeric cytokine to its receptor, as well as the biological mechanisms and effects that are triggered by such signalling).
  • the invention also relates to amino acid sequences and polypeptides of the invention that act as agonists of heterodimeric cytokine-mediated signalling.
  • such agonists may be amino acid sequences or polypeptides of the invention that can bind to a receptor for a heterodimeric cytokine (such as the receptor for IL-12, IL-23, IL-27 or IL-35) or to at least one subunit thereof so as to trigger receptor mediated signalling.
  • bispecific polypeptides that comprise at least one amino acid sequence of the invention that is directed against a heterodimeric cytokine (or against at least one subunit thereof) and at least one amino acid sequence of the invention that is directed against a receptor for said heterodimeric cytokine (or against at least one subunit thereof) may act as agonists for heterodimeric cytokine-mediated signalling, as further described herein.
  • such bispecific polypeptides preferably comprise amino acid sequences that do not neutralize binding of the heterodimeric cytokine to the receptor.
  • Such parts, fragments, analogs, mutants, variants, alleles and/or derivatives will usually contain (at least part of) a functional antigen-binding site for binding against heterodimeric cytokines and/or their receptors; and more preferably will be capable of specific binding to heterodimeric cytokines and/or their receptors, and even more preferably capable of binding to heterodimeric cytokines and/or their receptors with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on rate and/or a k off -rate, or alternatively as an IC 50 value, as further described herein) that is as defined herein.
  • fragments or polypeptides of the invention may also be provided by suitably combining (i.e. by linking or genetic fusion) one or more (smaller) parts or fragments as described herein.
  • analogs, mutants, variants, alleles, derivatives have an increased half-life in serum (as further described herein) compared to the amino acid sequence from which they have been derived.
  • an amino acid sequence of the invention may be linked (chemically or otherwise) to one or more groups or moieties that extend the half-life (such as PEG), so as to provide a derivative of an amino acid sequence of the invention with increased half-life.
  • the amino acid sequences of the invention may be amino acid sequences that comprise an immunoglobulin fold or may be amino acid sequences that, under suitable conditions (such as physiological conditions) are capable of forming an immunoglobulin fold (i.e. by folding).
  • suitable conditions such as physiological conditions
  • such an amino acid sequence when properly folded so as to form an immunoglobulin fold, is capable of specific binding (as defined herein) to heterodimeric cytokines and/or their receptors; and more preferably capable of binding to heterodimeric cytokines and/or their receptors with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value, as further described herein) that is as defined herein.
  • parts, fragments, analogs, mutants, variants, alleles and/or derivatives of such amino acid sequences are preferably such that they comprise an immunoglobulin fold or are capable for forming, under suitable conditions, an immunoglobulin fold.
  • the amino acid sequences of the invention may be amino acid sequences that essentially consist of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively); or any suitable fragment of such an amino acid sequence (which will then usually contain at least some of the amino acid residues that form at least one of the CDR's, as further described herein).
  • amino acid sequences of the invention may in particular be an immunoglobulin sequence or a suitable fragment thereof, and more in particular be an immunoglobulin variable domain sequence or a suitable fragment thereof, such as light chain variable domain sequence (e.g. a V L -sequence) or a suitable fragment thereof; or a heavy chain variable domain sequence (e.g. a V H -sequence) or a suitable fragment thereof.
  • immunoglobulin sequence or a suitable fragment thereof such as light chain variable domain sequence (e.g. a V L -sequence) or a suitable fragment thereof; or a heavy chain variable domain sequence (e.g. a V H -sequence) or a suitable fragment thereof.
  • the amino acid sequence of the invention when it is a heavy chain variable domain sequence, it may be a heavy chain variable domain sequence that is derived from a conventional four-chain antibody (such as, without limitation, a V H sequence that is derived from a human antibody) or be a so-called V HH -sequence (as defined herein) that is derived from a so-called “heavy chain antibody” (as defined herein).
  • a conventional four-chain antibody such as, without limitation, a V H sequence that is derived from a human antibody
  • V HH -sequence as defined herein
  • the invention is not limited as to the origin of the amino acid sequence of the invention (or of the nucleotide sequence of the invention used to express it), nor as to the way that the amino acid sequence or nucleotide sequence of the invention is (or has been) generated or obtained.
  • the amino acid sequences of the invention may be naturally occurring amino acid sequences (from any suitable species) or synthetic or semi-synthetic amino acid sequences.
  • the amino acid sequence is a naturally occurring immunoglobulin sequence (from any suitable species) or a synthetic or semi-synthetic immunoglobulin sequence, including but not limited to “humanized” (as defined herein) immunoglobulin sequences (such as partially or fully humanized mouse or rabbit immunoglobulin sequences, and in particular partially or fully humanized V HH sequences or Nanobodies), “camelized” (as defined herein) immunoglobulin sequences, as well as immunoglobulin sequences that have been obtained by techniques such as affinity maturation (for example, starting from synthetic, random or naturally occurring immunoglobulin sequences), CDR grafting, veneering, combining fragments derived from different immunoglobulin sequences, PCR assembly using overlapping primers, and similar techniques for engineering immunoglobulin sequences well known to the skilled person; or any suitable combination of any of the foregoing.
  • affinity maturation for example, starting from synthetic, random or naturally occurring immunoglobulin sequences
  • CDR grafting for example, starting from synthetic, random or
  • nucleotide sequences of the invention may be naturally occurring nucleotide sequences or synthetic or semi-synthetic sequences, and may for example be sequences that are isolated by PCR from a suitable naturally occurring template (e.g. DNA or RNA isolated from a cell), nucleotide sequences that have been isolated from a library (and in particular, an expression library), nucleotide sequences that have been prepared by introducing mutations into a naturally occurring nucleotide sequence (using any suitable technique known per se, such as mismatch PCR), nucleotide sequence that have been prepared by PCR using overlapping primers, or nucleotide sequences that have been prepared using techniques for DNA synthesis known per se.
  • a suitable naturally occurring template e.g. DNA or RNA isolated from a cell
  • nucleotide sequences that have been isolated from a library and in particular, an expression library
  • nucleotide sequences that have been prepared by introducing mutations into a naturally occurring nucleotide sequence using any suitable
  • amino acid sequences of the invention may in particular be a domain antibody (or an amino acid sequence that is suitable for use as a domain antibody), a single domain antibody (or an amino acid sequence that is suitable for use as a single domain antibody), a “dAb” (or an amino acid sequence that is suitable for use as a dAb) or a NanobodyTM (as defined herein, and including but not limited to a V HH sequence); other single variable domains, or any suitable fragment of any one thereof.
  • a domain antibody or an amino acid sequence that is suitable for use as a domain antibody
  • a single domain antibody or an amino acid sequence that is suitable for use as a single domain antibody
  • dAb or an amino acid sequence that is suitable for use as a dAb
  • NanobodyTM as defined herein, and including but not limited to a V HH sequence
  • single domain antibodies or single variable domains can be derived from certain species of shark (for example, the so-called “IgNAR domains”, see for example WO 05/18629).
  • the amino acid sequence of the invention may be a NanobodyTM (as defined herein) or a suitable fragment thereof.
  • NanobodyTM, NanobodiesTM and NanocloneTM are registered trademarks of Ablynx N.V.
  • Nanobodies directed against heterodimeric cytokines and/or their receptors will also be referred to herein as “Nanobodies of the invention”.
  • Nanobodies of the so-called “V H 3 class” i.e. Nanobodies with a high degree of sequence homology to human germline sequences of the V H 3 class such as DP-47, DP-51 or DP-29
  • V H 3 class i.e. Nanobodies with a high degree of sequence homology to human germline sequences of the V H 3 class such as DP-47, DP-51 or DP-29
  • the invention in its broadest sense generally covers any type of Nanobody directed against heterodimeric cytokines and/or their receptors, and for example also covers the Nanobodies belonging to the so-called “V H 4 class” (i.e.
  • Nanobodies in particular V HH sequences and partially humanized Nanobodies
  • V HH sequences and partially humanized Nanobodies can in particular be characterized by the presence of one or more “Hallmark residues” (as described herein) in one or more of the framework sequences (again as further described herein).
  • Nanobody can be defined as an amino acid sequence with the (general) structure
  • FR1 to FR4 refer to framework regions 1 to 4, respectively, and in which CDR1 to CDR3 refer to the complementarity determining regions 1 to 3, respectively, and in which one or more of the Hallmark residues are as further defined herein.
  • Nanobody can be an amino acid sequence with the (general) structure
  • FR1 to FR4 refer to framework regions 1 to 4, respectively, and in which CDR1 to CDR3 refer to the complementarity determining regions 1 to 3, respectively, and in which the framework sequences are as further defined herein.
  • Nanobody can be an amino acid sequence with the (general) structure
  • FR1 to FR4 refer to framework regions 1 to 4, respectively, and in which CDR1 to CDR3 refer to the complementarity determining regions 1 to 3, respectively, and in which:
  • the CDR sequences are generally as further defined herein.
  • the invention also relates to such Nanobodies that can bind to (as defined herein) and/or are directed against heterodimeric cytokines and/or their receptors, to suitable fragments thereof, as well as to polypeptides that comprise or essentially consist of one or more of such Nanobodies and/or suitable fragments.
  • FR1 Sequences Group 1 SEQ ID NO's: 126 to 136 and 2170 to 2175 CDR1 Sequences Group 2: SEQ ID NO's: 378 to 388 and 2215 to 2220 FR2 Sequences Group 3: SEQ ID NO's: 630 to 640 and 2260 to 2265 CDR2 Sequences Group 4: SEQ ID NO's: 882 to 892 and 2305 to 2310 FR3 Sequences Group 5: SEQ ID NO's: 1134 to 1144 and 2350 to 2355 CDR3 Sequences Group 6: SEQ ID NO's: 1386 to 1396 and 2395 to 2400 FR4 Sequences Group 7: SEQ ID NO's: 1638 to 1648 and 2440 to 2445 Framework sequences and CDR sequences derived from p19 ⁇ Nanobodies (see also FIG.
  • FR1 Sequences Group 8 SEQ ID NO's: 137 to 175 and 2187 to 2188 CDR1 Sequences Group 9: SEQ ID NO's: 389 to 427 and 2232 to 2233 FR2 Sequences Group 10: SEQ ID NO's: 641 to 679 and 2277 to 2278 CDR2 Sequences Group 11: SEQ ID NO's: 893 to 931 and 2322 to 2323 FR3 Sequences Group 12: SEQ ID NO's: 1145 to 1183 and 2367 to 2368 CDR3 Sequences Group 13: SEQ ID NO's: 1397 to 1435 and 2412 to 2413 FR4 Sequences Group 14: SEQ ID NO's: 1649 to 1687 and 2457 to 2458 Framework sequences and CDR sequences derived from p40 ⁇ Nanobodies (see also FIG.
  • FR1 Sequences Group 15 SEQ ID NO's: 176 to 181 and 191; 194; 204; 207; 208; 210 to 216; 219; 222; 225; 227; 228; 232; 238; 240; 242; 243; 259; 260; 264; 269 and 2189 to 2194 CDR1 Sequences Group 16: SEQ ID NO's: 428 to 433 and 443; 446; 456; 459; 460; 462 to 468; 471; 474; 477; 479; 480: 484; 490; 492; 494: 495; 511; 512; 516; 521 and 2234 to 2239 FR2 Sequences Group 17: SEQ ID NO's: 680 to 685 and 695; 698; 708; 711; 712; 714 to 720; 723; 726; 729; 731; 732; 736; 742; 744; 746; 747;
  • FR1 Sequences Group 22 SEQ ID NO's: 178; 182; 184; 186; 188; 189; 190; 192; 193; 195; 198 to 201; 203; 205; 206; 209; 217; 218; 220; 221; 223; 224; 226; 229; 230; 231; 233 to 237; 239; 241; 266 and 2195 to 2213 CDR1 Sequences Group 23: SEQ ID NO's: 430; 434; 436; 438; 440; 441; 442; 444; 445; 447; 450 to 453; 455; 457; 458; 461; 469; 470; 472; 473; 475; 476; 478; 481; 482; 483; 485 to 489; 491; 493; 518 and 2240 to 2258 FR2 Sequences Group 24: SEQ ID NO's: 682; 686; 688;
  • FR1 Sequences Group 29 SEQ ID NO's: 183; 185; 187; 196; 197; 202; 244 to 258; 261 to 263; 265; 267; 268; 270 to 273 and 2214 CDR1 Sequences Group 30: SEQ ID NO's: 435; 437; 439; 448; 449; 454; 496 to 510; 513 to 515; 517; 519; 520; 522 to 525 and 2259 FR2 Sequences Group 31: SEQ ID NO's: 687; 689; 691; 700; 701; 706; 748 to 762; 765 to 767; 769; 771; 772; 774 to 777 and 2304 CDR2 Sequences Group 32: SEQ ID NO's: 939; 941; 943; 952; 953; 958; 1000 to 1014; 1017 to 1019; 1021; 1023; 1024; 1026 to 1029 and 2349 FR3
  • FR1 Sequences Group 36 SEQ ID NO's: 274 to 312 CDR1 Sequences Group 37: SEQ ID NO's: 526 to 564 FR2 Sequences Group 38: SEQ ID NO's: 778 to 816 CDR2 Sequences Group 39: SEQ ID NO's: 1030 to 1068 FR3 Sequences Group 40: SEQ ID NO's: 1282 to 1320 CDR3 Sequences Group 41: SEQ ID NO's: 1534 to 1572 FR4 Sequences Group 42: SEQ ID NO's: 1786 to 1824 FR sequences and CDR sequences derived from Nanobodies against IL-12Rb1 (see also FIG.
  • FR1 Sequences Group 43 SEQ ID NO's: 313 to 339 CDR1 Sequences Group 44: SEQ ID NO's: 565 to 591 FR2 Sequences Group 45: SEQ ID NO's: 817 to 843 CDR2 Sequences Group 46: SEQ ID NO's: 1069 to 1095 FR3 Sequences Group 47: SEQ ID NO's: 1321 to 1347 CDR3 Sequences Group 48: SEQ ID NO's: 1573 to 1599 FR4 Sequences Group 49: SEQ ID NO's: 1825 to 1851 FR sequences and CDR sequences derived from Nanobodies against IL-12Rb2 (see also FIG.
  • FR1 Sequences Group 50 SEQ ID NO's: 340 to 360 CDR1 Sequences Group 51: SEQ ID NO's: 592 to 612 FR2 Sequences Group 52: SEQ ID NO's: 844 to 864 CDR2 Sequences Group 53: SEQ ID NO's: 1096 to 1116 FR3 Sequences Group 54: SEQ ID NO's: 1348 to 1368 CDR3 Sequences Group 55: SEQ ID NO's: 1600 to 1620 FR4 Sequences Group 56: SEQ ID NO's: 1852 to 1872 FR sequences and CDR sequences derived from Nanobodies against IL-23R (see also FIG.
  • FR1 Sequences Group 57 SEQ ID NO's: 361 to 377 CDR1 Sequences Group 58: SEQ ID NO's: 613 to 629 FR2 Sequences Group 59: SEQ ID NO's: 865 to 881 CDR2 Sequences Group 60: SEQ ID NO's: 1117 to 1133 FR3 Sequences Group 61: SEQ ID NO's: 1369 to 1385 CDR3 Sequences Group 62: SEQ ID NO's: 1621 to 1637 FR4 Sequences Group 63: SEQ ID NO's: 1873 to 1889
  • the SEQ ID NO's refer to the SEQ ID NO's given in the sequence listing and in FIGS. 20 to 27, respectively.
  • Group name SEQ ID NO's “P19+ sequences” see also FIG.
  • SEQ ID NO's 1890; 1891; 1892; 1893; 1894; 1895; 1896; 1897; 1898; 1899; 1900; 2485; 2486; 2487; 2488; 2489 and/or 2490 “P19 ⁇ sequences” (see also FIG.
  • the invention in some specific aspects provides:
  • Nanobodies of the invention are Nanobodies which can bind (as further defined herein) to and/or are directed against to heterodimeric cytokines and/or their receptors and which:
  • the CDR sequences are generally as further defined herein.
  • Nanobodies may be derived in any suitable manner and from any suitable source, and may for example be naturally occurring V HH sequences (i.e. from a suitable species of Camelid) or synthetic or semi-synthetic amino acid sequences, including but not limited to “humanized” (as defined herein) Nanobodies, “camelized” (as defined herein) immunoglobulin sequences (and in particular camelized heavy chain variable domain sequences), as well as Nanobodies that have been obtained by techniques such as affinity maturation (for example, starting from synthetic, random or naturally occurring immunoglobulin sequences), CDR grafting, veneering, combining fragments derived from different immunoglobulin sequences, PCR assembly using overlapping primers, and similar techniques for engineering immunoglobulin sequences well known to the skilled person; or any suitable combination of any of the foregoing as further described herein.
  • affinity maturation for example, starting from synthetic, random or naturally occurring immunoglobulin sequences
  • CDR grafting for example, starting from synthetic, random or naturally occurring
  • Nanobody when a Nanobody comprises a V HH sequence, said Nanobody may be suitably humanized, as further described herein, so as to provide one or more further (partially or fully) humanized Nanobodies of the invention.
  • a Nanobody when a Nanobody comprises a synthetic or semi-synthetic sequence (such as a partially humanized sequence), said Nanobody may optionally be further suitably humanized, again as described herein, again so as to provide one or more further (partially or fully) humanized Nanobodies of the invention.
  • humanized Nanobodies may be amino acid sequences that are as generally defined for Nanobodies in the previous paragraphs, but in which at least one amino acid residue is present (and in particular, in at least one of the framework residues) that is and/or that corresponds to a humanizing substitution (as defined herein).
  • a humanizing substitution as defined herein.
  • Some particularly preferred humanized Nanobodies of the invention are humanized variants of the Nanobodies of SEQ ID NO's: 1890 to 2141, 2485 to 2490 and/or 2502 to 2529, which may for example, be humanized variants of Nanobodies that are directed against p19 (for example, humanized variants of Nanobodies that are p19+ sequences or p19 ⁇ sequences, for example a humanized variant of one of the Nanobodies shown in FIGS. 20 and 21 , respectively), against p40 (for example humanized variants of Nanobodies that are p40 ⁇ sequences or p40+ sequences, for example a humanized variant of one of the Nanobodies shown in FIGS.
  • p19 for example, humanized variants of Nanobodies that are p19+ sequences or p19 ⁇ sequences, for example a humanized variant of one of the Nanobodies shown in FIGS.
  • p40 for example humanized variants of Nanobodies that are p40 ⁇ sequences or p40+ sequence
  • Nanobodies which can bind (as further defined herein) to heterodimeric cytokines and/or their receptors and which:
  • Another aspect of the invention relates to nanobodies that are directed against p19 from mouse.
  • Some non-limiting examples of such nanobodies are given in SEQ ID NO's: 2491-2501.
  • the invention provides a number of stretches of amino acid residues (i.e. small peptides) that are particularly suited for binding to heterodimeric cytokines and/or their receptors (i.e. to p19, p40, p35, IL-12, IL-23, IL-27, IL-12Rb1, IL-12Rb2, IL-23R, the cognate receptor for IL-12 or the cognate receptor for IL-23, respectively, as further described herein).
  • These stretches of amino acid residues may be present in, and/or may be corporated into, an amino acid sequence of the invention, in particular in such a way that they form (part of) the antigen binding site of an amino acid sequence of the invention.
  • CDR sequences As these stretches of amino acid residues were first generated as CDR sequences of heavy chain antibodies or V HH sequences that were raised against heterodimeric cytokines and/or their receptors (or may be based on and/or derived from such CDR sequences, as further described herein), they will also generally be referred to herein as “CDR sequences” (i.e. as CDR1 sequences, CDR2 sequences and CDR3 sequences, respectively).
  • the invention in its broadest sense is not limited to a specific structural role or function that these stretches of amino acid residues may have in an amino acid sequence of the invention, as long as these stretches of amino acid residues allow the amino acid sequence of the invention to bind to heterodimeric cytokines and/or their receptors.
  • the invention in its broadest sense comprises any amino acid sequence that is capable of binding to heterodimeric cytokines and/or their receptors and that comprises one or more CDR sequences as described herein, and in particular a suitable combination of two or more such CDR sequences, that are suitably linked to each other via one or more further amino acid sequences, such that the entire amino acid sequence forms a binding domain and/or binding unit that is capable of binding to heterodimeric cytokines and/or their receptors.
  • the amino acid sequence of the invention may be an amino acid sequence that comprises at least one amino acid sequence that is chosen from the group consisting of the CDR1 sequences, CDR2 sequences and CDR3 sequences that are described herein from or any suitable combination thereof.
  • Particularly suitable combinations will become clear to the skilled person based on the disclosure herein.
  • an amino acid sequence of the invention may be an amino acid sequence that comprises at least one antigen binding site, wherein said antigen binding site comprises at least one amino acid sequence that is chosen from the group consisting of the CDR1 sequences, CDR2 sequences and CDR3 sequences that are described herein or any suitable combination thereof, such as the combinations that are described herein.
  • the amino acid sequence of the invention may be any amino acid sequence that comprises at least one stretch of amino acid residues, in which said stretch of amino acid residues has an amino acid sequence that corresponds to the sequence of at least one of the CDR sequences described herein.
  • Such an amino acid sequence may or may not comprise an immunoglobulin fold.
  • such an amino acid sequence may be a suitable fragment of an immunoglobulin sequence that comprises at least one such CDR sequence, but that is not large enough to form a (complete) immunoglobulin fold (reference is for example again made to the “Expedite fragments” described in WO 03/050531).
  • such an amino acid sequence may be a suitable “protein scaffold” that comprises least one stretch of amino acid residues that corresponds to such a CDR sequence (i.e. as part of its antigen binding site).
  • Suitable scaffolds for presenting amino acid sequences will be clear to the skilled person, and for example comprise, without limitation, to binding scaffolds based on or derived from immunoglobulins (i.e. other than the immunoglobulin sequences already described herein), protein scaffolds derived from protein A domains (such as AffibodiesTM), tendamistat, fibronectin, lipocalin, CTLA-4, T-cell receptors, designed ankyrin repeats, avimers and PDZ domains (Binz et al., Nat. Biotech 2005, Vol 23:1257), and binding moieties based on DNA or RNA including but not limited to DNA or RNA aptamers (Ulrich et al., Comb Chem High Throughput Screen 2006 9(8):619-32).
  • any amino acid sequence of the invention that comprises one or more of these CDR sequences is preferably such that it can specifically bind (as defined herein) to heterodimeric cytokines and/or their receptors, and more in particular such that it can bind to heterodimeric cytokines and/or their receptors with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value, as further described herein), that is as defined herein.
  • amino acid sequences of the invention may be amino acid sequences that are directed against p19 (which may be “p19+ sequences” or “p19 ⁇ sequences”, both as defined herein); amino acid sequences that are directed against p40 (which may be “p40+ sequences” or “p40 ⁇ sequences”, both as defined herein); amino acid sequences that are directed against p35; amino acid sequences that are directed against IL-23 (which may be amino acid sequences that are directed against p19 or against p40); amino acid sequences that are directed against IL-12 (which may be amino acid sequences that are directed against p35 or against p40); amino acid sequences that are directed against IL-23 (which may be amino acid sequences that are directed against p19 or against p40); amino acid sequences that are directed against IL-27; amino acid sequences that are directed against IL-12Rb1; amino acid sequences that are directed against IL-12Rb2; amino acid sequences that are directed against IL-23R; amino acid sequences that are
  • amino acid sequences may be as further described herein and form further aspects of the invention (as do nucleotide sequences/nucleic acids encoding the same, polypeptides comprising the same and the use of these amino acid sequences in such constructs, methods for preparing the same and uses of the same, all as further described herein).
  • p19+ sequences which generally are defined herein as amino acid sequences of the invention that are directed against (as defined herein) the p19 subunit (as present in for example IL-23), and that are capable of modulating, neutralizing, blocking and/or inhibiting the binding of a heterodimeric cytokine comprising a p19 subunit to its receptor, and in particular capable of are capable of modulating, neutralizing, blocking and/or inhibiting the binding of IL-23 to IL-23R (for example in the alpha-screen assay of Example 19 or 22).
  • P19+ sequences may generally be as further described herein (for example, in terms of affinity, specificity etc. for p19) for amino acid sequences of the invention in general.
  • the p19+ sequences are preferably such that they form or are capable of forming (optionally after suitable folding) a single antigen binding domain or antigen binding unit, and may for example be amino acid sequences that comprise an immunoglobulin fold, amino acid sequences that are comprised of four framework regions and three CDR's, and may in particular be domain antibodies, single domain antibodies, VHH's, “dAb's” or Nanobodies (all as further described herein), or suitable fragments thereof.
  • a p19+ sequence may comprise one or more stretches of amino acid residues chosen from the group consisting of:
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to a)).
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to d)).
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to g)).
  • amino acid sequence preferably comprises one or more stretches of amino acid residues chosen from the group consisting of:
  • At least one of said stretches of amino acid residues forms part of the antigen binding site for binding against p19.
  • a p19+ sequence may comprise two or more stretches of amino acid residues chosen from the group consisting of:
  • amino acid sequence preferably comprises two or more stretches of amino acid residues chosen from the group consisting of:
  • the at least two stretches of amino acid residues again preferably form part of the antigen binding site for binding against p19.
  • a p19+ sequence may comprise three or more stretches of amino acid residues, in which the first stretch of amino acid residues is chosen from the group consisting of:
  • the second stretch of amino acid residues is chosen from the group consisting of:
  • the first stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 2”; the second stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 4”; and the third stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 6”.
  • the at least three stretches of amino acid residues forms part of the antigen binding site for binding against p19.
  • the CDR sequences have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the p19+ sequences listed in Table A-2 and FIG. 20 .
  • This degree of amino acid identity can for example be determined by determining the degree of amino acid identity (in a manner described herein) between said amino acid sequence and one or more of the sequences of SEQ ID NO's: 1890; 1891; 1892; 1893; 1894; 1895; 1896; 1897; 1898; 1899; 1900; 2485; 2486; 2487; 2488; 2489 and/or 2490 (see Table A-2 and FIG. 20 ), in which the amino acid residues that form the framework regions are disregarded. Also, such amino acid sequences of the invention can be as further described herein.
  • amino acid sequences are preferably such that they can specifically bind (as defined herein) to the p19 subunit; and more in particular bind to the p19 subunit with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • amino acid sequence of the invention essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), the amino acid sequence of the invention is preferably such that:
  • CDR1 is chosen from the group consisting of:
  • CDR2 is chosen from the group consisting of:
  • CDR3 is chosen from the group consisting of:
  • such an amino acid sequence of the invention may he such that CDR1 is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 2”; and/or CDR2 is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 4”; and/or CDR3 is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 6”.
  • amino acid sequence of the invention essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), the amino acid sequence of the invention is preferably such that:
  • CDR1 is chosen from the group consisting of:
  • CDR2 is chosen from the group consisting of:
  • CDR3 is chosen from the group consisting of:
  • such an amino acid sequence of the invention may be such that CDR1 is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 2”; and CDR2 is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 4”; and CDR3 is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 6”.
  • amino acid sequences are preferably such that they can specifically bind (as defined herein) to the p19 subunit; and more in particular bind to the p19 subunit with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • the invention relates to an amino acid sequence that essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which the CDR sequences of said amino acid sequence have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the amino acid sequences of SEQ ID NO's: 1890; 1891; 1892; 1893; 1894; 1895; 1896; 1897; 1898; 1899; 1900; 2485; 2486; 2487; 2488; 2489 and/or 2490 (see Table A-2 and FIG.
  • This degree of amino acid identity can for example be determined by determining the degree of amino acid identity (in a manner described herein) between said amino acid sequence and one or more of the sequences of SEQ ID NO's: 1890; 1891; 1892; 1893; 1894; 1895; 1896; 1897; 1898; 1899; 1900; 2485; 2486; 2487; 2488; 2489 and/or 2490 (see Table A-2 and FIG. 20 ), in which the amino acid residues that form the framework regions are disregarded.
  • amino acid sequences of the invention can be as further described herein.
  • p19+ sequences are the amino acid sequences of SEQ ID NO's: 1890; 1891; 1892; 1893; 1894; 1895; 1896; 1897; 1898; 1899; 1900; 2485; 2486; 2487; 2488; 2489 and/or 2490 (see Table A-2 and FIG. 20 ).
  • a p19+ sequence is an amino acid sequence that is directed against (as defined herein) the p19 subunit (as present in for example IL-23) and that are capable of modulating, neutralizing, blocking and/or inhibiting the binding of a heterodimeric cytokine comprising a p19 subunit to its receptor, and in particular capable of are capable of modulating, neutralizing, blocking and/or inhibiting the binding of IL-23 to IL-23R (for example in the alpha-screen assay of Example 19 or 22), and that either
  • a p19+ sequence is chosen from one of the amino acid sequences of SEQ ID NO's: 1890; 1891; 1892; 1893; 1894; 1895; 1896; 1897; 1898; 1899; 1900; 2485; 2486; 2487; 2488; 2489 and/or 2490 (see Table A-2 and FIG. 20 ).
  • p19 ⁇ sequences which generally are defined herein as amino acid sequences of the invention that are directed against (as defined herein) the p19 subunit (as present in for example IL-23), but that (essentially) are not capable of neutralizing or inhibiting the binding of a heterodimeric cytokine comprising a p19 subunit to its receptor (for example, in a suitable alpha-screen assay as exemplified in Examples 19 and 22 for IL-23 and its cognate receptor and for IL-12 and its cognate receptor).
  • P19 ⁇ sequences may generally be as further described herein (for example, in terms of affinity, specificity etc. for p19) for amino acid sequences of the invention in general.
  • the p19 ⁇ sequences are preferably such that they form or are capable of forming (optionally after suitable folding) a single antigen binding domain or antigen binding unit, and may for example be amino acid sequences that comprise an immunoglobulin fold, amino acid sequences that are comprised of four framework regions and three CDR's, and may in particular be domain antibodies, single domain antibodies, VHH's, “dAb's” or Nanobodies (all as further described herein), or suitable fragments thereof.
  • a p19 ⁇ sequence may comprise one or more stretches of amino acid residues chosen from the group consisting of:
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to a)).
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to d)).
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to g)).
  • amino acid sequence preferably comprises one or more stretches of amino acid residues chosen from the group consisting of:
  • At least one of said stretches of amino acid residues forms part of the antigen binding site for binding against p19.
  • a p19 ⁇ sequence may comprise two or more stretches of amino acid residues chosen from the group consisting of:
  • amino acid sequence preferably comprises two or more stretches of amino acid residues chosen from the group consisting of:
  • the at least two stretches of amino acid residues again preferably form part of the antigen binding site for binding against p19.
  • a p19 ⁇ sequence may comprise three or more stretches of amino acid residues, in which the first stretch of amino acid residues is chosen from the group consisting of:
  • the second stretch of amino acid residues is chosen from the group consisting of:
  • the first stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 9”; the second stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 11”; and the third stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 13”.
  • the at least three stretches of amino acid residues forms part of the antigen binding site for binding against p19.
  • the CDR sequences have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the p19 ⁇ sequences listed in Table A-2 and FIG. 21 .
  • This degree of amino acid identity can for example be determined by determining the degree of amino acid identity (in a manner described herein) between said amino acid sequence and one or more of the sequences of SEQ ID NO's: 1901; 1902; 1903; 1904; 1905; 1906; 1907; 1908; 1909; 1910; 1911; 1912; 1913; 1914; 1915; 1916; 1917; 1918; 1919; 1920; 1921; 1922; 1923; 1924; 1925; 1926; 1927; 1928; 1929; 1930; 1931; 1932; 1933; 1934; 1935; 1936; 1937; 1938; 1939; 2502 and/or 2503 (see Table A-2 and FIG. 21 ), in which the amino acid residues that form the framework regions are disregarded. Also, such amino acid sequences of the invention can be as further described herein.
  • amino acid sequences are preferably such that they can specifically bind (as defined herein) to the p19 subunit; and more in particular bind to the p19 subunit with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • amino acid sequence of the invention essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), the amino acid sequence of the invention is preferably such that:
  • CDR1 is chosen from the group consisting of:
  • CDR2 is chosen from the group consisting of:
  • CDR3 is chosen from the group consisting of:
  • such an amino acid sequence of the invention may be such that CDR1 is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 9”; and/or CDR2 is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 11”; and/or CDR3 is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 13”.
  • amino acid sequence of the invention essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), the amino acid sequence of the invention is preferably such that:
  • CDR1 is chosen from the group consisting of:
  • CDR2 is chosen from the group consisting of:
  • CDR3 is chosen from the group consisting of:
  • such an amino acid sequence of the invention may be such that CDR1 is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 9”; and CDR2 is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 11”; and CDR3 is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 13”.
  • amino acid sequences are preferably such that they can specifically bind (as defined herein) to the p19 subunit; and more in particular bind to the p 19 subunit with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • the invention relates to an amino acid sequence that essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which the CDR sequences of said amino acid sequence have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the amino acid sequences of SEQ ID NO's: 1901; 1902; 1903; 1904; 1905; 1906; 1907; 1908; 1909; 1910; 1911; 1912; 1913; 1914; 1915; 1916; 1917; 1918; 1919; 1920; 1921; 1922; 1923; 1924; 1925; 1926; 1927; 1928; 1929; 1930; 1931; 1932; 1933; 1934; 1935; 1936; 1937; 1938; 1939; 2502 and/or 2503 (see Table A-2 and FIG.
  • This degree of amino acid identity can for example be determined by determining the degree of amino acid identity (in a manner described herein) between said amino acid sequence and one or more of the sequences of SEQ ID NO's: 1901; 1902; 1903; 1904; 1905; 1906; 1907; 1908; 1909; 1910; 1911; 1912; 1913; 1914; 1915; 1916; 1917; 1918; 1919; 1920; 1921; 1922; 1923; 1924; 1925; 1926; 1927; 1928; 1929; 1930; 1931; 1932; 1933; 1934; 1935; 1936; 1937; 1938; 1939; 2502 and/or 2503 (see Table A-2 and FIG. 21 ), in which the amino acid residues that form the framework regions are disregarded.
  • amino acid sequences of the invention can be as further described herein.
  • p19 ⁇ sequence are the amino acid sequences of SEQ ID NO's: 1901; 1902; 1903; 1904; 1905; 1906; 1907; 1908; 1909; 1910; 1911; 1912; 1913; 1914; 1915; 1916; 1917; 1918; 1919; 1920; 1921; 1922; 1923; 1924; 1925; 1926; 1927; 1928; 1929; 1930; 1931; 1932; 1933; 1934; 1935; 1936; 1937; 1938; 1939; 2502 and/or 2503 (see Table A-2 and FIG. 21 ).
  • a p19 ⁇ sequence is an amino acid sequence that is directed against (as defined herein) the p19 subunit (as present in for example IL-23) but that (essentially) are not capable of neutralizing or inhibiting the binding of a heterodimeric cytokine comprising a p19 subunit to its receptor (for example, in a suitable alpha-screen assay as exemplified in Examples 19 and 22 for IL-23 and its cognate receptor and for IL-12 and its cognate receptor), and that either:
  • a p19 sequence is chosen from one of the amino acid sequences of SEQ ID NO's: 1901; 1902; 1903; 1904; 1905; 1906; 1907; 1908; 1909; 1910; 1911; 1912; 1913; 1914; 1915; 1916; 1917; 1918; 1919; 1920; 1921; 1922; 1923; 1924; 1925; 1926; 1927; 1928; 1929; 1930; 1931; 1932; 1933; 1934; 1935; 1936; 1937; 1938; 1939; 2502 and/or 2503 (see Table A-2 and FIG. 21 ).
  • p40 ⁇ sequences which generally are defined herein as amino acid sequences of the invention that are directed against (as defined herein) the p40 subunit (as present in for example IL-23 and IL-12), but that (essentially) are not capable of neutralizing or inhibiting the binding of a heterodimeric cytokine comprising a p40 subunit to its receptor (for example, in a suitable alpha-screen assay as exemplified in Examples 19 and 22 for IL-23 and its cognate receptor and for IL-12 and its cognate receptor).
  • P40 ⁇ sequences may generally be as further described herein (for example, in terms of affinity, specificity etc. for p40) for amino acid sequences of the invention in general.
  • the p40 ⁇ sequences are preferably such that they form or are capable of forming (optionally after suitable folding) a single antigen binding domain or antigen binding unit, and may for example be amino acid sequences that comprise an immunoglobulin fold, amino acid sequences that are comprised of four framework regions and three CDR's, and may in particular be domain antibodies, single domain antibodies, VHH's, “dAb's” or Nanobodies (all as further described herein), or suitable fragments thereof.
  • a p40 ⁇ sequence may comprise one or more stretches of amino acid residues chosen from the group consisting of:
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to a)).
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to d)).
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to g)).
  • amino acid sequence preferably comprises one or more stretches of amino acid residues chosen from the group consisting of:
  • At least one of said stretches of amino acid residues forms part of the antigen binding site for binding against p40.
  • a p40 ⁇ sequence may comprise two or more stretches of amino acid residues chosen from the group consisting of:
  • amino acid sequence preferably comprises two or more stretches of amino acid residues chosen from the group consisting of:
  • the at least two stretches of amino acid residues again preferably form part of the antigen binding site for binding against p40.
  • a p40 ⁇ sequence may comprise three or more stretches of amino acid residues, in which the first stretch of amino acid residues is chosen from the group consisting of:
  • the second stretch of amino acid residues is chosen from the group consisting of:
  • the first stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 16”; the second stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 18”; and the third stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 20”.
  • the at least three stretches of amino acid residues forms part of the antigen binding site for binding against p40.
  • the CDR sequences have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the p40 ⁇ sequences listed in Table A-2 and FIG. 22 .
  • This degree of amino acid identity can for example be determined by determining the degree of amino acid identity (in a manner described herein) between said amino acid sequence and one or more of the sequences of SEQ ID NO's: 1940; 1941; 1942; 1943; 1944; 1945; 1955; 1958; 1968; 1971; 1972; 1974; 1975; 1976; 1977; 1978; 1979; 1980; 1983; 1986; 1989; 1991; 1992; 1996; 2002; 2004; 2006; 2007; 2023; 2024; 2028; 2033; 2504; 2505; 2506; 2507; 2508 and/or 2509 (see Table A-2 and FIG. 22 ), in which the amino acid residues that form the framework regions are disregarded. Also, such amino acid sequences of the invention can be as further described herein.
  • amino acid sequences are preferably such that they can specifically bind (as defined herein) to the p40 subunit; and more in particular bind to the p40 subunit with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • amino acid sequence of the invention essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), the amino acid sequence of the invention is preferably such that:
  • CDR1 is chosen from the group consisting of:
  • CDR2 is chosen from the group consisting of:
  • CDR3 is chosen from the group consisting of:
  • such an amino acid sequence of the invention may be such that CDR1 is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 16”; and/or CDR2 is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 18”; and/or CDR3 is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 20”.
  • amino acid sequence of the invention essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), the amino acid sequence of the invention is preferably such that:
  • CDR1 is chosen from the group consisting of:
  • CDR2 is chosen from the group consisting of:
  • CDR3 is chosen from the group consisting of:
  • such an amino acid sequence of the invention may be such that CDR1 is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 16”; and CDR2 is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 18”; and CDR3 is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 20”.
  • amino acid sequences are preferably such that they can specifically bind (as defined herein) to the p40 subunit; and more in particular bind to the p40 subunit with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • the invention relates to an amino acid sequence that essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which the CDR sequences of said amino acid sequence have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the amino acid sequences of SEQ ID NO's: 1940; 1941; 1942; 1943; 1944; 1945; 1955; 1958; 1968; 1971; 1972; 1974; 1975; 1976; 1977; 1978; 1979; 1980; 1983; 1986; 1989; 1991; 1992; 1996; 2002; 2004; 2006; 2007; 2023; 2024; 2028; 2033; 2504; 2505; 2506; 2507; 2508 and/or 2509 (see Table A-2 and FIG.
  • This degree of amino acid identity can for example be determined by determining the degree of amino acid identity (in a manner described herein) between said amino acid sequence and one or more of the sequences of SEQ ID NO's: 1940; 1941; 1942; 1943; 1944; 1945; 1955; 1958; 1968; 1971; 1972; 1974; 1975; 1976; 1977; 1978; 1979; 1980; 1983; 1986; 1989; 1991; 1992; 1996; 2002; 2004; 2006; 2007; 2023; 2024; 2028; 2033; 2504; 2505; 2506; 2507; 2508 and/or 2509 (see Table A-2 and FIG. 22 ), in which the amino acid residues that form the framework regions are disregarded.
  • amino acid sequences of the invention can be as further described herein.
  • p40 ⁇ sequence are the amino acid sequences of SEQ ID NO's: 1940; 1941; 1942; 1943; 1944; 1945; 1955; 1958; 1968; 1971; 1972; 1974; 1975; 1976; 1977; 1978; 1979; 1980; 1983; 1986; 1989; 1991; 1992; 1996; 2002; 2004; 2006; 2007; 2023; 2024; 2028; 2033; 2504; 2505; 2506; 2507; 2508 and/or 2509 (see Table A-2 and FIG. 22 ).
  • a p40 ⁇ sequence is an amino acid sequence that is directed against (as defined herein) the p40 subunit (as present in for example IL-23 and IL-12) but that (essentially) are not capable of neutralizing or inhibiting the binding of a heterodimeric cytokine comprising a p40 subunit to its receptor (for example, in a suitable alpha-screen assay as exemplified in Examples 19 and 22 for IL-23 and its cognate receptor and for IL-12 and its cognate receptor), and that either:
  • a p40 sequence is chosen from one of the amino acid sequences of SEQ ID NO's: 1940; 1941; 1942; 1943; 1944; 1945; 1955; 1958; 1968; 1971; 1972; 1974; 1975; 1976; 1977; 1978; 1979; 1980; 1983; 1986; 1989; 1991; 1992; 1996; 2002; 2004; 2006; 2007; 2023; 2024; 2028; 2033; 2504; 2505; 2506; 2507; 2508 and/or 2509 (see Table A-2 and FIG. 22 ).
  • p40+ sequences which generally are defined herein as amino acid sequences of the invention that are directed against (as defined herein) the p40 subunit (as present in for example IL-23 and IL-12), and that are capable of modulating, neutralizing, blocking and/or inhibiting the binding of a heterodimeric cytokine comprising a p40 subunit to its receptor, and in particular capable of modulating, neutralizing, blocking and/or inhibiting the binding of IL-23 to its (cognate) receptor (in particular, in the alpha-screen assay of described in Example 19 or 22); and/or the binding of IL-12 to its (cognate) receptor (in particular, in the alpha-screen assay of described in Example 19).
  • P40+ sequences may generally be as further described herein (for example, in terms of affinity, specificity etc. for p40) for amino acid sequences of the invention in general.
  • the p40+ sequences are preferably such that they form or are capable of forming (optionally after suitable folding) a single antigen binding domain or antigen binding unit, and may for example be amino acid sequences that comprise an immunoglobulin fold, amino acid sequences that are comprised of four framework regions and three CDR's, and may in particular be domain antibodies, single domain antibodies, VHH's, “dAb's” or Nanobodies (all as further described herein), or suitable fragments thereof.
  • a p40+ sequence may comprise one or more stretches of amino acid residues chosen from the group consisting of:
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to a)).
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to d)).
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to g)).
  • amino acid sequence preferably comprises one or more stretches of amino acid residues chosen from the group consisting of:
  • At least one of said stretches of amino acid residues forms part of the antigen binding site for binding against p40.
  • a p40+ sequence may comprise two or more stretches of amino acid residues chosen from the group consisting of:
  • amino acid sequence preferably comprises two or more stretches of amino acid residues chosen from the group consisting of:
  • the at least two stretches of amino acid residues again preferably form part of the antigen binding site for binding against p40.
  • a p40+ sequence may comprise three or more stretches of amino acid residues, in which the first stretch of amino acid residues is chosen from the group consisting of:
  • the second stretch of amino acid residues is chosen from the group consisting of:
  • the first stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 23”; the second stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 25”; and the third stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 27”.
  • the at least three stretches of amino acid residues forms part of the antigen binding site for binding against p40.
  • the CDR sequences have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the p40+ sequences listed in Table A-2 and FIG. 23 .
  • This degree of amino acid identity can for example be determined by determining the degree of amino acid identity (in a manner described herein) between said amino acid sequence and one or more of the sequences of SEQ ID NO's: 1942; 1946; 1948; 1950; 1952; 1953; 1954; 1956; 1957; 1959; 1962; 1963; 1964; 1965; 1967; 1969; 1970; 1973; 1981; 1982; 1984; 1985; 1987; 1988; 1990; 1993; 1994; 1995; 1997; 1998; 1999; 2000; 2001; 2003; 2005; 2030; 2510; 2511; 2512; 2513; 2514; 2515; 2516; 2517; 2518; 2519; 2520; 2521; 2522; 2523; 2524; 2525; 2526; 2527 and/or 2528 (see Table A-2 and FIG. 23 ), in which the amino acid residues that form the framework regions are disregarded. Also, such amino acid sequences of the invention can be as further described herein.
  • amino acid sequences are preferably such that they can specifically bind (as defined herein) to the p40 subunit; and more in particular bind to the p40 subunit with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • amino acid sequence of the invention essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), the amino acid sequence of the invention is preferably such that:
  • CDR1 is chosen from the group consisting of:
  • CDR2 is chosen from the group consisting of:
  • CDR3 is chosen from the group consisting of:
  • such an amino acid sequence of the invention may be such that CDR1 is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 23”; and/or CDR2 is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 25”; and/or CDR3 is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 27”.
  • amino acid sequence of the invention essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), the amino acid sequence of the invention is preferably such that:
  • CDR1 is chosen from the group consisting of:
  • CDR2 is chosen from the group consisting of:
  • CDR3 is chosen from the group consisting of:
  • such an amino acid sequence of the invention may be such that CDR1 is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 23”; and CDR2 is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 25”; and CDR3 is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 27”.
  • amino acid sequences are preferably such that they can specifically bind (as defined herein) to the p40 subunit; and more in particular bind to the p40 subunit with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • the invention relates to an amino acid sequence that essentially consists of 4 framework regions (FR1 to FR4; respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which the CDR sequences of said amino acid sequence have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the amino acid sequences of SEQ ID NO's: 1942; 1946; 1948; 1950; 1952; 1953; 1954; 1956; 1957; 1959; 1962; 1963; 1964; 1965; 1967; 1969; 1970; 1973; 1981; 1982; 1984; 1985; 1987; 1988; 1990; 1993; 1994; 1995; 1997; 1998; 1999; 2000; 2001; 2003; 2005; 2030; 2510; 2511; 2512; 2513; 2514; 2515; 2516; 2517; 2518; 2519; 2520; 2521; 2522; 2523; 2524; 25
  • This degree of amino acid identity can for example be determined by determining the degree of amino acid identity (in a manner described herein) between said amino acid sequence and one or more of the sequences of SEQ ID NO's: 1942; 1946; 1948; 1950; 1952; 1953; 1954; 1956; 1957; 1959; 1962; 1963; 1964; 1965; 1967; 1969; 1970; 1973; 1981; 1982; 1984; 1985; 1987; 1988; 1990; 1993; 1994; 1995; 1997; 1998; 1999; 2000; 2001; 2003; 2005; 2030; 2510; 2511; 2512; 2513; 2514; 2515; 2516; 2517; 2518; 2519; 2520; 2521; 2522; 2523; 2524; 2525; 2526; 2527 and/or 2528 (see Table A-2 and FIG. 23 ), in which the amino acid residues that form the framework regions are disregarded.
  • amino acid sequences of the invention can be as further described herein.
  • p40+ sequences are the amino acid sequences of SEQ ID NO's: 1942; 1946; 1948; 1950; 1952; 1953; 1954; 1956; 1957; 1959; 1962; 1963; 1964; 1965; 1967; 1969; 1970; 1973; 1981; 1982; 1984; 1985; 1987; 1988; 1990; 1993; 1994; 1995; 1997; 1998; 1999; 2000; 2001; 2003; 2005; 2030; 2510; 2511; 2512; 2513; 2514; 2515; 2516; 2517; 2518; 2519; 2520; 2521; 2522; 2523; 2524; 2525; 2526; 2527 and/or 2528 (see Table A-2 and FIG. 23 ).
  • a p40+ sequence is an amino acid sequence that is directed against (as defined herein) the p40 subunit (as present in for example IL-23 and Il-12) and that are capable of modulating, neutralizing, blocking and/or inhibiting the binding of a heterodimeric cytokine comprising a p40 subunit to its receptor, and in particular capable of modulating, neutralizing, blocking and/or inhibiting the binding of IL-23 to its (cognate) receptor (in particular, in the alpha-screen assay of described in Example 19 or 22); and/or the binding of IL-12 to its (cognate) receptor (in particular, in the alpha-screen assay of described in Example 19), and that either
  • a p40+ sequence is chosen from one of the amino acid sequences of SEQ ID NO's: 1942; 1946; 1948; 1950; 1952; 1953; 1954; 1956; 1957; 1959; 1962; 1963; 1964; 1965; 1967; 1969; 1970; 1973; 1981; 1982; 1984; 1985; 1987; 1988; 1990; 1993; 1994; 1995; 1997; 1998; 1999; 2000; 2001; 2003; 2005; 2030; 2510; 2511; 2512; 2513; 2514; 2515; 2516; 2517; 2518; 2519; 2520; 2521; 2522; 2523; 2524; 2525; 2526; 2527 and/or 2528 (see Table A-2 and FIG. 23 ).
  • p35 sequences which generally are defined herein as amino acid sequences of the invention that are directed against (as defined herein) the p35 subunit (as present in for example IL-12).
  • P35 sequences may generally be as further described herein for amino acid sequences of the invention, i.e. in terms of affinity, specificity etc. for p35.
  • the p35 sequences are preferably such that they form or are capable of forming (optionally after suitable folding) a single antigen binding domain or antigen binding unit, and may for example be amino acid sequences that comprise an immunoglobulin fold, amino acid sequences that are comprised of four framework regions and three CDR's, and may in particular be domain antibodies, single domain antibodies, VHH's, “dAb's” or Nanobodies (all as further described herein), or suitable fragments thereof.
  • a p35 sequence may comprise one or more stretches of amino acid residues chosen from the group consisting of:
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to a)).
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to d)).
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to g)).
  • amino acid sequence preferably comprises one or more stretches of amino acid residues chosen from the group consisting of:
  • At least one of said stretches of amino acid residues forms part of the antigen binding site for binding against p35.
  • a p35 sequence may comprise two or more stretches of amino acid residues chosen from the group consisting of:
  • amino acid sequence preferably comprises two or more stretches of amino acid residues chosen from the group consisting of:
  • the at least two stretches of amino acid residues again preferably form part of the antigen binding site for binding against p35.
  • a p35 sequence may comprise three or more stretches of amino acid residues, in which the first stretch of amino acid residues is chosen from the group consisting of:
  • the second stretch of amino acid residues is chosen from the group consisting of:
  • the first stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 30”; the second stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 32”; and the third stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 34”.
  • the at least three stretches of amino acid residues forms part of the antigen binding site for binding against p35.
  • the CDR sequences have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the p35 sequences listed in Table A-2 and FIG. 24 .
  • This degree of amino acid identity can for example be determined by determining the degree of amino acid identity (in a manner described herein) between said amino acid sequence and one or more of the sequences of SEQ ID NO's: 1947; 1949; 1951; 1960; 1961; 1966; 2008; 2009; 2010; 2011; 2012; 2013; 2014; 2015; 2016; 2017; 2018; 2019; 2020; 2021; 2022; 2025; 2026; 2027; 2029; 2031; 2032; 2034; 2035; 2036; 2037 and/or 2529 (see Table A-2 and FIG. 24 ), in which the amino acid residues that form the framework regions are disregarded. Also, such amino acid sequences of the invention can be as further described herein.
  • amino acid sequences are preferably such that they can specifically bind (as defined herein) to the p35 subunit; and more in particular bind to the p35 subunit with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • amino acid sequence of the invention essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), the amino acid sequence of the invention is preferably such that:
  • CDR1 is chosen from the group consisting of:
  • CDR2 is chosen from the group consisting of:
  • CDR3 is chosen from the group consisting of:
  • such an amino acid sequence of the invention may be such that CDR1 is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 30”; and/or CDR2 is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 32”; and/or CDR3 is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 34”.
  • amino acid sequence of the invention essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), the amino acid sequence of the invention is preferably such that:
  • CDR1 is chosen from the group consisting of:
  • CDR2 is chosen from the group consisting of:
  • CDR3 is chosen from the group consisting of:
  • such an amino acid sequence of the invention may be such that CDR1 is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 30”; and CDR2 is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 32”; and CDR3 is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 34”.
  • amino acid sequences are preferably such that they can specifically bind (as defined herein) to the p35 subunit; and more in particular bind to the p35 subunit with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • the invention relates to an amino acid sequence that essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which the CDR sequences of said amino acid sequence have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the amino acid sequences of SEQ ID NO's: 1947; 1949; 1951; 1960; 1961; 1966; 2008; 2009; 2010; 2011; 2012; 2013; 2014; 2015; 2016; 2017; 2018; 2019; 2020; 2021; 2022; 2025; 2026; 2027; 2029; 2031; 2032; 2034; 2035; 2036; 2037 and/or 2529 (see Table A-2 and FIG.
  • This degree of amino acid identity can for example be determined by determining the degree of amino acid identity (in a manner described herein) between said amino acid sequence and one or more of the sequences of SEQ ID NO's: 1947; 1949; 1951; 1960; 1961; 1966; 2008; 2009; 2010; 2011; 2012; 2013; 2014; 2015; 2016; 2017; 2018; 2019; 2020; 2021; 2022; 2025; 2026; 2027; 2029; 2031; 2032; 2034; 2035; 2036; 2037 and/or 2529 (see Table A-2 and FIG. 24 ), in which the amino acid residues that form the framework regions are disregarded.
  • amino acid sequences of the invention can be as further described herein.
  • p35 sequences are the amino acid sequences of SEQ ID NO's: 1947; 1949; 1951; 1960; 1961; 1966; 2008; 2009; 2010; 2011; 2012; 2013; 2014; 2015; 2016; 2017; 2018; 2019; 2020; 2021; 2022; 2025; 2026; 2027; 2029; 2031; 2032; 2034; 2035; 2036; 2037 and/or 2529 (see Table A-2 and FIG. 24 ).
  • a p35 sequence is an amino acid sequence that is directed against (as defined herein) the p35 subunit (as present in for example IL-12) and that either:
  • a p35 sequence is chosen from one of the amino acid sequences of SEQ ID NO's: 1947; 1949; 1951; 1960; 1961; 1966; 2008; 2009; 2010; 2011; 2012; 2013; 2014; 2015; 2016; 2017; 2018; 2019; 2020; 2021; 2022; 2025; 2026; 2027; 2029; 2031; 2032; 2034; 2035; 2036; 2037 and/or 2529 (see Table A-2 and FIG. 24 ).
  • IL-27 sequences which generally are defined herein as amino acid sequences of the invention that are directed against (as defined herein) IL-27 (either against the EBI3 subunit or the p28 subunit).
  • IL-27 sequences may generally be as further described herein (for example, in terms of affinity, specificity etc. for IL-27 or one of its subunits) for amino acid sequences of the invention in general.
  • the IL-27 sequences are preferably such that they form or are capable of forming (optionally after suitable folding) a single antigen binding domain or antigen binding unit, and may for example be amino acid sequences that comprise an immunoglobulin fold, amino acid sequences that are comprised of four framework regions and three CDR's, and may in particular be domain antibodies, single domain antibodies, VHH's, “dAb's” or Nanobodies (all as further described herein), or suitable fragments thereof.
  • an IL-27 sequence may comprise one or more stretches of amino acid residues chosen from the group consisting of:
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to a)).
  • Optional Condition 1 Optional Condition II and/or Optional Condition III (all as defined herein) may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to d)).
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to g)).
  • amino acid sequence preferably comprises one or more stretches of amino acid residues chosen from the group consisting of:
  • At least one of said stretches of amino acid residues forms part of the antigen binding site for binding against IL-27.
  • an IL-27 sequence may comprise two or more stretches of amino acid residues chosen from the group consisting of:
  • amino acid sequence preferably comprises two or more stretches of amino acid residues chosen from the group consisting of:
  • the at least two stretches of amino acid residues again preferably form part of the antigen binding site for binding against IL-27.
  • an IL-27 sequence may comprise three or more stretches of amino acid residues, in which the first stretch of amino acid residues is chosen from the group consisting of:
  • the second stretch of amino acid residues is chosen from the group consisting of:
  • the first stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 37”; the second stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 39”; and the third stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 41”.
  • the at least three stretches of amino acid residues forms part of the antigen binding site for binding against IL-27.
  • the CDR sequences have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the IL-27 sequences listed in Table A-2 and FIG. 26 .
  • This degree of amino acid identity can for example be determined by determining the degree of amino acid identity (in a manner described herein) between said amino acid sequence and one or more of the sequences of SEQ ID NO's: 2038; 2039; 2040; 2041; 2042; 2043; 2044; 2045; 2046; 2047; 2048; 2049; 2050; 2051; 2052; 2053; 2054; 2055; 2056; 2057; 2058; 2059; 2060; 2061; 2062; 2063; 2064; 2065; 2066; 2067; 2068; 2069; 2070; 2071; 2072; 2073; 2074; 2075 and/or 2076 (see Table A-2 and FIG. 26 ), in which the amino acid residues that form the framework regions are disregarded. Also, such amino acid sequences of the invention can be as further described herein.
  • amino acid sequences are preferably such that they can specifically bind (as defined herein) to IL-27 (i.e. to the EBI3 subunit or the p28 subunit); and more in particular bind to IL-27 with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • affinity suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • amino acid sequence of the invention essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), the amino acid sequence of the invention is preferably such that:
  • CDR1 is chosen from the group consisting of:
  • CDR2 is chosen from the group consisting of:
  • CDR3 is chosen from the group consisting of:
  • such an amino acid sequence of the invention may be such that CDR1 is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 37”; and/or CDR2 is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 39”; and/or CDR3 is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 41”.
  • amino acid sequence of the invention essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), the amino acid sequence of the invention is preferably such that:
  • CDR1 is chosen from the group consisting of:
  • CDR2 is chosen from the group consisting of:
  • CDR3 is chosen from the group consisting of:
  • such an amino acid sequence of the invention may be such that CDR1 is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 37”; and CDR2 is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 39”; and CDR3 is chosen from the group consisting of the amino acid sequences from the “CDR3. Sequences Group 41”.
  • amino acid sequences are preferably such that they can specifically bind (as defined herein) to IL-27; and more in particular bind to IL-27 with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • the invention relates to an amino acid sequence that essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which the CDR sequences of said amino acid sequence have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the amino acid sequences of SEQ ID NO's: 2038; 2039; 2040; 2041; 2042; 2043; 2044; 2045; 2046; 2047; 2048; 2049; 2050; 2051; 2052; 2053; 2054; 2055; 2056; 2057; 2058; 2059; 2060; 2061; 2062; 2063; 2064; 2065; 2066; 2067; 2068; 2069; 2070; 2071; 2072; 2073; 2074; 2075 and/or 2076 (FR1 to FR4, respectively) and
  • This degree of amino acid identity can for example be determined by determining the degree of amino acid identity (in a manner described herein) between said amino acid sequence and one or more of the sequences of SEQ ID NO's: 2038; 2039; 2040; 2041; 2042; 2043; 2044; 2045; 2046; 2047; 2048; 2049; 2050; 2051; 2052; 2053; 2054; 2055; 2056; 2057; 2058; 2059; 2060; 2061; 2062; 2063; 2064; 2065; 2066; 2067; 2068; 2069; 2070; 2071; 2072; 2073; 2074; 2075 and/or 2076 (see Table A-2 and FIG. 26 ), in which the amino acid residues that form the framework regions are disregarded.
  • amino acid sequences of the invention can be as further described herein.
  • an IL-27 sequence is an amino acid sequence that is directed against (as defined herein) IL-27 and that either:
  • an IL-27 sequence is chosen from one of the amino acid sequences of SEQ ID NO's: 2038; 2039; 2040; 2041; 2042; 2043; 2044; 2045; 2046; 2047; 2048; 2049; 2050; 2051; 2052; 2053; 2054; 2055; 2056; 2057; 2058; 2059; 2060; 2061; 2062; 2063; 2064; 2065; 2066; 2067; 2068; 2069; 2070; 2071; 2072; 2073; 2074; 2075 and/or 2076 (see Table A-2 and FIG. 26 ).
  • IL-12Rb1 sequences are defined herein as amino acid sequences of the invention that are directed against (as defined herein) the IL-12Rb1 subunit, as present in both the receptor for IL-12 as well as the receptor for IL-23 (and thereby, against both the receptor for IL-12 as well as IL-23).
  • IL-12Rb1 sequences may generally be as further described herein (for example, in terms of affinity, specificity etc. for IL-12Rb1) for amino acid sequences of the invention in general. Also, as described herein for the amino acid sequences of the invention, the IL-
  • Rb1 sequences are preferably such that they form or are capable of forming (optionally after suitable folding) a single antigen binding domain or antigen binding unit, and may for example be amino acid sequences that comprise an immunoglobulin fold, amino acid sequences that are comprised of four framework regions and three CDR's, and may in particular be domain antibodies, single domain antibodies, VHH's, “dAb's” or Nanobodies (all as further described herein), or suitable fragments thereof.
  • an IL-l2Rb1 sequence may comprise one or more stretches of amino acid residues chosen from the group consisting of:
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to a)).
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to d)).
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to g)).
  • amino acid sequence preferably comprises one or more stretches of amino acid residues chosen from the group consisting of:
  • At least one of said stretches of amino acid residues forms part of the antigen binding site for binding against IL-I2Rb1.
  • an IL-12Rb1 sequence may comprise two or more stretches of amino acid residues chosen from the group consisting of:
  • amino acid sequence preferably comprises two or more stretches of amino acid residues chosen from the group consisting of:
  • the at least two stretches of amino acid residues again preferably form part of the antigen binding site for binding against IL-12Rb1.
  • an IL-12Rb1 sequence may comprise three or more stretches of amino acid residues, in which the first stretch of amino acid residues is chosen from the group consisting of:
  • the first stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 44”; the second stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 46”; and the third stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 48”.
  • the at least three stretches of amino acid residues forms part of the antigen binding site for binding against IL-12Rb1.
  • the CDR sequences have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the IL-12Rb1 sequences listed in Table A-2 and FIG. 27 .
  • This degree of amino acid identity can for example be determined by determining the degree of amino acid identity (in a manner described herein) between said amino acid sequence and one or more of the sequences of SEQ ID NO's: 2077; 2078; 2079; 2080; 2081; 2082; 2083; 2084; 2085; 2086; 2087; 2088; 2089; 2090; 2091; 2092; 2093; 2094; 2095; 2096; 2097; 2098; 2099; 2100; 2101; 2102 and/or 2103 (see Table A-2 and FIG. 27 ), in which the amino acid residues that form the framework regions are disregarded. Also, such amino acid sequences of the invention can be as further described herein.
  • amino acid sequences are preferably such that they can specifically bind (as defined herein) to the IL-12Rb1 subunit (i.e. as present in the receptor for IL-12 and/or in the receptor for IL-23); and more in particular bind to the IL-12Rb1 subunit with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • amino acid sequence of the invention essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), the amino acid sequence of the invention is preferably such that:
  • such an amino acid sequence of the invention may be such that CDR1 is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 44”; and/or CDR2 is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 46”; and/or CDR3 is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 48”.
  • amino acid sequence of the invention essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), the amino acid sequence of the invention is preferably such that:
  • such an amino acid sequence of the invention may be such that CDR1 is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 44”; and CDR2 is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 46”; and CDR3 is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 48”.
  • amino acid sequences are preferably such that they can specifically bind (as defined herein) to IL-12Rb1; and more in particular bind to IL-12Rb1 with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • the invention relates to an amino acid sequence that essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which the CDR sequences of said amino acid sequence have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the amino acid sequences of SEQ ID NO's: 2077; 2078; 2079; 2080; 2081; 2082; 2083; 2084; 2085; 2086; 2087; 2088; 2089; 2090; 2091; 2092; 2093; 2094; 2095; 2096; 2097; 2098; 2099; 2100; 2101; 2102 and/or 2103 (see Table A-2 and FIG.
  • This degree of amino acid identity can for example be determined by determining the degree of amino acid identity (in a manner described herein) between said amino acid sequence and one or more of the sequences of SEQ ID NO's: 2077; 2078; 2079; 2080; 2081; 2082; 2083; 2084; 2085; 2086; 2087; 2088; 2089; 2090; 2091; 2092; 2093; 2094; 2095; 2096; 2097; 2098; 2099; 2100; 2101; 2102 and/or 2103 (see Table A-2 and FIG. 27 ), in which the amino acid residues that form the framework regions are disregarded.
  • amino acid sequences of the invention can be as further described herein.
  • an IL-12Rb1 sequence is an amino acid sequence that is directed against (as defined herein) IL-12Rb1 and that either:
  • an IL-12Rb1 sequence is chosen from one of the amino acid sequences of SEQ ID NO's: 2077; 2078; 2079; 2080; 2081; 2082; 2083; 2084; 2085; 2086; 2087; 2088; 2089; 2090; 2091; 2092; 2093; 2094; 2095; 2096; 2097; 2098; 2099; 2100; 2101; 2102 and/or 2103 (see Table A-2 and FIG. 27 ).
  • IL-12Rb2 sequences which generally are defined herein as amino acid sequences of the invention that are directed against (as defined herein) the IL-12Rb2 subunit, for example as present in the receptor for 1L-12 (and thereby against the receptor for IL-12).
  • IL-12Rb2 sequences may generally be as further described herein (for example, in terms of affinity, specificity etc. for IL-12Rb2) for amino acid sequences of the invention in general.
  • the IL-12Rb2 sequences are preferably such that they form or are capable of forming (optionally after suitable folding) a single antigen binding domain or antigen binding unit, and may for example be amino acid sequences that comprise an immunoglobulin fold, amino acid sequences that are comprised of four framework regions and three CDR's, and may in particular be domain antibodies, single domain antibodies, VHH's, “dAb's” or Nanobodies (all as further described herein), or suitable fragments thereof.
  • an IL-12Rb2 sequence may comprise one or more stretches of amino acid residues chosen from the group consisting of:
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to a)).
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to d)).
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to g)).
  • amino acid sequence preferably comprises one or more stretches of amino acid residues chosen from the group consisting of:
  • At least one of said stretches of amino acid residues forms part of the antigen binding site for binding against IL-12Rb2.
  • an IL-12Rb2 sequence may comprise two or more stretches of amino acid residues chosen from the group consisting of:
  • amino acid sequence preferably comprises two or more stretches of amino acid residues chosen from the group consisting of:
  • the at least two stretches of amino acid residues again preferably form part of the antigen binding site for binding against IL-12Rb2.
  • an 11-12Rb2 sequence may comprise three or more stretches of amino acid residues, in which the first stretch of amino acid residues is chosen from the group consisting of:
  • the first stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 51”; the second stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 53”; and the third stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 55”.
  • the at least three stretches of amino acid residues forms part of the antigen binding site for binding against IL-12Rb2.
  • the CDR sequences have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the IL-12Rb2 sequences listed in Table A-2 and FIG. 28 .
  • This degree of amino acid identity can for example be determined by determining the degree of amino acid identity (in a manner described herein) between said amino acid sequence and one or more of the sequences of SEQ ID NO's: 2104; 2105; 2106; 2107; 2108; 2109; 2110; 2111; 2112; 2113; 2114; 2115; 2116; 2117; 2118; 2119; 2120; 2121; 2122; 2123 and/or 2124 (see Table A-2 and FIG. 28 ), in which the amino acid residues that form the framework regions are disregarded. Also, such amino acid sequences of the invention can be as further described herein.
  • amino acid sequences are preferably such that they can specifically bind (as defined herein) to the IL-12Rb2 subunit (i.e. as present in the receptor for IL-12); and more in particular bind to the IL-12Rb2 subunit with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • amino acid sequence of the invention essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), the amino acid sequence of the invention is preferably such that:
  • such an amino acid sequence of the invention may be such that CDR1 is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 51”; and/or CDR2 is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 53”; and/or CDR3 is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 55”.
  • amino acid sequence of the invention essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), the amino acid sequence of the invention is preferably such that:
  • such an amino acid sequence of the invention may be such that CDR1 is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 51”; and CDR2 is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 53”; and CDR3 is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 55”.
  • amino acid sequences are preferably such that they can specifically bind (as defined herein) to IL-12Rb2; and more in particular bind to IL-12Rb2 with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • the invention relates to an amino acid sequence that essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which the CDR sequences of said amino acid sequence have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the amino acid sequences of SEQ ID NO's: 2104; 2105; 2106; 2107; 2108; 2109; 2110; 2111; 2112; 2113; 2114; 2115; 2116; 2117; 2118; 2119; 2120; 2121; 2122; 2123 and/or 2124 (see Table A-2 and FIG.
  • This degree of amino acid identity can for example be determined by determining the degree of amino acid identity (in a manner described herein) between said amino acid sequence and one or more of the sequences of SEQ ID NO's: 2104; 2105; 2106; 2107; 2108; 2109; 2110; 2111; 2112; 2113; 2114; 2115; 2116; 2117; 2118; 2119; 2120; 2121; 2122; 2123 and/or 2124 (see Table A-2 and FIG. 28 ), in which the amino acid residues that form the framework regions are disregarded.
  • amino acid sequences of the invention can be as further described herein.
  • IL-12Rb2 sequences are the amino acid sequences of SEQ ID NO's: 2104; 2105; 2106; 2107; 2108; 2109; 2110; 2111; 2112; 2113; 2114; 2115; 2116; 2117; 2118; 2119; 2120; 2121; 2122; 2123 and/or 2124 (see Table A-2 and FIG. 28 ).
  • an IL-12Rb2 sequence is an amino acid sequence that is directed against (as defined herein) IL-12Rb2 and that either:
  • an IL-12Rb2 sequence is chosen from one of the amino acid sequences of SEQ ID NO's: 2104; 2105; 2106; 2107; 2108; 2109; 2110; 2111; 2112; 2113; 2114; 2115; 2116; 2117; 2118; 2119; 2120; 2121; 2122; 2123 and/or 2124 (see Table A-2 and FIG. 28 ).
  • IL-23R sequences which generally are defined herein as amino acid sequences of the invention that are directed against (as defined herein) the IL-23R subunit, for example as present in the (cognate) receptor for IL-23 (and thereby against the receptor for IL-23).
  • IL-23R sequences may generally be as further described herein (for example, in terms of affinity, specificity etc. for IL-23R) for amino acid sequences of the invention in general.
  • the IL-23R sequences are preferably such that they form or are capable of forming (optionally after suitable folding) a single antigen binding domain or antigen binding unit, and may for example be amino acid sequences that comprise an immunoglobulin fold, amino acid sequences that are comprised of four framework regions and three CDR's, and may in particular be domain antibodies, single domain antibodies, VHH's, “dAb's” or Nanobodies (all as further described herein), or suitable fragments thereof.
  • an IL-23R sequence may comprise one or more stretches of amino acid residues chosen from the group consisting of:
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to a)).
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to d)).
  • Optional Condition I, Optional Condition II and/or Optional Condition III may apply to said amino acid sequence (i.e. compared to the original amino acid sequence according to g)).
  • amino acid sequence preferably comprises one or more stretches of amino acid residues chosen from the group consisting of:
  • At least one of said stretches of amino acid residues forms part of the antigen binding site for binding against IL-23R.
  • an IL-23R sequence may comprise two or more stretches of amino acid residues chosen from the group consisting of
  • amino acid sequence preferably comprises two or more stretches of amino acid residues chosen from the group consisting of:
  • the at least two stretches of amino acid residues again preferably form part of the antigen binding site for binding against IL-23R.
  • an IL-23R sequence may comprise three or more stretches of amino acid residues, in which the first stretch of amino acid residues is chosen from the group consisting of:
  • the first stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 58”; the second stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 60”; and the third stretch of amino acid residues is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 62”.
  • the at least three stretches of amino acid residues forms part of the antigen binding site for binding against IL-23R.
  • the CDR sequences have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the IL-23R sequences listed in Table A-2 and FIG. 29 .
  • This degree of amino acid identity can for example be determined by determining the degree of amino acid identity (in a manner described herein) between said amino acid sequence and one or more of the sequences of SEQ ID NO's: 2125; 2126; 2127; 2128; 2129; 2130; 2131; 2132; 2133; 2134; 2135; 2136; 2137; 2138; 2139; 2140 and/or 2141 (see Table A-2 and FIG. 29 ), in which the amino acid residues that form the framework regions are disregarded. Also, such amino acid sequences of the invention can be as further described herein.
  • amino acid sequences are preferably such that they can specifically bind (as defined herein) to the IL-23R subunit (i.e. as present in the receptor for IL-23); and more in particular bind to the IL-23R subunit with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • amino acid sequence of the invention essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), the amino acid sequence of the invention is preferably such that:
  • such an amino acid sequence of the invention may be such that CDR1 is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 58”; and/or CDR2 is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 60”; and/or CDR3 is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 62”.
  • amino acid sequence of the invention essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), the amino acid sequence of the invention is preferably such that:
  • such an amino acid sequence of the invention may be such that CDR1 is chosen from the group consisting of the amino acid sequences from the “CDR1 Sequences Group 58”; and CDR2 is chosen from the group consisting of the amino acid sequences from the “CDR2 Sequences Group 60”; and CDR3 is chosen from the group consisting of the amino acid sequences from the “CDR3 Sequences Group 62”.
  • amino acid sequences are preferably such that they can specifically bind (as defined herein) to IL-23R; and more in particular bind to IL-23R with an affinity (suitably measured and/or expressed as a K D -value (actual or apparent), a K A -value (actual or apparent), a k on -rate and/or a k off -rate, or alternatively as an IC 50 value (all as further) described herein) that is as defined herein.
  • the invention relates to an amino acid sequence that essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which the CDR sequences of said amino acid sequence have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the amino acid sequences of SEQ ID NO's: 2125; 2126; 2127; 2128; 2129; 2130; 2131; 2132; 2133; 2134; 2135; 2136; 2137; 2138; 2139; 2140 and/or 2141 (see Table A-2 and FIG.
  • This degree of amino acid identity can for example be determined by determining the degree of amino acid identity (in a manner described herein) between said amino acid sequence and one or more of the sequences of SEQ ID NO's: 2125; 2126; 2127; 2128; 2129; 2130; 2131; 2132; 2133; 2134; 2135; 2136; 2137; 2138; 2139; 2140 and/or 2141 (see Table A-2 and FIG. 29 ), in which the amino acid residues that form the framework regions are disregarded.
  • amino acid sequences of the invention can be as further described herein.
  • an IL-23R sequence is an amino acid sequence that is directed against (as defined herein) IL-23R, and that either:
  • an IL-23R sequence is chosen from one of the amino acid sequences of SEQ ID NO's: 2125; 2126; 2127; 2128; 2129; 2130; 2131; 2132; 2133; 2134; 2135; 2136; 2137; 2138; 2139; 2140 and/or 2141 (see Table A-2 and FIG. 29 ).
  • the invention relates to:
  • amino acid sequences, proteins or polypeptides can be as further described herein.
  • the invention also relates to nucleotide sequences/nucleic acids encoding the same, to preparations and formulations comprising the same, to methods for producing the same and to uses of the same, all as further described herein.
  • the framework sequences may be any suitable framework sequences, and examples of suitable framework sequences will be clear to the skilled person, for example on the basis the standard handbooks and the further disclosure and prior art mentioned herein.
  • the framework sequences are preferably (a suitable combination of) immunoglobulin framework sequences or framework sequences that have been derived from immunoglobulin framework sequences (for example, by humanization or camelization).
  • the framework sequences may be framework sequences derived from a light chain variable domain (e.g. a V L -sequence) and/or from a heavy chain variable domain (e.g. a V H -sequence).
  • the framework sequences are either framework sequences that have been derived from V HH -sequence (in which said framework sequences may optionally have been partially or fully humanized) or are conventional V H sequences that have been camelized (as defined herein).
  • the framework sequences are preferably such that the amino acid sequence of the invention is a domain antibody (or an amino acid sequence that is suitable for use as a domain antibody); is a single domain antibody (or an amino acid sequence that is suitable for use as a single domain antibody); is a “dAb” (or an amino acid sequence that is suitable for use as a dAb); or is a NanobodyTM (including but not limited to V HH sequence).
  • suitable framework sequences will be clear to the skilled person, for example on the basis the standard handbooks and the further disclosure and prior art mentioned herein.
  • the framework sequences present in the amino acid sequences of the invention may contain one or more of Hallmark residues (as defined herein), such that the amino acid sequence of the invention is a NanobodyTM.
  • Hallmark residues as defined herein
  • the amino acid sequence of the invention is a NanobodyTM.
  • fragments that contain one or more CDR sequences, suitably flanked by and/or linked via one or more framework sequences (for example, in the same order as these CDR's and framework sequences may occur in the full-sized immunoglobulin sequence from which the fragment has been derived).
  • Such fragments may also again be such that they comprise or can form an immunoglobulin fold, or alternatively be such that they do not comprise or cannot form an immunoglobulin fold.
  • such a fragment comprises a single CDR sequence as described herein (and in particular a CDR3 sequence), that is flanked on each side by (part of) a framework sequence (and in particular, part of the framework sequence(s) that, in the immunoglobulin sequence from which the fragment is derived, are adjacent to said CDR sequence.
  • a CDR3 sequence may be preceded by (part of) a FR3 sequence and followed by (part of) a FR4 sequence).
  • Such a fragment may also contain a disulphide bridge, and in particular a disulphide bridge that links the two framework regions that precede and follow the CDR sequence, respectively (for the purpose of forming such a disulphide bridge, cysteine residues that naturally occur in said framework regions may be used, or alternatively cysteine residues may be synthetically added to or introduced into said framework regions).
  • a disulphide bridge for the purpose of forming such a disulphide bridge, cysteine residues that naturally occur in said framework regions may be used, or alternatively cysteine residues may be synthetically added to or introduced into said framework regions.
  • the invention relates to a compound or construct, and in particular a protein or polypeptide (also referred to herein as a “compound of the invention” or “polypeptide of the invention”, respectively) that comprises or essentially consists of one or more amino acid sequences of the invention (or suitable fragments thereof), and optionally further comprises one or more other groups, residues, moieties or binding units.
  • a protein or polypeptide also referred to herein as a “compound of the invention” or “polypeptide of the invention”, respectively
  • such further groups, residues, moieties, binding units or amino acid sequences may or may not provide further functionality to the amino acid sequence of the invention (and/or to the compound or construct in which it is present) and may or may not modify the properties of the amino acid sequence of the invention.
  • such further groups, residues, moieties or binding units may be one or more additional amino acid sequences, such that the compound or construct is a (fusion) protein or (fusion) polypeptide.
  • said one or more other groups, residues, moieties or binding units are immunoglobulin sequences.
  • said one or more other groups, residues, moieties or binding units are chosen from the group consisting of domain antibodies, amino acid sequences that are suitable for use as a domain antibody, single domain antibodies, amino acid sequences that are suitable for use as a single domain antibody, “dAb”'s, amino acid sequences that are suitable for use as a dAb, or Nanobodies.
  • such groups, residues, moieties or binding units may for example be chemical groups, residues, moieties, which may or may not by themselves be biologically and/or pharmacologically active.
  • such groups may be linked to the one or more amino acid sequences of the invention so as to provide a “derivative” of an amino acid sequence or polypeptide of the invention, as further described herein.
  • compounds or constructs that comprises or essentially consists of one or more derivatives as described herein, and optionally further comprises one or more other groups, residues, moieties or binding units, optionally linked via one or more linkers.
  • said one or more other groups, residues, moieties or binding units are amino acid sequences.
  • the one or more amino acid sequences of the invention and the one or more groups, residues, moieties or binding units may be linked directly to each other and/or via one or more suitable linkers or spacers.
  • the linkers may also be amino acid sequences, so that the resulting compound or construct is a fusion (protein) or fusion (polypeptide).
  • the compounds or polypeptides of the invention can generally be prepared by a method which comprises at least one step of suitably linking the one or more amino acid sequences of the invention to the one or more further groups, residues, moieties or binding units, optionally via the one or more suitable linkers, so as to provide the compound or polypeptide of the invention.
  • Polypeptides of the invention can also be prepared by a method which generally comprises at least the steps of providing a nucleic acid that encodes a polypeptide of the invention, expressing said nucleic acid in a suitable manner, and recovering the expressed polypeptide of the invention. Such methods can be performed in a manner known per se, which will be clear to the skilled person, for example on the basis of the methods and techniques further described herein.
  • a compound of the invention or a polypeptide of the invention may have an increased half-life, compared to the corresponding amino acid sequence of the invention.
  • Some preferred, but non-limiting examples of such compounds and polypeptides will become clear to the skilled person based on the further disclosure herein, and for example comprise amino acid sequences or polypeptides of the invention that have been chemically modified to increase the half-life thereof (for example, by means of pegylation); amino acid sequences of the invention that comprise at least one additional binding site for binding to a serum protein (such as serum albumin; see for example EP 0 368 684 B1, page 4); or polypeptides of the invention that comprise at least one amino acid sequence of the invention that is linked to at least one moiety (and in particular at least one amino acid sequence) that increases the half-life of the amino acid sequence of the invention.
  • polypeptides of the invention that comprise such half-life extending moieties or amino acid sequences will become clear to the skilled person based on the further disclosure herein; and for example include, without limitation, polypeptides in which the one or more amino acid sequences of the invention are suitable linked to one or more serum proteins or fragments thereof (such as (human) serum albumin or suitable fragments thereof) or to one or more binding units that can bind to serum proteins (such as, for example, domain antibodies, amino acid sequences that are suitable for use as a domain antibody, single domain antibodies, amino acid sequences that are suitable for use as a single domain antibody, “dAb”'s, amino acid sequences that are suitable for use as a dAb, or Nanobodies that can bind to serum proteins such as serum albumin (such as human serum albumin), serum immunoglobulins such as IgG, or transferrine; reference is made to the further description and references mentioned herein); polypeptides in which an amino acid sequence of the invention is linked to an Fc portion (such as a human
  • the compounds or polypeptides of the invention with increased half-life preferably have a half-life that is at least 1.5 times, preferably at least 2 times, such as at least 5 times, for example at least 10 times or more than 20 times, greater than the half-life of the corresponding amino acid sequence of the invention per se.
  • the compounds or polypeptides of the invention with increased half-life may have a half-life that is increased with more than 1 hours, preferably more than 2 hours, more preferably more than 6 hours, such as more than 12 hours, or even more than 24, 48 or 72 hours, compared to the corresponding amino acid sequence of the invention per se.
  • such compounds or polypeptides of the invention have a serum half-life that is increased with more than 1 hours, preferably more than 2 hours, more preferably more than 6 hours, such as more than 12 hours, or even more than 24, 48 or 72 hours, compared to the corresponding amino acid sequence of the invention per se.
  • such compounds or polypeptides of the invention exhibit a serum half-life in human of at least about 12 hours, preferably at least 24 hours, more preferably at least 48 hours, even more preferably at least 72 hours or more.
  • compounds or polypeptides of the invention may have a half-life of at least 5 days (such as about 5 to 10 days), preferably at least 9 days (such as about 9 to 14 days), more preferably at least about 10 days (such as about 10 to 15 days), or at least about 11 days (such as about 11 to 16 days), more preferably at least about 12 days (such as about 12 to 18 days or more), or more than 14 days (such as about 14 to 19 days).
  • polypeptides of the invention are:
  • polypeptides suitable for use in the invention of amino acid sequences of the invention (or nucleotide sequences/nucleic acids comprising the same) that can be used in such polypeptides (such as the p19+ sequences, p19 ⁇ sequences, p40 + sequences, p40 ⁇ sequences, p35 sequences, IL-27 sequences, IL-12Rb1 sequences, IL-12Rb2 sequences and IL-23 sequences described herein), and how polypeptides of the invention can be constructed and produced using such amino acid sequences of the invention will be clear to the skilled person based on the disclosure herein.
  • the invention in another aspect, relates to a nucleic acid that encodes an amino acid sequence of the invention (such as a (single) domain antibody and/or Nanobody of the invention) or a polypeptide of the invention (or a suitable fragment thereof).
  • a nucleic acid will also be referred to herein as a “nucleic acid of the invention” and may for example be in the form of a genetic construct, as further described herein.
  • the invention in another aspect, relates to a host or host cell that expresses (or that under suitable circumstances is capable of expressing) an amino acid sequence of the invention (such as a (single) domain antibody and/or Nanobody of the invention) and/or a polypeptide of the invention; and/or that contains a nucleic acid of the invention.
  • an amino acid sequence of the invention such as a (single) domain antibody and/or Nanobody of the invention
  • a polypeptide of the invention and/or that contains a nucleic acid of the invention.
  • the invention further relates to a product or composition containing or comprising at least one amino acid sequence of the invention, at least one polypeptide of the invention (or a suitable fragment thereof) and/or at least one nucleic acid of the invention, and optionally one or more further components of such compositions known per se, i.e. depending on the intended use of the composition.
  • a product or composition may for example be a pharmaceutical composition (as described herein), a veterinary composition or a product or composition for diagnostic use (as also described herein).
  • the invention also relates to the use of an amino acid sequence, Nanobody or polypeptide of the invention, or of a composition comprising the same, in (methods or compositions for) modulating (as defined herein) a heterodimeric cytokine, a receptor for a heterodimeric cytokine and/or heterodimeric cytokine-mediated signalling (as defined herein), either in vitro (e.g. in an in vitro or cellular assay) or in vivo (e.g.
  • the invention also relates to methods for modulating (as defined herein) a heterodimeric cytokine, a receptor for a heterodimeric cytokine and/or heterodimeric cytokine-mediated signalling (as defined herein), either in vitro (e.g. in an in vitro or cellular assay) or in vivo (e.g.
  • a method comprises at least the step of contacting a heterodimeric cytokine and/or a receptor of a heterodimeric cytokine with at least one amino acid sequence, Nanobody or polypeptide of the invention, or with a composition comprising the same, in a manner and in an amount suitable to modulate the heterodimeric cytokine, the receptor and/or heterodimeric cytokine-mediated signalling.
  • the invention also relates to the use of an one amino acid sequence, Nanobody or polypeptide of the invention in the preparation of a composition (such as, without limitation, a pharmaceutical composition or preparation as further described herein) for modulating (as defined herein) a heterodimeric cytokine, a receptor for a heterodimeric cytokine and/or heterodimeric cytokine-mediated signalling (as defined herein), either in vitro (e.g. in an in vitro or cellular assay) or in vivo (e.g.
  • cytokines and their receptors in an a single cell or multicellular organism, and in particular in a mammal, and more in particular in a human being, such as in a human being that is at risk of or suffers from a disease or disorder associated with heterodimeric cytokines and their receptors).
  • the invention further relates to methods for preparing or generating the amino acid sequences, compounds, constructs, polypeptides, nucleic acids, host cells, products and compositions described herein. Some preferred but non-limiting examples of such methods will become clear from the further description herein.
  • these methods may comprise the steps of:
  • the set, collection or library of amino acid sequences may be any suitable set, collection or library of amino acid sequences.
  • the set, collection or library of amino acid sequences may be a set, collection or library of immunoglobulin sequences (as described herein), such as a na ⁇ ve set, collection or library of immunoglobulin sequences; a synthetic or semi-synthetic set, collection or library of immunoglobulin sequences; and/or a set, collection or library of immunoglobulin sequences that have been subjected to affinity maturation.
  • the set, collection or library of amino acid sequences may be a set, collection or library of heavy chain variable domains (such as V H domains or V HH domains) or of light chain variable domains.
  • the set, collection or library of amino acid sequences may be a set, collection or library of domain antibodies or single domain antibodies, or may be a set, collection or library of amino acid sequences that are capable of functioning as a domain antibody or single domain antibody.
  • the set, collection or library of amino acid sequences may be an immune set, collection or library of immunoglobulin sequences, for example derived from a mammal that has been suitably immunized with heterodimeric cytokines and/or their receptors or with a suitable antigenic determinant based thereon or derived therefrom, such as an antigenic part, fragment, region, domain, loop or other epitope thereof.
  • said antigenic determinant may be an extracellular part, region, domain, loop or other extracellular epitope(s).
  • the set, collection or library of amino acid sequences may be displayed on a phage, phagemid, ribosome or suitable micro-organism (such as yeast), such as to facilitate screening.
  • suitable methods, techniques and host organisms for displaying and screening (a set, collection or library of) amino acid sequences will be clear to the person skilled in the art, for example on the basis of the further disclosure herein. Reference is also made to the review by Hoogenboom in Nature Biotechnology, 23, 9, 1105-1116 (2005).
  • the method for generating amino acid sequences comprises at least the steps of:
  • the collection or sample of cells may for example be a collection or sample of B-cells.
  • the sample of cells may be derived from a mammal that has been suitably immunized with heterodimeric cytokines and/or their receptors or with a suitable antigenic determinant based thereon or derived therefrom, such as an antigenic part, fragment, region, domain, loop or other epitope thereof.
  • said antigenic determinant may be an extracellular part, region, domain, loop or other extracellular epitope(s).
  • step b) is preferably performed using a flow cytometry technique such as FACS.
  • FACS flow cytometry technique
  • the method for generating an amino acid sequence directed against heterodimeric cytokines and/or their receptors may comprise at least the steps of:
  • the set, collection or library of nucleic acid sequences encoding amino acid sequences may for example be a set, collection or library of nucleic acid sequences encoding a na ⁇ ve set, collection or library of immunoglobulin sequences; a set, collection or library of nucleic acid sequences encoding a synthetic or semi-synthetic set, collection or library of immunoglobulin sequences; and/or a set, collection or library of nucleic acid sequences encoding a set, collection or library of immunoglobulin sequences that have been subjected to affinity maturation.
  • the set, collection or library of nucleic acid sequences may encode a set, collection or library of heavy chain variable domains (such as V H domains or V HH domains) or of light chain variable domains.
  • the set, collection or library of nucleic acid sequences may encode a set, collection or library of domain antibodies or single domain antibodies, or a set, collection or library of amino acid sequences that are capable of functioning as a domain antibody or single domain antibody.
  • the set, collection or library of amino acid sequences may be an immune set, collection or library of nucleic acid sequences, for example derived from a mammal that has been suitably immunized with heterodimeric cytokines and/or their receptors or with a suitable antigenic determinant based thereon or derived therefrom, such as an antigenic part, fragment, region, domain, loop or other epitope thereof.
  • said antigenic determinant may be an extracellular part, region, domain, loop or other extracellular epitope(s).
  • the set, collection or library of nucleic acid sequences may for example encode an immune set, collection or library of heavy chain variable domains or of light chain variable domains.
  • the set, collection or library of nucleotide sequences may encode a set, collection or library of V HH sequences.
  • the set, collection or library of nucleotide sequences may be displayed on a phage, phagemid, ribosome or suitable micro-organism (such as yeast), such as to facilitate screening.
  • suitable methods, techniques and host organisms for displaying and screening (a set, collection or library of) nucleotide sequences encoding amino acid sequences will be clear to the person skilled in the art, for example on the basis of the further disclosure herein. Reference is also made to the review by Hoogenboom in Nature Biotechnology, 23, 9, 1105-1116 (2005).
  • the invention also relates to amino acid sequences that are obtained by the above methods, or alternatively by a method that comprises the one of the above methods and in addition at least the steps of determining the nucleotide sequence or amino acid sequence of said immunoglobulin sequence; and of expressing or synthesizing said amino acid sequence in a manner known per se, such as by expression in a suitable host cell or host organism or by chemical synthesis.
  • one or more amino acid sequences of the invention may be suitably humanized (or alternatively camelized); and/or the amino acid sequence(s) thus obtained may be linked to each other or to one or more other suitable amino acid sequences (optionally via one or more suitable linkers) so as to provide a polypeptide of the invention.
  • nucleic acid sequence encoding an amino acid sequence of the invention may be suitably humanized (or alternatively camelized) and suitably expressed; and/or one or more nucleic acid sequences encoding an amino acid sequence of the invention may be linked to each other or to one or more nucleic acid sequences that encode other suitable amino acid sequences (optionally via nucleotide sequences that encode one or more suitable linkers), after which the nucleotide sequence thus obtained may be suitably expressed so as to provide a polypeptide of the invention.
  • the invention further relates to applications and uses of the amino acid sequences, polypeptides, nucleic acids, host cells, products and compositions described herein, as well as to methods for the prevention and/or treatment for diseases and disorders associated with heterodimeric cytokines and/or their receptors.
  • a protein or polypeptide comprising at least one amino acid sequence that is directed against the p35 subunit and at least one amino acid sequence that is directed against the p40 subunit, optionally linked via a suitable linker, and optionally comprising one or more further amino acid sequences, binding domains and/or binding units.
  • amino acid sequences of the invention such as (single) domain antibodies and/or Nanobodies
  • constructs, polypeptides and proteins described herein in all their various and/or preferred aspects, preferably have 1050 values as follows:
  • Nanobodies generally offer certain advantages (outlined herein) compared to “dAb's” or similar (single) domain antibodies or immunoglobulin sequences, which advantages are also provided by the Nanobodies of the invention.
  • advantages outlined herein
  • similar (single) domain antibodies or immunoglobulin sequences which advantages are also provided by the Nanobodies of the invention.
  • the more general aspects of the teaching below can also be applied (either directly or analogously) to other amino acid sequences of the invention.
  • an amino acid residue is referred to in this Table as being either charged or uncharged at pH 6.0 to 7.0 does not reflect in any way on the charge said amino acid residue may have at a pH lower than 6.0 and/or at a pH higher than 7.0; the amino acid residues mentioned in the Table can be either charged and/or uncharged at such a higher or lower pH, as will be clear to the skilled person.
  • the charge of a His residue is greatly dependant upon even small shifts in pH, but a His residu can generally be considered essentially uncharged at a pH of about 6.5.
  • the degree of sequence identity between two or more nucleotide sequences may be calculated using a known computer algorithm for sequence alignment such as NCBI Blast v2.0, using standard settings.
  • nucleotide sequence with the greatest number of nucleotides will be taken as the “first” nucleotide sequence, and the other nucleotide sequence will be taken as the “second” nucleotide sequence;
  • the degree of sequence identity between two amino acid sequences may be calculated using a known computer algorithm, such as those mentioned above for determining the degree of sequence identity for nucleotide sequences, again using standard settings.
  • amino acid sequence with the greatest number of amino acid residues will be taken as the “first” amino acid sequence, and the other amino acid sequence will be taken as the “second” amino acid sequence.
  • amino acid substitutions can generally be described as amino acid substitutions in which an amino acid residue is replaced with another amino acid residue of similar chemical structure and which has little or essentially no influence on the function, activity or other biological properties of the polypeptide.
  • Such conservative amino acid substitutions are well known in the art, for example from WO 04/037999, GB-A-4 357 768, WO 98/49185, WO 00/46383 and WO 01/09300; and (preferred) types and/or combinations of such substitutions may be selected on the basis of the pertinent teachings from WO 04/037999 as well as WO 98/49185 and from the further references cited therein.
  • Such conservative substitutions preferably are substitutions in which one amino acid within the following groups (a)-(e) is substituted by another amino acid residue within the same group: (a) small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr, Pro and Gly; (b) polar, negatively charged residues and their (uncharged) amides: Asp, Asn, Glu and Gln; (c) polar, positively charged residues: His, Arg and Lys; (d) large aliphatic, nonpolar residues: Met, Leu, Ile, Val and Cys; and (e) aromatic residues: Phe, Tyr and Trp.
  • Particularly preferred conservative substitutions are as follows: Ala into Gly or into Ser; Arg into Lys; Asn into Gin or into His; Asp into Glu; Cys into Ser; Gln into Asn; Glu into Asp; Gly into Ala or into Pro; His into Asn or into Gin; Ile into Leu or into Val; Leu into Ile or into Val; Lys into Arg, into Gln or into Glu; Met into Leu, into Tyr or into Ile; Phe into Met, into Leu or into Tyr; Ser into Thr; Thr into Ser; Trp into Tyr; Tyr into Trp; and/or Phe into Val, into Ile or into Leu.
  • Any amino acid substitutions applied to the polypeptides described herein may also be based on the analysis of the frequencies of amino acid variations between homologous proteins of different species developed by Schulz et al., Principles of Protein Structure, Springer-Verlag, 1978, on the analyses of structure forming potentials developed by Chou and Fasman, Biochemistry 13: 211, 1974 and Adv. Enzymol., 47: 45-149, 1978, and on the analysis of hydrophobicity patterns in proteins developed by Eisenberg et al., Proc. Nad. Acad Sci. USA 81: 140-144, 1984; Kyte & Doolittle; J Molec. Biol. 157: 105-132, 198 1, and Goldman et al., Ann. Rev.
  • the dissociation constant may be the actual or apparent dissociation constant, as will be clear to the skilled person. Methods for determining the dissociation constant will be clear to the skilled person, and for example include the techniques mentioned herein. In this respect, it will also be clear that it may not be possible to measure dissociation constants of more then 10 ⁇ 4 moles/liter or 10 ⁇ 3 moles/liter (e,g, of 10 ⁇ 2 moles/liter).
  • the affinity denotes the strength or stability of a molecular interaction.
  • the affinity is commonly given as by the K D , or dissociation constant, which has units of mol/liter (or M).
  • the affinity can also be expressed as an association constant, K A , which equals 1/K D and has units of (mol/liter) ⁇ 1 (or M ⁇ 1 ).
  • K A association constant
  • the K D for biological interactions which are considered meaningful are typically in the range of 10 ⁇ 10 M (0.1 nM) to 10 ⁇ 5 M (10000 nM). The stronger an interaction is, the lower is its K D .
  • the off-rate k off has units s ⁇ 1 (where s is the SI unit notation of second).
  • the on-rate k on has units M ⁇ 1 s ⁇ 1 .
  • the on-rate may vary between 10 2 M ⁇ 1 s ⁇ 1 to about 10 7 M ⁇ 1 s ⁇ 1 , approaching the diffusion-limited association rate constant for bimolecular interactions.
  • the affinity of a molecular interaction between two molecules can be measured via different techniques known per se, such as the well known surface plasmon resonance (SPR) biosensor technique (see for example Ober et al., Intern. Immunology, 13, 1551-1559, 2001) where one molecule is immobilized on the biosensor chip and the other molecule is passed over the immobilized molecule under flow conditions yielding k on , k off measurements and hence K D (or K A ) values.
  • SPR surface plasmon resonance
  • This can for example be performed using the well-known Biacore instruments (see for example Example 12 or 20),
  • the measured K D may correspond to the apparent K D if the measuring process somehow influences the intrinsic binding affinity of the implied molecules for example by artefacts related to the coating on the biosensor of one molecule. Also, an apparent K D may be measured if one molecule contains more than one recognition sites for the other molecule. In such situation the measured affinity may be affected by the avidity of the interaction by the two molecules.
  • K D K D and apparent K D should be treated with equal importance or relevance.
  • the experienced scientist may judge it to be convenient to determine the binding affinity relative to some reference molecule.
  • a reference molecule C that is known to bind to B and that is suitably labelled with a fluorophore or chromophore group or other chemical moiety, such as biotin for easy detection in an ELISA or FACS (Fluorescent activated cell sorting) or other format (the fluorophore for fluorescence detection, the chromophore for light absorption detection, the biotin for streptavidin-mediated ELISA detection).
  • the reference molecule C is kept at a fixed concentration and the concentration of A is varied for a given concentration or amount of B.
  • an IC 50 value is obtained corresponding to the concentration of A at which the signal measured for C in absence of A is halved.
  • K D ref the K D of the reference molecule
  • the measurement of the IC 50 is performed in a consistent way (e.g. keeping c ref fixed) for the binders that are compared, the strength or stability of a molecular interaction can be assessed by the IC 50 and this measurement is judged as equivalent to K D or to apparent K D throughout this text.
  • the half-life can be expressed using parameters such as the t1/2-alpha, t1/2-beta and the area under the curve (AUC).
  • an “increase in half-life” refers to an increase in any one of these parameters, such as any two of these parameters, or essentially all three these parameters.
  • increase in half-life or “increased half-life” in particular refers to an increase in the t1/2-beta, either with or without an increase in the t1/2-alpha and/or the AUC or both.
  • V1 steady state volume
  • AUC AUC corrected for actual dose administered
  • “modulating” may also involve effecting a change (which may either be an increase or a decrease) in affinity, avidity, specificity and/or selectivity of a target or antigen for one or more of its ligands, binding partners, partners for association into a homomultimeric or heteromultimeric form, or substrates; and/or effecting a change (which may either be an increase or a decrease) in the sensitivity of the target or antigen for one or more conditions in the medium or surroundings in which the target or antigen is present (such as pH, ion strength, the presence of co-factors, etc.), compared to the same conditions but without the presence of the construct of the invention.
  • this may again be determined in any suitable manner and/or using any suitable assay known per se, depending on the target or antigen involved.
  • Modulating may also mean effecting a change (i.e. an activity as an agonist, as an antagonist or as a reverse agonist, respectively, depending on the target or antigen and the desired biological or physiological effect) with respect to one or more biological or physiological mechanisms, effects, responses, functions, pathways or activities in which the target or antigen (or in which its substrate(s), ligand(s) or pathway(s) are involved, such as its signalling pathway or metabolic pathway and their associated biological or physiological effects) is involved.
  • a change i.e. an activity as an agonist, as an antagonist or as a reverse agonist, respectively, depending on the target or antigen and the desired biological or physiological effect
  • a change i.e. an activity as an agonist, as an antagonist or as a reverse agonist, respectively, depending on the target or antigen and the desired biological or physiological effect
  • a change i.e. an activity as an agonist, as an antagonist or as a reverse agonist, respectively, depending on the target or antigen and the desired biological or physiological effect
  • an action as an agonist or antagonist may be such that an intended biological or physiological activity is increased or decreased, respectively, by at least 1%, preferably at least 5%, such as at least 10% or at least 25%, for example by at least 50%, at least 60%, at least 70%, at least 80%, or 90% or more, compared to the biological or physiological activity in the same assay under the same conditions but without the presence of the construct of the invention.
  • Modulating may for example also involve allosteric modulation of the target or antigen; and/or reducing or inhibiting the binding of the target or antigen to one of its substrates or ligands and/or competing with a natural ligand, substrate for binding to the target or antigen. Modulating may also involve activating the target or antigen or the mechanism or pathway in which it is involved. Modulating may for example also involve effecting a change in respect of the folding or confirmation of the target or antigen, or in respect of the ability of the target or antigen to fold, to change its confirmation (for example, upon binding of a ligand), to associate with other (sub)units, or to disassociate. Modulating may for example also involve effecting a change in the ability of the target or antigen to transport other compounds or to serve as a channel for other compounds (such as ions).
  • Modulating may be reversible or irreversible, but for pharmaceutical and pharmacological purposes will usually be in a reversible manner.
  • the Biacore machine for example the Biacore 3000
  • the target protein is coupled to a CM5 Biacore chip using standard amine coupling chemistry to generate a surface that is coated with the target.
  • 200-800 resonance units of the target would be coupled to the chip (an amount that gives easily measurable levels of binding but that is readily saturable by the concentrations of test reagent being used).
  • test amino acid sequences (termed A* and B*) to be assessed for their ability to cross-block each other are mixed at a one to one molar ratio of binding sites in a suitable buffer to create the test mixture.
  • concentrations on a binding site basis the molecular weight of an amino acid sequence is assumed to be the total molecular weight of the amino acid sequence divided by the number of target binding sites on that amino acid sequence.
  • concentration of each amino acid sequence in the test mix should be high enough to readily saturate the binding sites for that amino acid sequence on the target molecules captured on the Biacore chip.
  • the amino acid sequences in the mixture are at the same molar concentration (on a binding basis) and that concentration would typically be between 1.00 and 1.5 micromolar (on a binding site basis).
  • A* and B* in these solutions should be in the same buffer and at the same concentration as in the test mix.
  • the test mixture is passed over the target-coated.
  • Biacore chip and the total amount of binding recorded.
  • the chip is then treated in such a way as to remove the bound amino acid sequences without damaging the chip-bound target. Typically this is done by treating the chip with 30 mM HCl for 60 seconds.
  • the solution of A* alone is then passed over the target-coated surface and the amount of binding recorded.
  • the chip is again treated to remove all of the bound amino acid sequences without damaging the chip-bound target.
  • the solution of B* alone is then passed over the target-coated surface and the amount of binding recorded.
  • a cross-blocking amino acid sequence or other binding agent according to the invention is one which will bind to the target in the above Biacore cross-blocking assay such that during the assay and in the presence of a second amino acid sequence or other binding agent of the invention the recorded binding is between 80% and 0.1% (e.g. 80% to 4%) of the maximum theoretical binding, specifically between 75% and 0.1% (e.g.
  • the Biacore assay described above is a primary assay used to determine if amino acid sequences or other binding agents cross-block each other according to the invention. On rare occasions particular amino acid sequences or other binding agents may not bind to target coupled via amine chemistry to a CM5 Biacore chip (this usually occurs when the relevant binding site on target is masked or destroyed by the coupling to the chip). In such cases cross-blocking can be determined using a tagged version of the target, for example a N-terminal His-tagged version.
  • an anti-His amino acid sequence would be coupled to the Biacore chip and then the His-tagged target would be passed over the surface of the chip and captured by the anti-His amino acid sequence.
  • the cross blocking analysis would be carried out essentially as described above, except that after each chip regeneration cycle, new His-tagged target would be loaded back onto the anti-His amino acid sequence coated surface.
  • C-terminal His-tagged target could alternatively be used.
  • various other tags and tag binding protein combinations that are known in the art could be used for such a cross-blocking analysis (e.g. HA tag with anti-HA antibodies; FLAG tag with anti-FLAG antibodies; biotin tag with streptavidin).
  • the general principal of the assay is to have an amino acid sequence or binding agent that is directed against the target coated onto the wells of an ELISA plate. An excess amount of a second, potentially cross-blocking, anti-target amino acid sequence is added in solution (i.e. not bound to the ELISA plate). A limited amount of the target is then added to the wells. The coated amino acid sequence and the amino acid sequence in solution compete for binding of the limited number of target molecules.
  • the plate is washed to remove excess target that has not been bound by the coated amino acid sequence and to also remove the second, solution phase amino acid sequence as well as any complexes formed between the second, solution phase amino acid sequence and target.
  • the amount of bound target is then measured using a reagent that is appropriate to detect the target.
  • An amino acid sequence in solution that is able to cross-block the coated amino acid sequence will be able to cause a decrease in the number of target molecules that the coated amino acid sequence can bind relative to the number of target molecules that the coated amino acid sequence can bind in the absence of the second, solution phase, amino acid sequence.
  • the first amino acid sequence e.g.
  • an Ab-X is chosen to be the immobilized amino acid sequence, it is coated onto the wells of the ELISA plate, after which the plates are blocked with a suitable blocking solution to minimize non-specific binding of reagents that are subsequently added.
  • An excess amount of the second amino acid sequence, i.e. Ab-Y is then added to the ELISA plate such that the moles of Ab-Y [target] binding sites per well are at least 10 fold higher than the moles of Ab-X [target] binding sites that were used, per well, during the coating of the ELISA plate.
  • [target] is then added such that the moles of [target] added per well are at least 25-fold lower than the moles of Ab-X [target] binding sites that were used for coating each well.
  • the background signal for the assay is defined as the signal obtained in wells with the coated amino acid sequence (in this case Ab-X), second solution phase amino acid sequence (in this case Ab-Y), [target] buffer only (i.e. no target) and target detection reagents.
  • the positive control signal for the assay is defined as the signal obtained in wells with the coated amino acid sequence (in this case Ab-X), second solution phase amino acid sequence buffer only (i.e. no second solution phase amino acid sequence), target and target detection reagents.
  • the ELISA assay may be run in such a manner so as to have the positive control signal be at least 6 times the background signal.
  • the cross-blocking assay may to be run in two formats: 1) format 1 is where Ab-X is the amino acid sequence that is coated onto the ELISA plate and Ab-Y is the competitor amino acid sequence that is in solution and 2) format 2 is where Ab-Y is the amino acid sequence that is coated onto the ELISA plate and Ab-X is the competitor amino acid sequence that is in solution.
  • Ab-X and Ab-Y are defined as cross-blocking if, either in format 1 or in format 2, the solution phase anti-target amino acid sequence is able to cause a reduction of between 60% and 100%, specifically between 70% and 100%, and more specifically between 80% and 100%, of the target detection signal ⁇ i.e. the amount of target bound by the coated amino acid sequence) as compared to the target detection signal obtained in the absence of the solution phase anti-target amino acid sequence (i.e. the positive control wells).
  • variable domains present in naturally occurring heavy chain antibodies will also be referred to as “V HH domains”, in order to distinguish them from the heavy chain variable domains that are present in conventional 4-chain antibodies (which will be referred to hereinbelow as “V H domains”) and from the light chain variable domains that are present in conventional 4-chain antibodies (which will be referred to hereinbelow as “V L domains”).
  • V HH domains have a number of unique structural characteristics and functional properties which make isolated V HH domains (as well as Nanobodies based thereon, which share these structural characteristics and functional properties with the naturally occurring V HH domains) and proteins containing the same highly advantageous for use as functional antigen-binding domains or proteins.
  • V HH domains which have been “designed” by nature to functionally bind to an antigen without the presence of, and without any interaction with, a light chain variable domain
  • Nanobodies can function as a single, relatively small, functional antigen-binding structural unit, domain or protein.
  • V HH domains from the V H and V L domains of conventional 4-chain antibodies, which by themselves are generally not suited for practical application as single antigen-binding proteins or domains, but need to be combined in some form or another to provide a functional antigen-binding unit (as in for example conventional antibody fragments such as Fab fragments; in ScFv's fragments, which consist of a V H domain covalently linked to a V L domain).
  • a functional antigen-binding unit as in for example conventional antibody fragments such as Fab fragments; in ScFv's fragments, which consist of a V H domain covalently linked to a V L domain.
  • V HH domains and Nanobodies as single antigen-binding proteins or as antigen-binding domains (i.e. as part of a larger protein or polypeptide) offers a number of significant advantages over the use of conventional V H and V L domains, scFv's or conventional antibody fragments (such as Fab- or F(ab′) 2 -fragments):
  • the invention provides Nanobodies against heterodimeric cytokines and/or their receptors, and in particular Nanobodies against heterodimeric cytokines and/or their receptors from a warm-blooded animal, and more in particular Nanobodies against heterodimeric cytokines and/or their receptors from a mammal, and especially Nanobodies against human heterodimeric cytokines and/or their receptors; as well as proteins and/or polypeptides comprising at least one such Nanobody.
  • the invention provides Nanobodies against heterodimeric cytokines and/or their receptors, and proteins and/or polypeptides comprising the same, that have improved therapeutic and/or pharmacological properties and/or other advantageous properties (such as, for example, improved ease of preparation and/or reduced costs of goods), compared to conventional antibodies against heterodimeric cytokines and/or their receptors or fragments thereof, compared to constructs that could be based on such conventional antibodies or antibody fragments (such as Fab′ fragments, F(ab′) 2 fragments, ScFv constructs, “diabodies” and other multispecific constructs (see for example the review by Holliger and Hudson, Nat Biotechnol.
  • the Nanobodies of the invention are preferably in essentially isolated form (as defined herein), or form part of a protein or polypeptide of the invention (as defined herein), which may comprise or essentially consist of one or more Nanobodies of the invention and which may optionally further comprise one or more further amino acid sequences (all optionally linked via one or more suitable linkers).
  • the one or more amino acid sequences of the invention may be used as a binding unit in such a protein or polypeptide, which may optionally contain one or more further amino acid sequences that can serve as a binding unit (i.e.
  • such a protein or polypeptide may comprise or essentially consist of one or more Nanobodies of the invention and optionally one or more (other) Nanobodies (i.e. directed against other targets than heterodimeric cytokines and/or their receptors), all optionally linked via one or more suitable linkers, so as to provide a monovalent, multivalent or multispecific Nanobody construct, respectively, as further described herein.
  • Such proteins or polypeptides may also be in essentially isolated form (as defined herein).
  • the binding site for binding against heterodimeric cytokines and/or their receptors is preferably formed by the CDR sequences.
  • a Nanobody of the invention may also, and in addition to the at least one binding site for binding against heterodimeric cytokines and/or their receptors, contain one or more further binding sites for binding against other antigens, proteins or targets.
  • a Nanobody of the invention when a Nanobody of the invention (or a polypeptide of the invention comprising the same) is intended for administration to a subject (for example for therapeutic and/or diagnostic purposes as described herein), it is preferably directed against human heterodimeric cytokines and/or their receptors; whereas for veterinary purposes, it is preferably directed against heterodimeric cytokines and/or their receptors from the species to be treated.
  • a Nanobody of the invention may or may not be cross-reactive (i.e.
  • heterodimeric cytokines and/or their receptors from two or more species of mammal, such as against human heterodimeric cytokines and/or their receptors and heterodimeric cytokines and/or their receptors from at least one of the species of mammal mentioned herein).
  • the Nanobodies of the invention may generally be directed against any antigenic determinant, epitope, part, domain, subunit or confirmation (where applicable) of heterodimeric cytokines and/or their receptors, such as an interaction site (as defined herein) or a site, antigenic determinant, epitope, part, domain that is not an interaction site.
  • the amino acid sequence and structure of a Nanobody can be considered—without however being limited thereto—to be comprised of four framework regions or “FR's” (or sometimes also referred to as “FW's”), which are referred to in the art and herein as “Framework region 1” or “FR1”; as “Framework region 2” or “FR2”; as “Framework region 3” or “FR3”; and as “Framework region 4” or “FR4”, respectively; which framework regions are interrupted by three complementary determining regions or “CDR's”, which are referred to in the art as “Complementarity Determining Region 1” or “CDR1”; as “Complementarity Determining Region 2” or “CDR2”; and as “Complementarity Determining Region 3” or “CDR3”, respectively.
  • Some preferred framework sequences and CDR's (and combinations thereof) that are present in the Nanobodies of the invention are as described herein. Other suitable CDR sequences
  • the CDR sequences present in) the Nanobodies of the invention are such that:
  • the CDR sequences present in) the Nanobodies of the invention are such that: a monovalent Nanobody of the invention (or a polypeptide that contains only one Nanobody of the invention) is preferably such that it will bind to heterodimeric cytokines and/or their receptors with an affinity less than 500 nM, preferably less than 200 nM, more preferably less than 10 nM, such as less than 500 pM.
  • the affinity of the Nanobody of the invention against heterodimeric cytokines and/or their receptors can be determined in a manner known per se, for example using the general techniques for measuring K D .
  • Nanobodies of the invention and of polypeptides comprising the same
  • IC50 values for binding of the Nanobodies of the invention (and of polypeptides comprising the same) to heterodimeric cytokines and/or their receptors will become clear from the further description and examples herein.
  • the invention relates to a (single) domain antibody and/or a Nanobody (as defined herein) which is a p19+ sequence (as defined herein), which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which:
  • the invention relates to a (single) domain antibody and/or a Nanobody (as defined herein) which is a p19+ sequence, which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which:
  • the invention relates to a (single) domain antibody and/or a Nanobody (as defined herein) which is a p19-sequence (as defined herein), which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which:
  • the invention relates to a (single) domain antibody and/or a Nanobody (as defined herein) which is a p19-sequence, which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which:
  • the invention relates to a (single) domain antibody and/or a Nanobody (as defined herein) which is a p40-sequence (as defined herein), which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which:
  • the invention relates to a (single) domain antibody and/or a Nanobody (as defined herein) which is a p40-sequence, which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which:
  • the invention relates to a (single) domain antibody and/or a Nanobody (as defined herein) which is a p40+ sequence (as defined herein), which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which:
  • the invention relates to a (single) domain antibody and/or a Nanobody (as defined herein) which is a p40+ sequence, which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which:
  • the invention relates to a (single) domain antibody and/or a Nanobody (as defined herein) which is a p35 sequence (as defined herein), which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which:
  • the invention relates to a (single) domain antibody and/or a Nanobody (as defined herein) which is a p35 sequence, which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which:
  • the invention relates to a (single) domain antibody and/or a Nanobody (as defined herein) which is an IL-27 sequence (as defined herein), which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which:
  • the invention relates to a (single) domain antibody and/or a Nanobody (as defined herein) which is an IL-27 sequence, which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which:
  • the invention relates to a (single) domain antibody and/or a Nanobody (as defined herein) which is an IL-12Rb1 sequence (as defined herein), which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which:
  • the invention relates to a (single) domain antibody and/or a Nanobody (as defined herein) which is an IL-12Rb1 sequence, which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which:
  • the invention relates to a (single) domain antibody and/or a Nanobody (as defined herein) which is an IL-12Rb2 sequence (as defined herein), which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which:
  • the invention relates to a (single) domain antibody and/or a Nanobody (as defined herein) which is an IL-12Rb2 sequence, which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which:
  • the invention relates to a (single) domain antibody and/or a Nanobody (as defined herein) which is an IL-23R sequence (as defined herein), which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which:
  • the invention relates to a (single) domain antibody and/or a Nanobody (as defined herein) which is an IL-23R sequence, which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which:
  • Nanobodies with the above CDR sequences may be as further described herein, and preferably have framework sequences that are also as further described herein.
  • such Nanobodies may be naturally occurring Nanobodies (from any suitable species), naturally occurring V HH sequences (i.e. from a suitable species of Camelid) or synthetic or semi-synthetic amino acid sequences or Nanobodies, including but not limited to partially humanized Nanobodies or V HH sequences, fully humanized Nanobodies or V HH sequences, camelized heavy chain variable domain sequences, as well as Nanobodies that have been obtained by the techniques mentioned herein.
  • the above p19+, p19 ⁇ , p40+, p40 ⁇ , anti p35, anti-IL-27, anti IL-12Rb1, anti IL-12Rb2 and anti IL-23R Nanobodies respectively, preferably as described herein in terms of degree of sequence identity with, the number of amino acid differences with, and/or of the ability to cross-block and/or compete, with the p19+ sequences, p19 ⁇ sequences, p40 ⁇ sequences, p40+ sequences, p35 sequences, IL-27 sequences, IL-12Rb1 sequences, IL-12Rb2 sequences or IL-23R sequences, respectively,that are mentioned in Table A-2.
  • the p19+, p19 ⁇ , p40+, p40 ⁇ , anti p35, anti-IL-27, anti IL-12Rb1, anti IL-12Rb2 and anti IL-23R Nanobodies are chosen from the corresponding sequences mentioned in Table A-2.
  • the invention relates to a humanized Nanobody, which consists of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which CDR1 to CDR3 are as defined herein and in which said humanized Nanobody comprises at least one humanizing substitution (as defined herein), and in particular at least one humanizing substitution in at least one of its framework sequences (as defined herein).
  • Another preferred, but non-limiting aspect of the invention relates to humanized variants of the above p19+, p19 ⁇ , p40+, p40 ⁇ , anti p35, anti-IL-27, anti IL-12Rb1, anti IL-12Rb2 and anti IL-23R Nanobodies, that comprise, compared to the corresponding native V HH sequence (i.e. as mentioned in Table A-2), at least one humanizing substitution (as defined herein), and in particular at least one humanizing substitution in at least one of its framework sequences (as defined herein).
  • Examples of such humanized Nanobodies are given in SEQ ID NO's: 2559 to 2614 (see also FIG. 31 ), and the skilled person will be able to find other suitable humanized variants based on the disclosure herein, optionally after some limited trial-and-error.
  • polypeptides of the invention comprise or essentially consist of at least one Nanobody of the invention.
  • Some preferred, but non-limiting examples of polypeptides of the invention are given in SEQ ID NO's: 2142 to 2169 and 2530 to 2558 (see also FIG. 30 ), as well as SEQ ID NO:2615 to 2622 (see FIGS. 32 ), 2623 to 2629 , 2643 and 2644 (see FIG. 33 ), SEQ ID NO: 2630 to 2641 (see FIG. 34 ), SEQ ID NO: 2645 and 2646 (see FIG. 35 ) and SEQ ID NO: 2647 and 2648 (see FIG. 36 ).
  • the invention also relates to polypeptides that have at least 70%, such as at least 80%, for example at least 90% sequence identity with at least one of these polypeptides.
  • Nanobodies that are mentioned herein as “preferred” (or “more preferred”, “even more preferred”, etc.) are also preferred (or more preferred, or even more preferred, etc.) for use in the polypeptides described herein.
  • polypeptides that comprise or essentially consist of one or more “preferred” Nanobodies of the invention will generally be preferred, and polypeptides that comprise or essentially consist of one or more “more preferred” Nanobodies of the invention will generally be more preferred, etc.
  • proteins or polypeptides that comprise or essentially consist of a single Nanobody will be referred to herein as “monovalent” proteins or polypeptides or as “monovalent constructs”.
  • Proteins and polypeptides that comprise or essentially consist of two or more Nanobodies (such as at least two Nanobodies of the invention or at least one Nanobody of the invention and at least one other Nanobody) will be referred to herein as “multivalent” proteins or polypeptides or as “multivalent constructs”, and these may provide certain advantages compared to the corresponding monovalent Nanobodies of the invention.
  • a polypeptide of the invention comprises or essentially consists of at least two Nanobodies of the invention, such as two or three Nanobodies of the invention.
  • multivalent constructs can provide certain advantages compared to a protein or polypeptide comprising or essentially consisting of a single Nanobody of the invention, such as a much improved avidity for heterodimeric cytokines and/or their receptors.
  • Such multivalent constructs will be clear to the skilled person based on the disclosure herein.
  • a polypeptide of the invention comprises or essentially consists of at least one Nanobody of the invention and at least one other binding unit (i.e. directed against another epitope, antigen, target, protein or polypeptide), which is preferably also a Nanobody.
  • Such proteins or polypeptides are also referred to herein as “multispecific” proteins or polypeptides or as “multispecific constructs”, and these may provide certain advantages compared to the corresponding monovalent Nanobodies of the invention (as will become clear from the further discussion herein of some preferred, but-nonlimiting multispecific constructs).
  • Such multispecific constructs will be clear to the skilled person based on the disclosure herein, and may in particular be biparatopic constructs (as mentioned herein).
  • Some preferred, but non-limiting examples of such multispecific Nanobody constructs will be clear to the skilled person based on the disclosure herein.
  • a polypeptide of the invention comprises or essentially consists of at least one Nanobody of the invention, optionally one or more further Nanobodies, and at least one other amino acid sequence (such as a protein or polypeptide) that confers at least one desired property to the Nanobody of the invention and/or to the resulting fusion protein.
  • at least one other amino acid sequence such as a protein or polypeptide
  • such fusion proteins may provide certain advantages compared to the corresponding monovalent Nanobodies of the invention.
  • the one or more Nanobodies and/or other amino acid sequences may be directly linked to each other and/or suitably linked to each other via one or more linker sequences.
  • linkers Some suitable but non-limiting examples of such linkers will become clear from the further description herein.
  • a Nanobody of the invention or a compound, construct or polypeptide of the invention comprising at least one Nanobody of the invention may have an increased half-life, compared to the corresponding amino acid sequence of the invention.
  • Some preferred, but non-limiting examples of such Nanobodies, compounds and polypeptides will become clear to the skilled person based on the further disclosure herein, and for example comprise Nanobodies sequences or polypeptides of the invention that have been chemically modified to increase the half-life thereof (for example, by means of pegylation); amino acid sequences of the invention that comprise at least one additional binding site for binding to a serum protein (such as serum albumin; or polypeptides of the invention that comprise at least one Nanobody of the invention that is linked to at least one moiety (and in particular at least one amino acid sequence) that increases the half-life of the Nanobody of the invention.
  • polypeptides of the invention that comprise such half-life extending moieties or amino acid sequences will become clear to the skilled person based on the further disclosure herein; and for example include, without limitation, polypeptides in which the one or more Nanobodies of the invention are suitable linked to one or more serum proteins or fragments thereof (such as serum albumin or suitable fragments thereof) or to one or more binding units that can bind to serum proteins (such as, for example, Nanobodies or (single) domain antibodies that can bind to serum proteins such as serum albumin, serum immunoglobulins such as IgG, or transferrine); polypeptides in which a Nanobody of the invention is linked to an Fe portion (such as a human Fe) or a suitable part or fragment thereof; or polypeptides in which the one or more Nanobodies of the invention are suitable linked to one or more small proteins or peptides that can bind to serum proteins (such as, without limitation, the proteins and peptides described in WO 91/01743, WO 01/45746
  • Nanobodies, compounds, constructs or polypeptides may contain one or more additional groups, residues, moieties or binding units, such as one or more further amino acid sequences and in particular one or more additional Nanobodies (i.e. not directed against heterodimeric cytokines and/or their receptors), so as to provide a tri- of multispecific Nanobody construct.
  • the Nanobodies of the invention (or compounds, constructs or polypeptides comprising the same) with increased half-life preferably have a half-life that is at least 1.5 times, preferably at least 2 times, such as at least 5 times, for example at least 10 times or more than 20 times, greater than the half-life of the corresponding amino acid sequence of the invention per se.
  • the Nanobodies, compounds, constructs or polypeptides of the invention with increased half-life may have a half-life that is increased with more than 1 hours, preferably more than 2 hours, more preferably more than 6 hours, such as more than 12 hours, or even more than 24, 48 or 72 hours, compared to the corresponding amino acid sequence of the invention per se.
  • Nanobodies, compound, constructs or polypeptides of the invention exhibit a serum half-life in human of at least about 12 hours, preferably at least 24 hours, more preferably at least 48 hours, even more preferably at least 72 hours or more.
  • compounds or polypeptides of the invention may have a half-life of at least 5 days (such as about 5 to 10 days), preferably at least 9 days (such as about 9 to 14 days), more preferably at least about 10 days (such as about 10 to 15 days), or at least about 11 days (such as about 11 to 16 days), more preferably at least about 12 days (such as about 12 to 18 days or more), or more than 14 days (such as about 14 to 19 days).
  • a polypeptide of the invention comprises one or more (such as two or preferably one) Nanobodies of the invention linked (optionally via one or more suitable linker sequences) to one or more (such as two and preferably one) amino acid sequences that allow the resulting polypeptide of the invention to cross the blood brain barrier.
  • said one or more amino acid sequences that allow the resulting polypeptides of the invention to cross the blood brain barrier may be one or more (such as two and preferably one) Nanobodies, such as the Nanobodies described in WO 02/057445, of which FC44 (SEQ ID NO: 189 of WO 06/040153) and FC5 (SEQ ID NO: 190 of WO 06/040154) are preferred examples.
  • polypeptides comprising one or more Nanobodies of the invention are preferably such that they:
  • a polypeptide that contains only one amino acid sequence of the invention is preferably such that it will bind to heterodimeric cytokines and/or their receptors with an affinity less than 500 nM, preferably less than 200 nM, more preferably less than 10 nM, such as less than 500 pM.
  • a polypeptide that contains two or more Nanobodies of the invention may bind to heterodimeric cytokines and/or their receptors with an increased avidity, compared to a polypeptide that contains only one amino acid sequence of the invention.
  • IC 50 values for binding of the amino acid sequences or polypeptides of the invention to heterodimeric cytokines and/or their receptors will become clear from the further description and examples herein.
  • nucleic acid that encodes a Nanobody of the invention or a polypeptide of the invention comprising the same.
  • a nucleic acid may be in the form of a genetic construct, as defined herein.
  • the invention relates to host or host cell that expresses or that is capable of expressing an amino acid sequence (such as a (single) domain antibody and/or Nanobody) of the invention and/or a polypeptide of the invention comprising the same; and/or that contains a nucleic acid of the invention.
  • an amino acid sequence such as a (single) domain antibody and/or Nanobody
  • a polypeptide of the invention comprising the same; and/or that contains a nucleic acid of the invention.
  • Another aspect of the invention relates to a product or composition containing or comprising at least one amino acid sequence (such as a (single) domain antibody and/or Nanobody) of the invention, at least one polypeptide of the invention and/or at least one nucleic acid of the invention, and optionally one or more further components of such compositions known per se, i.e. depending on the intended use of the composition.
  • a product or composition may for example be a pharmaceutical composition (as described herein), a veterinary composition or a product or composition for diagnostic use (as also described herein).
  • the invention further relates to methods for preparing or generating the amino acid sequences, compounds, constructs, polypeptides, nucleic acids, host cells, products and compositions described herein. Some preferred but non-limiting examples of such methods will become clear from the further description herein.
  • the invention further relates to applications and uses of the amino acid sequences, compounds, constructs, polypeptides, nucleic acids, host cells, products and compositions described herein, as well as to methods for the prevention and/or treatment for diseases and disorders associated with heterodimeric cytokines and/or their receptors.
  • the term Nanobody as used herein in its broadest sense is not limited to a specific biological source or to a specific method of preparation.
  • the Nanobodies of the invention can generally be obtained: (1) by isolating the V HH domain of a naturally occurring heavy chain antibody; (2) by expression of a nucleotide sequence encoding a naturally occurring V HH domain; (3) by “humanization” (as described herein) of a naturally occurring V HH domain or by expression of a nucleic acid encoding a such humanized V HH domain; (4) by “camelisation” (as described herein) of a naturally occurring V H domain from any animal species, and in particular a from species of mammal, such as from a human being, or by expression of a nucleic acid encoding such a camelized V H domain; (5) by “camelisation” of a “domain antibody” or “Dab” as described by Ward et al (su).
  • V HH sequences corresponds to the V HH domains of naturally occurring heavy chain antibodies directed against heterodimeric cytokines and/or their receptors.
  • V HH sequences can generally be generated or obtained by suitably immunizing a species of Camelid with heterodimeric cytokines and/or their receptors (i.e. so as to raise an immune response and/or heavy chain antibodies directed against heterodimeric cytokines and/or their receptors), by obtaining a suitable biological sample from said Camelid (such as a blood sample, serum sample or sample of B-cells), and by generating V HH sequences directed against heterodimeric cytokines and/or their receptors, starting from said sample, using any suitable technique known per se. Such techniques will be clear to the skilled person and/or are further described herein.
  • V HH domains against heterodimeric cytokines and/or their receptors can be obtained from na ⁇ ve libraries of Camelid V HH sequences, for example by screening such a library using heterodimeric cytokines and/or their receptors, or at least one part, fragment, antigenic determinant or epitope thereof using one or more screening techniques known per se.
  • libraries and techniques are for example described in WO 99/37681, WO 01/90190, WO 03/025020 and WO 03/035694.
  • improved synthetic or semi-synthetic libraries derived from na ⁇ ve V HH libraries may be used, such as V HH libraries obtained from na ⁇ ve V HH libraries by techniques such as random mutagenesis and/or CDR shuffling, as for example described in WO 00/43507.
  • the invention relates to a method for generating Nanobodies, that are directed against heterodimeric cytokines and/or their receptors.
  • said method at least comprises the steps of:
  • the set, collection or library of Nanobody sequences may be a na ⁇ ve set, collection or library of Nanobody sequences; a synthetic or semi-synthetic set, collection or library of Nanobody sequences; and/or a set, collection or library of Nanobody sequences that have been subjected to affinity maturation.
  • the set, collection or library of Nanobody sequences may be an immune set, collection or library of Nanobody sequences, and in particular an immune set, collection or library of V HH sequences, that have been derived from a species of Camelid that has been suitably immunized with heterodimeric cytokines and/or their receptors or with a suitable antigenic determinant based thereon or derived therefrom, such as an antigenic part, fragment, region, domain, loop or other epitope thereof.
  • said antigenic determinant may be an extracellular part, region, domain, loop or other extracellular epitope(s).
  • the set, collection or library of Nanobody or V HH sequences may be displayed on a phage, phagemid, ribosome or suitable micro-organism (such as yeast), such as to facilitate screening.
  • suitable methods, techniques and host organisms for displaying and screening (a set, collection or library of) Nanobody sequences will he clear to the person skilled in the art, for example on the basis of the further disclosure herein. Reference is also made to WO 03/054016 and to the review by Hoogenboom in Nature Biotechnology, 23, 9, 1105-1116 (2005).
  • the method for generating Nanobody sequences comprises at least the steps of:
  • the collection or sample of cells may for example be a collection or sample of B-cells.
  • the sample of cells may be derived from a Camelid that has been suitably immunized with heterodimeric cytokines and/or their receptors or a suitable antigenic determinant based thereon or derived therefrom, such as an antigenic part, fragment, region, domain, loop or other epitope thereof.
  • said antigenic determinant may be an extracellular part, region, domain, loop or other extracellular epitope(s).
  • step b) is preferably performed using a flow cytometry technique such as FACS.
  • FACS flow cytometry technique
  • Lieby et al. Blood, Vol. 97, No. 12, 3820.
  • Particular reference is made to the so-called “NanocloneTM” technique described in International application WO 06/079372 by Ablynx N.V.
  • the method for generating an amino acid sequence directed against heterodimeric cytokines and/or their receptors may comprise at least the steps of:
  • the set, collection or library of nucleic acid sequences encoding heavy chain antibodies or Nanobody sequences may for example be a set, collection or library of nucleic acid sequences encoding a na ⁇ ve set, collection or library of heavy chain antibodies or V HH sequences; a set, collection or library of nucleic acid sequences encoding a synthetic or semi-synthetic set, collection or library of Nanobody sequences; and/or a set, collection or library of nucleic acid sequences encoding a set, collection or library of Nanobody sequences that have been subjected to affinity maturation.
  • the set, collection or library of nucleic acid sequences may be an immune set, collection or library of nucleic acid sequences encoding heavy chain antibodies or V HH sequences derived from a Camelid that has been suitably immunized with heterodimeric cytokines and/or their receptors or with a suitable antigenic determinant based thereon or derived therefrom, such as an antigenic part, fragment, region, domain, loop or other epitope thereof.
  • said antigenic determinant may be an extracellular part, region, domain, loop or other extracellular epitope(s).
  • the set, collection or library of nucleotide sequences may be displayed on a phage, phagemid, ribosome or suitable micro-organism (such as yeast), such as to facilitate screening.
  • suitable methods, techniques and host organisms for displaying and screening (a set, collection or library of) nucleotide sequences encoding amino acid sequences will be clear to the person skilled in the art, for example on the basis of the further disclosure herein. Reference is also made to WO 03/054016 and to the review by Hoogenboom in Nature Biotechnology, 23, 9, 1105-1116 (2005).
  • the screening step of the methods described herein can also be performed as a selection step.
  • the term “screening” as used in the present description can comprise selection, screening or any suitable combination of selection and/or screening techniques.
  • a set, collection or library of sequences it may contain any suitable number of sequences, such as 1, 2, 3 or about 5, 10, 50, 100, 500, 1000, 5000, 10 4 , 10 5 , 10 6 , 10 7 , 10 8 or more sequences.
  • sequences in the above set, collection or library of amino acid sequences may be obtained or defined by rational, or semi-empirical approaches such as computer modelling techniques or biostatics or datamining techniques.
  • such a set, collection or library can comprise one, two or more sequences that are variants from one another (e.g. with designed point mutations or with randomized positions), compromise multiple sequences derived from a diverse set of naturally diversified sequences (e.g. an immune library)), or any other source of diverse sequences (as described for example in Hoogenboom et al, Nat Biotechnol 23:1105, 2005 and Binz et al, Nat Biotechnol 2005, 23:1247).
  • Such set, collection or library of sequences can be displayed on the surface of a phage particle, a ribosome, a bacterium, a yeast cell, a mammalian cell, and linked to the nucleotide sequence encoding the amino acid sequence within these carriers.
  • a sequence is displayed on a suitable host or host cell, it is also possible (and customary) to first isolate from said host or host cell a nucleotide sequence that encodes the desired sequence, and then to obtain the desired sequence by suitably expressing said nucleotide sequence in a suitable host organism. Again, this can be performed in any suitable manner known per se, as will be clear to the skilled person.
  • Yet another technique for obtaining V HH sequences or Nanobody sequences directed against heterodimeric cytokines and/or their receptors involves suitably immunizing a transgenic mammal that is capable of expressing heavy chain antibodies (i.e. so as to raise an immune response and/or heavy chain antibodies directed against heterodimeric cytokines and/or their receptors), obtaining a suitable biological sample from said transgenic mammal that contains (nucleic acid sequences encoding) said V HH sequences or Nanobody sequences (such as a blood sample, serum sample or sample of B-cells), and then generating V HH sequences directed against heterodimeric cytokines and/or their receptors, starting from said sample, using any suitable technique known per se (such as any of the methods described herein or a hybridoma technique).
  • a transgenic mammal that is capable of expressing heavy chain antibodies (i.e. so as to raise an immune response and/or heavy chain antibodies directed against heterodimeric cytokines and/or their receptor
  • heavy chain antibody-expressing mice and the further methods and techniques described in WO 02/085945, WO 04/049794 and WO 06/008548 and Janssens et al., Proc. Natl. Acad. Sci. USA. 2006 Oct. 10; 103(41):15130-5 can be used.
  • heavy chain antibody expressing mice can express heavy chain antibodies with any suitable (single) variable domain, such as (single) variable domains from natural sources (e.g. human (single) variable domains, Camelid (single) variable domains or shark (single) variable domains), as well as for example synthetic or semi-synthetic (single) variable domains.
  • the invention also relates to the V HH sequences or Nanobody sequences that are obtained by the above methods, or alternatively by a method that comprises the one of the above methods and in addition at least the steps of determining the nucleotide sequence or amino acid sequence of said V HH sequence or Nanobody sequence; and of expressing or synthesizing said V HH sequence or Nanobody sequence in a manner known per se, such as by expression in a suitable host cell or host organism or by chemical synthesis.
  • Nanobodies of the invention comprises Nanobodies with an amino acid sequence that corresponds to the amino acid sequence of a naturally occurring V HH domain, but that has been “humanized”, i.e. by replacing one or more amino acid residues in the amino acid sequence of said naturally occurring V HH sequence (and in particular in the framework sequences) by one or more of the amino acid residues that occur at the corresponding position(s) in a V H domain from a conventional 4-chain antibody from a human being (e.g. indicated above).
  • This can be performed in a manner known per se, which will be clear to the skilled person, for example on the basis of the further description herein and the prior art on humanization referred to herein.
  • Nanobodies of the invention can be obtained in any suitable manner known per se (i.e. as indicated under points (1)-(8) above) and thus are not strictly limited to polypeptides that have been obtained using a polypeptide that comprises a naturally occurring V HH domain as a starting material.
  • Nanobodies of the invention comprises Nanobodies with an amino acid sequence that corresponds to the amino acid sequence of a naturally occurring V H domain, but that has been “camelized”, i.e. by replacing one or more amino acid residues in the amino acid sequence of a naturally occurring V H domain from a conventional 4-chain antibody by one or more of the amino acid residues that occur at the corresponding position(s) in a V HH domain of a heavy chain antibody.
  • This can be performed in a manner known per se, which will be clear to the skilled person, for example on the basis of the further description herein.
  • the V H sequence that is used as a starting material or starting point for generating or designing the camelized Nanobody is preferably a V H sequence from a mammal, more preferably the V H sequence of a human being, such as a V H 3 sequence.
  • camelized Nanobodies of the invention can be obtained in any suitable manner known per se (i.e. as indicated under points (1)-(8) above) and thus are not strictly limited to polypeptides that have been obtained using a polypeptide that comprises a naturally occurring V H domain as a starting material.
  • both “humanization” and “camelization” can be performed by providing a nucleotide sequence that encodes a naturally occurring V HH domain or V H domain, respectively, and then changing, in a manner known per se, one or more codons in said nucleotide sequence in such a way that the new nucleotide sequence encodes a “humanized” or “camelized” Nanobody of the invention, respectively.
  • This nucleic acid can then be expressed in a manner known per se, so as to provide the desired Nanobody of the invention.
  • the amino acid sequence of the desired humanized or camelized Nanobody of the invention can be designed and then synthesized de novo using techniques for peptide synthesis known per se.
  • a nucleotide sequence encoding the desired humanized or camelized Nanobody of the invention can be designed and then synthesized de novo using techniques for nucleic acid synthesis known per se, after which the nucleic acid thus obtained can be expressed in a manner known per se, so as to provide the desired Nanobody of the invention.
  • Nanobodies of the invention and/or nucleic acids encoding the same starting from naturally occurring V H sequences or preferably V HH sequences, will be clear from the skilled person, and may for example comprise combining one or more parts of one or more naturally occurring V H sequences (such as one or more FR sequences and/or CDR sequences), one or more parts of one or more naturally occurring V HH sequences (such as one or more FR sequences or CDR sequences), and/or one or more synthetic or semi-synthetic sequences, in a suitable manner, so as to provide a Nanobody of the invention or a nucleotide sequence or nucleic acid encoding the same (which may then be suitably expressed).
  • V H sequences such as one or more FR sequences and/or CDR sequences
  • synthetic or semi-synthetic sequences such as one or more synthetic or semi-synthetic sequences
  • Nucleotide sequences encoding framework sequences of V HH sequences or Nanobodies will be clear to the skilled person based on the disclosure herein and/or the further prior art cited herein (and/or may alternatively be obtained by PCR starting from the nucleotide sequences obtained using the methods described herein) and may be suitably combined with nucleotide sequences that encode the desired CDR's (for example, by PCR assembly using overlapping primers), so as to provide a nucleic acid encoding a Nanobody of the invention.
  • Nanobodies may in particular be characterized by the presence of one or more “Hallmark residues” (as described herein) in one or more of the framework sequences.
  • a Nanobody in its broadest sense can be generally defined as a polypeptide comprising:
  • a Nanobody of the invention may have the structure
  • FR1 to FR4 refer to framework regions 1 to 4, respectively, and in which CDR1 to CDR3 refer to the complementarity determining regions 1 to 3, respectively, and in which
  • Nanobody in its broadest sense can be generally defined as a polypeptide comprising:
  • a Nanobody of the invention may have the structure
  • FR1 to FR4 refer to framework regions 1 to 4, respectively, and in which CDR1 to CDR3 refer to the complementarity determining regions 1 to 3, respectively, and in which
  • Nanobody against heterodimeric cytokines and/or their receptors may have the structure:
  • FR1 to FR4 refer to framework regions 1 to 4, respectively, and in which CDR1 to CDR3 refer to the complementarity determining regions 1 to 3, respectively, and in which
  • a Nanobody can generally be defined as a polypeptide comprising an amino acid sequence that is comprised of four framework regions/sequences interrupted by three complementarity determining regions/sequences, in which;
  • a Nanobody of the invention may have the structure
  • FR1 to FR4 refer to framework regions 1 to 4, respectively, and in which.
  • CDR1 to CDR3 refer to the complementarity determining regions I to 3, respectively, and in which:
  • Nanobody of the invention may have the structure
  • FR1 to FR4 refer to framework regions 1 to 4, respectively, and in which CDR1 to CDR3 refer to the complementarity determining regions 1 to 3, respectively, and in which:
  • Nanobody of the invention may have the structure
  • FR1 to FR4 refer to framework regions 1 to 4, respectively, and in which CDR1 to CDR3 refer to the complementarity determining regions 1 to 3, respectively, and in which:
  • Nanobodies of the invention are those according to a) above; according to (a-1) to (A-5) above; according to b) above; according to (b-1) to (b-4) above; according to (c) above; and/or according to (c-1) to (c-4) above, in which either:
  • a Nanobody of the invention may have the structure
  • FR1 to FR4 refer to framework regions 1 to 4, respectively, and in which CDR1 to CDR3 refer to the complementarity determining regions 1 to 3, respectively, and in which:
  • Nanobody of the invention may have the structure
  • FR1 to FR4 refer to framework regions 1 to 4, respectively, and in which CDR1 to CDR3 refer to the complementarity determining regions 1 to 3, respectively, and in which:
  • the amino acid residue at position 37 is most preferably F.
  • the amino acid residue at position 37 is chosen from the group consisting of Y, H, I, L, V or F, and is most preferably V.
  • the Nanobodies of the invention can generally be classified on the basis of the following three groups:
  • Nanobodies may belong to (i.e. have characteristics of) two or more of these classes.
  • one specifically preferred group of Nanobodies has GLEW or a GLEW-like sequence at positions 44-47; P, R or S (and in particular R) at position 103; and Q at position 108 (which may be humanized to L).
  • Nanobodies in the form of a native (i.e. non-humanized) V HH sequence, and that humanized variants of these Nanobodies may contain other amino acid residues than those indicated above (i.e. one or more humanizing substitutions as defined herein).
  • humanized Nanobodies of the GLEW-group or the 103 P, R, S-group, Q at position 108 may be humanized to 108L.
  • other humanizing substitutions and suitable combinations thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US12/745,052 2007-11-27 2008-11-27 Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same Abandoned US20110053865A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/745,052 US20110053865A1 (en) 2007-11-27 2008-11-27 Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US433207P 2007-11-27 2007-11-27
US533107P 2007-12-04 2007-12-04
US532407P 2007-12-04 2007-12-04
US526507P 2007-12-04 2007-12-04
PCT/EP2008/066365 WO2009068627A2 (en) 2007-11-27 2008-11-27 Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US12/745,052 US20110053865A1 (en) 2007-11-27 2008-11-27 Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same

Publications (1)

Publication Number Publication Date
US20110053865A1 true US20110053865A1 (en) 2011-03-03

Family

ID=40377235

Family Applications (5)

Application Number Title Priority Date Filing Date
US12/745,052 Abandoned US20110053865A1 (en) 2007-11-27 2008-11-27 Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US12/744,991 Active 2030-10-24 US8975382B2 (en) 2007-11-27 2008-11-27 Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
US12/745,023 Abandoned US20110189203A1 (en) 2007-11-27 2008-11-27 Immunoglobulin constructs
US12/744,970 Abandoned US20110028695A1 (en) 2007-11-27 2008-11-28 Method for obtaining polypeptide constructs comprising two or more single domain antibodies
US14/592,022 Active US9969805B2 (en) 2007-11-27 2015-01-08 Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors

Family Applications After (4)

Application Number Title Priority Date Filing Date
US12/744,991 Active 2030-10-24 US8975382B2 (en) 2007-11-27 2008-11-27 Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
US12/745,023 Abandoned US20110189203A1 (en) 2007-11-27 2008-11-27 Immunoglobulin constructs
US12/744,970 Abandoned US20110028695A1 (en) 2007-11-27 2008-11-28 Method for obtaining polypeptide constructs comprising two or more single domain antibodies
US14/592,022 Active US9969805B2 (en) 2007-11-27 2015-01-08 Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors

Country Status (12)

Country Link
US (5) US20110053865A1 (https=)
EP (5) EP2650311A3 (https=)
JP (1) JP2011504740A (https=)
KR (1) KR20100097716A (https=)
CN (1) CN101970490A (https=)
AU (4) AU2008328779B2 (https=)
BR (1) BRPI0819656A2 (https=)
CA (4) CA2705890A1 (https=)
IL (1) IL205734A0 (https=)
MX (1) MX2010005783A (https=)
WO (5) WO2009068628A1 (https=)
ZA (1) ZA201004057B (https=)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110028695A1 (en) * 2007-11-27 2011-02-03 Hilde Adi Pierrette Revets Method for obtaining polypeptide constructs comprising two or more single domain antibodies
US20160251440A1 (en) * 2013-09-26 2016-09-01 Ablynx N.V. Bispecific nanobodies
US20170066843A1 (en) * 2014-09-26 2017-03-09 Closed Joint Stock Company "Biocad" High affinity and aggregatively stable antibodies on the basis of variable domains vl and a derivative vhh
CN111675760A (zh) * 2019-03-11 2020-09-18 松下知识产权经营株式会社 抗体、复合物、使用它们的检测装置和检测方法
WO2022055641A3 (en) * 2020-08-05 2022-08-11 Synthekine, Inc. Compositions and methods related to receptor pairings
US20230074145A1 (en) * 2021-08-27 2023-03-09 Innovative Cellular Therapeutics Holdings, Ltd. Nanobody Target GCC and Uses in Chimeric Antigen Receptor Cell Therapy
US20230295314A1 (en) * 2020-08-05 2023-09-21 Synthekine, Inc. IL27RAlpha Binding Molecules and Methods of Use
WO2023201336A3 (en) * 2022-04-15 2023-11-23 Valitor, Inc. Humanized multivalent protein conjugates
US11859001B2 (en) 2020-08-05 2024-01-02 Synthekine, Inc. IL12RB1-Binding molecules and methods of use
US11873349B1 (en) 2020-08-05 2024-01-16 Synthekine, Inc. Compositions and methods related to IL27 receptor binding
US12012457B1 (en) 2020-08-05 2024-06-18 Synthekine, Inc. IL23R binding molecules and methods of use
US12018085B2 (en) 2020-08-05 2024-06-25 Synthekine, Inc. Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases
WO2024129897A3 (en) * 2022-12-13 2024-08-29 Bj Bioscience Inc. Anti-cd3 antibodies and bispecific antibodies
US12077594B2 (en) 2020-08-05 2024-09-03 Synthekine, Inc. IL2RG binding molecules and methods of use
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
US12139545B2 (en) 2020-08-05 2024-11-12 Synthekine, Inc. IL10 receptor binding molecules and methods of use
US12234291B2 (en) 2020-08-05 2025-02-25 Synthekine, Inc. IL2RB binding molecules and methods of use
US12286482B2 (en) 2020-08-05 2025-04-29 Synthekine, Inc. IL10RB binding molecules and encoding nucleic acids
US12291572B2 (en) 2020-08-05 2025-05-06 Synthekine, Inc. IL12 receptor synthetic cytokines and methods of use
US12297281B2 (en) 2020-08-05 2025-05-13 Synthekine, Inc. IL10RA binding molecules and methods of use
US12448457B2 (en) 2020-08-05 2025-10-21 Synthekine, Inc. GP130 binding molecules and methods of use
US12540188B2 (en) 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines
US12599663B2 (en) 2018-03-09 2026-04-14 Valitor, Inc. Multivalent peptide conjugates for sustained intra-articular treatment of joint inflammation

Families Citing this family (304)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
AU2009324354B2 (en) 2008-12-10 2016-04-14 Ablynx Nv Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
CN102257003B (zh) 2008-12-19 2017-04-05 埃博灵克斯股份有限公司 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
US10005830B2 (en) 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
NZ595461A (en) 2009-04-10 2013-01-25 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
AU2010243551B2 (en) 2009-04-30 2015-03-26 Ablynx Nv Method for the production of domain antibodies
US20120264917A1 (en) * 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
PT2438087T (pt) 2009-06-05 2017-08-04 Ablynx Nv Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório
WO2011003622A1 (en) 2009-07-10 2011-01-13 Ablynx N.V. Method for the production of variable domains
LT2805731T (lt) 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
WO2011042398A1 (en) 2009-10-09 2011-04-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP3309176B1 (en) 2009-12-14 2025-10-01 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
GB201000467D0 (en) * 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
DK2533761T3 (da) 2010-02-11 2019-06-24 Ablynx Nv Fremgangsmåder og sammensætninger til fremstilling af aerosoler
NZ601117A (en) * 2010-03-03 2014-06-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
WO2011135026A1 (en) 2010-04-30 2011-11-03 Ablynx Nv Amino acid sequences of nanobodies directed against p19 subunit of the heterodimeric cytokine il-23
EP2571901B1 (en) 2010-05-20 2019-01-02 Ablynx N.V. Biological materials related to her3
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
EP2576621B1 (en) 2010-05-27 2019-04-10 Genmab A/S Monoclonal antibodies against her2
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
DE102010026061A1 (de) 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-markiertes Peptid zur Detektion eines Tumors, der einen Her2/neu-Rezeptor exprimiert
CN103119062A (zh) * 2010-07-16 2013-05-22 埃博灵克斯股份有限公司 修饰的单结构域抗原结合分子及其应用
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
PL3279214T3 (pl) 2010-10-29 2025-03-24 Ablynx Nv Sposób wytwarzania pojedynczych domen zmiennych immunoglobuliny
JP5736764B2 (ja) * 2010-12-21 2015-06-17 Jnc株式会社 発光活性を有する融合蛋白質
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
AU2012234282B2 (en) 2011-03-28 2015-07-16 Ablynx Nv Method for producing solid formulations comprising immunoglobulin single variable domains
EP4520771A3 (en) * 2011-04-20 2025-07-16 Genmab A/S Bispecifc antibodies against her2
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
WO2012152823A1 (en) 2011-05-09 2012-11-15 Ablynx Nv Method for the production of immunoglobulin single variable domains
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP2723772A1 (en) 2011-06-23 2014-04-30 Ablynx N.V. Immunoglobulin single variable domains directed against ige
EP4350345A3 (en) 2011-06-23 2024-07-24 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
SG10201805064SA (en) 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
RS55775B2 (sr) 2011-06-23 2022-10-31 Ablynx Nv Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina
EP2723771B1 (en) 2011-06-23 2019-09-11 Ablynx NV Serum albumin binding proteins
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
JP6219287B2 (ja) 2011-09-30 2017-10-25 アブリンクス エン．ヴェー． ｃ−Ｍｅｔに関連する生物学的物質
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
CN102399288B (zh) * 2011-10-19 2013-06-05 山西德丰信成生物科技有限公司 针对免疫球蛋白Fc段的单域重链抗体
DK2797957T3 (da) * 2011-11-23 2019-09-23 Medimmune Llc Bindingsmolekyler specifikke for her3 og anvendelser deraf
EP2620772A1 (en) * 2012-01-25 2013-07-31 APP Latvijas Biomedicinas petijumu un studiju centrs Gastric cancer biomarkers and methods of use thereof
EP3473708B1 (en) 2012-07-24 2021-01-27 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
WO2014035474A1 (en) * 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
EP2719706A1 (en) 2012-10-15 2014-04-16 Universität Zürich Bispecific HER2 ligands for cancer therapy
WO2014060365A1 (en) 2012-10-15 2014-04-24 Universität Zürich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
EP2738180A1 (en) * 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
WO2014111550A1 (en) * 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
EP3666795A1 (en) 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
WO2014182970A1 (en) * 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
WO2015002985A2 (en) * 2013-07-01 2015-01-08 University Of Maryland Fc coupled compositions and methods of their use
AU2014357292B2 (en) 2013-11-27 2020-06-25 Zymeworks Bc Inc. Bispecific antigen-binding constructs targeting HER2
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
CN112851769A (zh) 2014-01-27 2021-05-28 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
JP6935195B2 (ja) 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
ES2809729T3 (es) 2014-03-11 2021-03-05 Molecular Templates Inc Proteínas que comprenden regiones efectoras de la subunidad A de la toxina Shiga próximas al extremo amino terminal y regiones de unión de tipo inmunoglobulina de reconocimiento celular capaces de unirse específicamente a HER2/neu/ErbB2
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
KR102399028B1 (ko) 2014-03-21 2022-05-17 엑스-바디 인코포레이티드 이중-특이적 항원-결합 폴리펩티드
US20190202908A1 (en) * 2014-04-15 2019-07-04 President And Fellows Of Harvard College Bi-specific agents
EP4707303A2 (en) * 2014-05-16 2026-03-11 Ablynx NV Improved immunoglobulin variable domains
US11009511B2 (en) 2014-05-16 2021-05-18 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
CN106604934A (zh) 2014-06-11 2017-04-26 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
TWI719942B (zh) 2014-07-21 2021-03-01 瑞士商諾華公司 使用ｃｄ３３嵌合抗原受體治療癌症
WO2016016329A1 (en) 2014-07-29 2016-02-04 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
EP3718574A1 (en) * 2014-07-29 2020-10-07 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
MX2017002205A (es) 2014-08-19 2017-08-21 Novartis Ag Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
JP6839074B2 (ja) 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2016082044A1 (en) 2014-11-27 2016-06-02 Zymeworks Inc. Methods of using bispecific antigen-binding constructs targeting her2
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
US11001625B2 (en) 2014-12-10 2021-05-11 Tufts University VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
SG11201706840WA (en) 2015-03-31 2017-09-28 Vhsquared Ltd Peptide construct having a protease-cleavable linker
CA3255406A1 (en) 2015-03-31 2025-07-03 Sorriso Pharmaceuticals, Inc. Tnf-alpha binding polypeptides
JP6961490B2 (ja) 2015-04-08 2021-11-05 ノバルティス アーゲー Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN114920848B (zh) 2015-05-13 2024-10-11 埃博灵克斯股份有限公司 基于cd3反应性的t细胞募集多肽
LT3611192T (lt) 2015-05-13 2025-06-25 Ablynx N.V. T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
ES3057390T3 (en) 2015-05-13 2026-03-02 Zymeworks Bc Inc Antigen-binding constructs targeting her2
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
MX390949B (es) 2015-07-17 2025-03-21 Univ Brussel Vrije Fragmentos de anticuerpos radiomarcados para uso en tratamiento de cancer.
MX2018000948A (es) 2015-07-23 2018-09-27 Inhibrx Inc Proteinas de fusion que se unen a gitir multivalentes y multiespecificas.
KR20180030085A (ko) 2015-07-26 2018-03-21 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2018028647A1 (en) 2016-08-10 2018-02-15 Legend Biotech Usa Inc. Chimeric antigen receptors targeting bcma and methods of use thereof
CN105085656B (zh) * 2015-09-01 2018-04-27 中国人民解放军军事医学科学院基础医学研究所 P19/Ebi3复合物及其多克隆抗体在系统性红斑狼疮诊治中的应用
EP3368092B9 (en) 2015-10-29 2020-07-29 Novartis AG Antibody conjugates comprising toll-like receptor agonist
CN108350069B (zh) 2015-10-30 2021-11-12 埃博灵克斯股份有限公司 针对il-23的多肽
NO2768984T3 (https=) 2015-11-12 2018-06-09
LT3374392T (lt) 2015-11-13 2022-01-25 Ablynx Nv Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
AU2016355569B2 (en) 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc CTLA4 binders
IL300122A (en) 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
CA3003777A1 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1/ctla4 binders
US20200261573A1 (en) 2015-12-17 2020-08-20 Novartis Ag Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
EP4643874A3 (en) 2015-12-22 2026-02-11 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
WO2017120213A1 (en) * 2016-01-05 2017-07-13 Colorado State University Research Foundation Compositions comprising resurfaced cell-penetrating nanobodies and methods of use thereof
MA55746A (fr) 2016-01-21 2022-03-02 Novartis Ag Molécules multispécifiques ciblant cll-1
KR20180118175A (ko) 2016-03-04 2018-10-30 노파르티스 아게 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
CN109071636A (zh) 2016-03-29 2018-12-21 斯特库比股份有限公司 用于选择特异性结合糖基化免疫检查点蛋白的抗体的方法
ES2883297T3 (es) 2016-03-29 2021-12-07 Stcube Inc Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos
CN109715808A (zh) 2016-04-15 2019-05-03 诺华股份有限公司 用于选择性蛋白质表达的组合物和方法
WO2017210617A2 (en) 2016-06-02 2017-12-07 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
AU2017281421B2 (en) 2016-06-23 2024-07-25 Ablynx N.V. Improved pharmacokinetic assays for immunoglobulin single variable domains
SG11201900344YA (en) 2016-07-15 2019-02-27 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
CN109715666B (zh) 2016-07-20 2023-02-21 斯特库比股份有限公司 癌症治疗方法和使用结合糖基化pd-l1的抗体的组合的疗法
AU2017302668B9 (en) 2016-07-28 2023-06-22 Novartis Ag Combination therapies of chimeric antigen receptors and PD-1 inhibitors
BR112019002035A2 (pt) 2016-08-01 2019-05-14 Novartis Ag tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2
CN109790206A (zh) 2016-09-22 2019-05-21 分子组合公司 重组结合蛋白及其用途
BR112019006781A2 (pt) 2016-10-07 2019-07-30 Novartis Ag receptores de antígeno quiméricos para o tratamento de câncer
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
GB201618432D0 (en) * 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
BR112019010061A2 (pt) 2016-11-16 2019-08-13 Ablynx Nv polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
RU2022101604A (ru) 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
IL267897B2 (en) 2017-01-17 2025-02-01 Ablynx Nv Improved serum albumin binders
JP7219220B2 (ja) 2017-01-17 2023-02-07 アブリンクス エン．ヴェー． 改善された血清アルブミン結合剤
ES2912408T3 (es) 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
JP7186401B2 (ja) * 2017-02-28 2022-12-09 フエー・イー・ベー・フエー・ゼツト・ウエー タンパク質の経口送達のための手段及び方法
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
CN106866823A (zh) * 2017-03-08 2017-06-20 康众（北京）生物科技有限公司 一种抗Her2的纳米抗体
US12480957B2 (en) 2017-03-31 2025-11-25 Ablynx N.V. Method of screening for anti-drug antibodies against immunoglobulin single variable domain-based drugs
EP3609580A4 (en) * 2017-04-09 2021-03-24 Combio Pharmaceutical, Inc. COMMON LIGHT CHAIN BIPARATOPIC AND MULTIPARATOPIC ANTIBODIES AND METHOD OF USE
SG11201909160WA (en) 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN109096401B (zh) 2017-06-20 2021-07-27 和迈生物科技有限公司 抗Her2纳米抗体及其编码序列和用途
CN109096396B (zh) * 2017-06-20 2022-01-04 华兰生物工程股份有限公司 一种抗pd-l1人源化纳米抗体及其应用
MY204117A (en) 2017-06-22 2024-08-08 Novartis Ag Antibody molecules to cd73 and uses thereof
CA3066747A1 (en) 2017-06-27 2019-01-03 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
AU2018301393B2 (en) 2017-07-11 2025-02-27 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
JP2020527572A (ja) 2017-07-20 2020-09-10 ノバルティス アーゲー 抗ｌａｇ−３抗体の投薬量レジメンおよびその使用
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
EP3732203A4 (en) 2017-12-28 2021-12-15 Nanjing Legend Biotech Co., Ltd. ANTIBODIES AND THEIR VARIANTS DIRECTED AGAINST PD-L1
CN117050184A (zh) 2017-12-28 2023-11-14 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
BR112020013244A2 (pt) * 2018-01-04 2020-12-01 Shanghai Lumosa Therapeutics Co., Ltd. proteínas de fusão de anticorpo citosina-desaminase de domínio único
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
CN111699200B (zh) 2018-01-15 2023-05-26 南京传奇生物科技有限公司 针对pd-1的单域抗体和其变体
AU2019215031C1 (en) 2018-01-31 2026-02-26 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3758755A1 (en) 2018-02-26 2021-01-06 Ablynx N.V. Improved nucleotide sequences encoding peptide linkers
JP2021516682A (ja) 2018-03-13 2021-07-08 スミヴェット ビー．ブイ．Ｓｍｉｖｅｔ Ｂ．Ｖ． 破傷風神経毒素に結合する単一ドメイン抗体
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
TW202003567A (zh) 2018-03-30 2020-01-16 大陸商南京傳奇生物科技有限公司 針對lag-3之單一結構域抗體及其用途
WO2019198731A1 (ja) * 2018-04-10 2019-10-17 国立大学法人東北大学 抗体断片及び該抗体断片を含む二重特異性抗体
KR20260046525A (ko) 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
CA3099308A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
TWI890660B (zh) 2018-06-13 2025-07-21 瑞士商諾華公司 Bcma 嵌合抗原受體及其用途
CN112654394B (zh) 2018-06-19 2025-07-11 阿塔盖有限责任公司 针对补体成分5的抗体分子和其用途
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
JP2021531306A (ja) 2018-07-25 2021-11-18 アドバンスド アクセラレーター アプリケーションズ エスエー 神経内分泌腫瘍の処置の方法
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
EP3850013A4 (en) 2018-09-10 2022-10-05 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND USES THEREOF
BR112021005670A2 (pt) 2018-10-08 2021-06-22 Universität Zürich polipeptídeos tetraméricos de ligação a her2
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
EP3897648B1 (en) 2018-12-20 2023-08-23 Novartis AG Extended low dose regimens for mdm2 inhibitors
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
WO2020172553A1 (en) 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
BR112021019337A2 (pt) 2019-03-29 2021-12-07 Atarga Llc Anticorpo anti-fgf23
RU2754760C2 (ru) 2019-04-02 2021-09-07 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция анти-il17a антитела и ее применение
CN111848805B (zh) * 2019-04-30 2023-05-05 非同（成都）生物科技有限公司 用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体
US12559552B2 (en) 2019-06-21 2026-02-24 Sorriso Pharmaceuticals, Inc. IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides
KR20220063148A (ko) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. 조성물
CA3144567A1 (en) 2019-06-21 2020-12-24 Scott Crowe Polypeptides
CN110499259B (zh) * 2019-07-22 2021-07-27 浙江工业大学 一种解酯耶氏酵母yw100-1及其应用
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
BR112022007179A2 (pt) 2019-10-21 2022-08-23 Novartis Ag Inibidores de tim-3 e usos dos mesmos
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
IL293215A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors that bind bcma and cd19 and their uses
IL293561A (en) 2019-12-06 2022-08-01 Ablynx Nv Polypeptides comprising immunoglobulin with one variable domain targeting TNFa and IL-23
BR112022011902A2 (pt) 2019-12-20 2022-09-06 Novartis Ag Terapias de combinação
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
WO2021146636A1 (en) 2020-01-17 2021-07-22 Becton, Dickinson And Company Methods and compositions for single cell secretomics
BR112022012310A2 (pt) 2020-01-17 2022-09-06 Novartis Ag Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
JP7481856B2 (ja) * 2020-02-25 2024-05-13 シスメックス株式会社 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
CN115397460A (zh) 2020-02-27 2022-11-25 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
JP7512413B2 (ja) * 2020-03-31 2024-07-08 ビオテウス・インコーポレイテッド 抗ｐｄ－ｌ１およびｐｄ－ｌ２抗体ならびにその誘導体および用途
WO2021198396A1 (en) * 2020-03-31 2021-10-07 Biotalys NV Anti-fungal polypeptides
US12080426B2 (en) * 2020-04-06 2024-09-03 University Of Florida Research Foundation, Incorporated Functional deep neural network for high-dimensional data analysis
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
KR20230043118A (ko) 2020-06-24 2023-03-30 사프렘 테크놀로지스 비.브이. 사포닌 및 단일-도메인 항체의 접합체, 상기 접합체를 포함하는 약학적 조성물, 이의 치료 용도
AU2020454675B2 (en) 2020-06-24 2025-06-26 Sapreme Technologies B.V. Combination comprising an ADC or an AOC comprising a VHH, and a saponin or a ligand-saponin conjugate
WO2021259507A1 (en) 2020-06-24 2021-12-30 Sapreme Technologies B.V. Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
EP4117731A1 (en) 2020-06-24 2023-01-18 Sapreme Technologies B.V. Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
US12077576B2 (en) 2020-07-02 2024-09-03 Trustees Of Tufts College VHH polypeptides that bind to Clostridium difficile toxin b and methods of use thereof
KR102486958B1 (ko) * 2020-07-08 2023-01-11 한국과학기술원 인간 상피세포 증식인자 수용체 2형의 도메인 4에 특이적으로 결합하는 신규 폴리펩티드 및 이의 용도
TW202216761A (zh) 2020-07-16 2022-05-01 瑞士商諾華公司 抗β細胞素抗體、其片段及多特異性結合分子
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
US20230279126A1 (en) * 2020-08-05 2023-09-07 Synthekine, Inc. Il23 receptor synthetic cytokines and methods of use
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
US20240002539A1 (en) * 2020-11-03 2024-01-04 Ab Studio Inc. Multispecific antibodies and uses thereof
US20240002509A1 (en) 2020-11-06 2024-01-04 Novartis Ag ANTIBODY Fc VARIANTS
CA3198447A1 (en) 2020-11-13 2022-05-19 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
IL303740A (en) 2020-12-18 2023-08-01 Sanofi Sa T cell recruiting polypeptides based on tcr alpha/beta reactivity
WO2022127889A1 (zh) * 2020-12-18 2022-06-23 江苏先声药业有限公司 Her2抗体及其应用
US20240141060A1 (en) 2021-01-29 2024-05-02 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
BR112023016706A2 (pt) 2021-02-19 2023-10-31 Seoul Nat Univ R&Db Foundation Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
JP7773237B2 (ja) 2021-02-19 2025-11-19 シャペロン インク． Ｃｄ４７に対する単一ドメイン抗体及びその用途
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
EP4365203A4 (en) 2021-07-01 2025-09-24 Ningbo T Maximum Biopharmaceuticals Co Ltd ANTIGEN-BINDING POLYPEPTIDE TARGETING B7H3 AND ITS APPLICATION
EP4512826A3 (en) 2021-07-09 2025-04-02 Luxembourg Institute Of Health (LIH) Dimeric protein complexes and uses thereof
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
CN113813380B (zh) * 2021-09-15 2023-03-07 深圳大学 一种靶向her2的光热纳米材料及其制备方法与应用
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
EP4413038A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1 binding affimers
US20240409638A1 (en) 2021-10-07 2024-12-12 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
WO2023070317A1 (zh) * 2021-10-26 2023-05-04 江苏省农业科学院 基于dc细胞的双功能纳米抗体及其构建方法和应用
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
US20250295800A1 (en) 2021-12-22 2025-09-25 Sapreme Technologies B.V. Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
TW202342548A (zh) 2022-02-07 2023-11-01 美商威特拉公司 抗獨特型(anti-idiotype)抗體分子及其用途
CN119213021A (zh) 2022-02-10 2024-12-27 艾菲赛尔治疗株式会社 与CD40L特异性结合的Stefin A蛋白变体及其用途
WO2023183317A2 (en) * 2022-03-21 2023-09-28 Ab Therapeutics, Inc. Multispecific antibodies and uses thereof
EP4504796A4 (en) * 2022-04-04 2026-03-18 Nat Inst Biotechnology Negev Ltd SPECIFIC BINDING MOLECULES OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2
CN114805578B (zh) * 2022-05-06 2022-12-06 浙江大学 一种白细胞免疫球蛋白样受体亚家族b成员2的羊驼纳米抗体、制备方法及其应用
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
IL316990A (en) * 2022-05-23 2025-01-01 Cereius Inc HER2 binding agents and their uses
CN114920839B (zh) * 2022-06-17 2023-03-10 天津大学 特异性结合il-23的纳米抗体及其用途
US20240132624A1 (en) 2022-07-27 2024-04-25 Ablynx N.V. Polypeptides binding to a specific epitope of the neonatal fc receptor
JP2025528068A (ja) 2022-08-03 2025-08-26 ボイジャー セラピューティクス インコーポレイテッド 血液脳関門を通過させるための組成物及び方法
CN117986362A (zh) * 2022-11-04 2024-05-07 茂行制药(苏州)有限公司 靶向b7h3的通用型car-t细胞及其制备方法和应用
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
AR131494A1 (es) 2022-12-23 2025-03-26 Ablynx Nv Vehículos de conjugación a base de proteína
IL322055A (en) 2023-01-13 2025-09-01 Regeneron Pharma IL12 receptor agonists and methods of using them
WO2024168061A2 (en) 2023-02-07 2024-08-15 Ayan Therapeutics Inc. Antibody molecules binding to sars-cov-2
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
FR3147278A1 (fr) 2023-03-31 2024-10-04 Avacta Life Sciences Limited Polypeptides de liaison au tnfr2 et procedes d'utilisation
CN121013863A (zh) 2023-03-31 2025-11-25 艾菲赛尔治疗株式会社 Tnfr2结合多肽及使用方法
EP4701667A1 (en) 2023-04-24 2026-03-04 Merck Sharp & Dohme LLC Trop2 binders and conjugates thereof
WO2024259305A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
EP4731770A1 (en) 2023-06-22 2026-04-29 Ablynx NV Chimeric proteins for modulating cytokine receptor activity
WO2025008537A1 (en) 2023-07-05 2025-01-09 Ablynx Nv Improved fcrn antagonists for treatment of igg-related diseases and disorders
CN116574186B (zh) * 2023-07-07 2023-11-28 云南大学 特异性结合her2的纳米抗体及其应用
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
TW202521562A (zh) 2023-08-11 2025-06-01 美商默沙東有限責任公司 單價介白素-12(IL-12) 異二聚體Fc蛋白
TW202532432A (zh) 2023-09-22 2025-08-16 比利時商艾伯霖克斯公司 二及多價白蛋白結合劑
TW202540169A (zh) 2023-11-08 2025-10-16 法商賽諾菲公司 基於ｃｄ２５的溶酶體降解物及其用途
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025175359A1 (en) * 2024-02-23 2025-08-28 HAFENSTEIN, Patrick Immunoconjugate, pharmaceutical composition comprising the same, and uses thereof in treating cancers
GB202403780D0 (en) 2024-03-15 2024-05-01 Avacta Life Sciences Ltd Polypeptides and methods for detecting and quantifying small molecules
WO2025207946A1 (en) 2024-03-28 2025-10-02 Genzyme Corporation Polypeptides binding to a specific epitope of the transferrin receptor 1
US20260007757A1 (en) 2024-06-18 2026-01-08 Ablynx Nv Antibody-recruiting molecules
WO2026036047A1 (en) 2024-08-08 2026-02-12 Altus Enterprises, Inc. Antibody molecules to fixa and fx and uses thereof
WO2026052756A1 (en) 2024-09-05 2026-03-12 Ablynx Nv Her2 binding immunoglobulin single variable domains, constructs comprising the same and uses thereof
WO2026058155A1 (en) 2024-09-11 2026-03-19 Novartis Ag Antibodies targeting il-31
WO2026076388A1 (en) 2024-10-03 2026-04-09 The Broad Institute, Inc. Vhh polypeptides that bind to claudin-18, compositions and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821337A (en) * 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
US20100135998A1 (en) * 2007-02-28 2010-06-03 Schering Corporation Combination therapy for treatment of immune disorders
US20110028695A1 (en) * 2007-11-27 2011-02-03 Hilde Adi Pierrette Revets Method for obtaining polypeptide constructs comprising two or more single domain antibodies

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU572654B2 (en) 1984-05-11 1988-05-12 Premier Submers-A-Lite Pty. Ltd. Tail light assembly
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5038508A (en) 1989-08-08 1991-08-13 Brown Frank C Safety device for a firearm
DE69034249T2 (de) 1989-12-22 2008-05-29 F. Hoffmann-La Roche Ag Monoklonale Antikörper spezifisch für den zytotoxischen Lymphozyten-Reifefaktor
CA2079802C (en) 1990-04-05 2001-09-18 Roberto Crea Walk-through mutagenesis
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
EP0640130B1 (en) 1992-05-08 1998-04-15 Creative Biomolecules, Inc. Chimeric multivalent protein analogues and methods of use thereof
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
EP0698097B1 (en) 1993-04-29 2001-08-16 Unilever N.V. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
CA2276420A1 (en) 1997-10-31 1999-05-14 Terry Strom Use of anti-il-12 antibodies in transplantation rejection
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
KR20010034512A (ko) 1998-02-19 2001-04-25 베렌슨, 론 림프구 활성화 조절을 위한 조성물 및 그 방법
EP0967284A1 (en) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
EP1141711A1 (en) 1999-01-05 2001-10-10 Unilever Plc Binding of antibody fragments to solid supports
DK1144616T4 (da) 1999-01-19 2009-03-30 Unilever Nv Fremgangsmåde til fremstilling af antistoffragmenter
CA2361678A1 (en) 1999-02-05 2000-08-10 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
DE60035163T2 (de) 1999-03-15 2008-02-21 University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
HUP0200575A3 (en) 1999-03-25 2004-11-29 Abbott Gmbh & Co Kg Human antibodies that bind human il-12 and methods for producing
CA2370351A1 (en) 1999-04-22 2000-11-02 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
CN100513570C (zh) 1999-06-18 2009-07-15 Cv治疗公司 结合框运输蛋白abc1的调节作用
CN100340575C (zh) * 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
IL147920A0 (en) 1999-08-02 2002-08-14 Keygene Nv Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants
AU780163B2 (en) 1999-09-09 2005-03-03 Merck Sharp & Dohme Corp. Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
ES2331051T3 (es) 1999-11-29 2009-12-21 Bac Ip B.V. Inmovilizacion de moleculas de union de antigenos de un dominio.
WO2001040310A2 (en) 1999-11-29 2001-06-07 Unilever Plc Immobilisation of proteins using a polypeptide segment
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
ES2324280T3 (es) 2000-03-14 2009-08-04 Unilever N.V. Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
JP2003531588A (ja) * 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
CN1549726A (zh) 2000-07-31 2004-11-24 耶鲁大学 先天性免疫系统指导的疫苗
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
ATE513854T1 (de) 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
RU2420537C2 (ru) 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
EP1456237A2 (en) 2001-12-21 2004-09-15 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Method for cloning of variable domain sequences
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
WO2003087163A1 (en) 2002-04-15 2003-10-23 Chugai Seiyaku Kabushiki Kaisha METHOD OF CONSTRUCTING scDb LIBRARY
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
WO2004008099A2 (en) 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
EP1382615A1 (en) 2002-07-15 2004-01-21 Xerion Pharmaceuticals AG MCAM inhibitors
BRPI0315666B8 (pt) 2002-10-23 2021-05-25 Ludwig Inst For Cancer Res Ltd dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
ES2374068T3 (es) 2002-12-03 2012-02-13 Ucb Pharma, S.A. Ensayo para identificar células productoras de anticuerpos.
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
AU2003301114B2 (en) 2002-12-31 2010-03-18 Merck Sharp & Dohme Corp. Uses of mammalian cytokine; related reagents
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
BRPI0412007A (pt) 2003-06-27 2006-08-15 Bioren Inc mutagênese look-through
EP1656128A4 (en) 2003-08-12 2007-02-28 William M Yarbrough SINGLE ACNE TREATMENT AND METHOD OF USE
ES2385829T3 (es) 2003-08-20 2012-08-01 Ucb Pharma, S.A. Métodos para obtener anticuerpos
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
CN1942201B (zh) 2004-02-17 2012-06-20 先灵公司 调节il-23活性的方法；相关试剂
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
JP4550470B2 (ja) 2004-04-14 2010-09-22 住友電装株式会社 コネクタ
US20050279676A1 (en) 2004-06-21 2005-12-22 Izzy Zuhair A Fluid filter assembly for a dispensing faucet
CA2572917C (en) 2004-07-06 2012-04-03 Bioren Inc. Look-through mutagenesis for developing altered polypeptides with enhanced properties
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
DE102004051767B4 (de) 2004-07-20 2018-03-29 Witte-Velbert Gmbh & Co. Kg Getriebeanordnung zum Öffnen/Schließen einer Tür, einer Klappe o. dgl.
KR101151957B1 (ko) 2004-07-22 2012-06-01 로저 킹돈 크레이그 결합 분자
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2006040154A2 (en) 2004-10-14 2006-04-20 Dublin City University Prokaryotic two hybrid system
US7820168B2 (en) 2004-12-20 2010-10-26 Schering Corporation Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17
MY157915A (en) 2004-12-21 2016-08-15 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses.
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) * 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
CN103145842A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
DE602006015830D1 (de) 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
US20080199460A1 (en) 2005-09-01 2008-08-21 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
WO2007042289A2 (en) * 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies™ and polypeptides against egfr and igf-ir
HUE034269T2 (en) * 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
AU2007237501A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. DP-78-like nanobodies
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
AU2009324354B2 (en) * 2008-12-10 2016-04-14 Ablynx Nv Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821337A (en) * 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
US20100135998A1 (en) * 2007-02-28 2010-06-03 Schering Corporation Combination therapy for treatment of immune disorders
US20110028695A1 (en) * 2007-11-27 2011-02-03 Hilde Adi Pierrette Revets Method for obtaining polypeptide constructs comprising two or more single domain antibodies
US20110059090A1 (en) * 2007-11-27 2011-03-10 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
US20110189203A1 (en) * 2007-11-27 2011-08-04 Ablynx N.V. Immunoglobulin constructs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cheong et al BBRC, 173, 1990, 795-800, abstract only. *
Tso et al. (Journal of Hematother. , 1995 , 389-394, abstract only *
Ward et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341, 544 - 546 (12 October 1989). *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110028695A1 (en) * 2007-11-27 2011-02-03 Hilde Adi Pierrette Revets Method for obtaining polypeptide constructs comprising two or more single domain antibodies
US20110059090A1 (en) * 2007-11-27 2011-03-10 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
US20110189203A1 (en) * 2007-11-27 2011-08-04 Ablynx N.V. Immunoglobulin constructs
US8975382B2 (en) 2007-11-27 2015-03-10 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
US9969805B2 (en) 2007-11-27 2018-05-15 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
US20160251440A1 (en) * 2013-09-26 2016-09-01 Ablynx N.V. Bispecific nanobodies
US20170066843A1 (en) * 2014-09-26 2017-03-09 Closed Joint Stock Company "Biocad" High affinity and aggregatively stable antibodies on the basis of variable domains vl and a derivative vhh
US10442869B2 (en) * 2014-09-26 2019-10-15 Closed Joint Stock Company “Biocad” Anti-IL-17A Antibodies
US11447574B2 (en) 2014-09-26 2022-09-20 Joint Stock Company “Biocad” Method for treatment of an IL-17A-mediated disease through antibody administration specific to human IL-17A
US12599663B2 (en) 2018-03-09 2026-04-14 Valitor, Inc. Multivalent peptide conjugates for sustained intra-articular treatment of joint inflammation
CN111675760A (zh) * 2019-03-11 2020-09-18 松下知识产权经营株式会社 抗体、复合物、使用它们的检测装置和检测方法
US12209132B2 (en) 2020-08-05 2025-01-28 Synthekine, Inc. Compositions and methods related to IL27 receptor binding
US12139545B2 (en) 2020-08-05 2024-11-12 Synthekine, Inc. IL10 receptor binding molecules and methods of use
WO2022055641A3 (en) * 2020-08-05 2022-08-11 Synthekine, Inc. Compositions and methods related to receptor pairings
US11859001B2 (en) 2020-08-05 2024-01-02 Synthekine, Inc. IL12RB1-Binding molecules and methods of use
US11873349B1 (en) 2020-08-05 2024-01-16 Synthekine, Inc. Compositions and methods related to IL27 receptor binding
US12540188B2 (en) 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines
US12012457B1 (en) 2020-08-05 2024-06-18 Synthekine, Inc. IL23R binding molecules and methods of use
US12018085B2 (en) 2020-08-05 2024-06-25 Synthekine, Inc. Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases
US12448457B2 (en) 2020-08-05 2025-10-21 Synthekine, Inc. GP130 binding molecules and methods of use
US12077594B2 (en) 2020-08-05 2024-09-03 Synthekine, Inc. IL2RG binding molecules and methods of use
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
US20230295314A1 (en) * 2020-08-05 2023-09-21 Synthekine, Inc. IL27RAlpha Binding Molecules and Methods of Use
US12157773B2 (en) * 2020-08-05 2024-12-03 Synthekine, Inc. IL27RAlpha binding molecules and methods of use
US12297281B2 (en) 2020-08-05 2025-05-13 Synthekine, Inc. IL10RA binding molecules and methods of use
US12234291B2 (en) 2020-08-05 2025-02-25 Synthekine, Inc. IL2RB binding molecules and methods of use
US12286482B2 (en) 2020-08-05 2025-04-29 Synthekine, Inc. IL10RB binding molecules and encoding nucleic acids
US12291572B2 (en) 2020-08-05 2025-05-06 Synthekine, Inc. IL12 receptor synthetic cytokines and methods of use
US20230074145A1 (en) * 2021-08-27 2023-03-09 Innovative Cellular Therapeutics Holdings, Ltd. Nanobody Target GCC and Uses in Chimeric Antigen Receptor Cell Therapy
US11970548B2 (en) * 2021-08-27 2024-04-30 Innovative Cellular Therapeutics Holdings, Ltd. Nanobody target GCC and uses in chimeric antigen receptor cell therapy
WO2023201336A3 (en) * 2022-04-15 2023-11-23 Valitor, Inc. Humanized multivalent protein conjugates
WO2024129897A3 (en) * 2022-12-13 2024-08-29 Bj Bioscience Inc. Anti-cd3 antibodies and bispecific antibodies

Also Published As

Publication number Publication date
US20150232562A1 (en) 2015-08-20
CA2705890A1 (en) 2009-06-04
WO2009068630A1 (en) 2009-06-04
US9969805B2 (en) 2018-05-15
EP2650311A2 (en) 2013-10-16
AU2008328781A1 (en) 2009-06-04
JP2011504740A (ja) 2011-02-17
US20110189203A1 (en) 2011-08-04
CA2706200A1 (en) 2009-06-04
AU2008328779B2 (en) 2014-06-05
WO2009068631A1 (en) 2009-06-04
EP2215123A1 (en) 2010-08-11
IL205734A0 (en) 2010-11-30
EP2225278A2 (en) 2010-09-08
AU2008328784B2 (en) 2014-03-27
EP2220120A2 (en) 2010-08-25
MX2010005783A (es) 2010-08-10
WO2009068627A2 (en) 2009-06-04
WO2009068625A2 (en) 2009-06-04
US20110028695A1 (en) 2011-02-03
AU2008328779A1 (en) 2009-06-04
CA2706425A1 (en) 2009-06-04
WO2009068628A1 (en) 2009-06-04
ZA201004057B (en) 2011-04-28
WO2009068625A3 (en) 2009-08-06
US8975382B2 (en) 2015-03-10
AU2008328784A1 (en) 2009-06-04
AU2008328785A1 (en) 2009-06-04
KR20100097716A (ko) 2010-09-03
US20110059090A1 (en) 2011-03-10
CN101970490A (zh) 2011-02-09
WO2009068627A3 (en) 2009-10-01
EP2215125A1 (en) 2010-08-11
BRPI0819656A2 (pt) 2015-06-23
CA2706675A1 (en) 2009-06-04
EP2650311A3 (en) 2014-06-04

Similar Documents

Publication Publication Date Title
US11858997B2 (en) Amino acid sequences that modulate the interaction between cells of the immune system
US20110053865A1 (en) Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US10618966B2 (en) Methods for the treatment of interleukin-6 receptor-related diseases and disorders
US11078290B2 (en) Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
US8557965B2 (en) Single variable domains against notch pathway members
US20100136018A1 (en) Anti-FC-receptor single domain antibodies (nanobodies-tm) and therapeutic use
US20110059101A9 (en) Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling
WO2009095489A2 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling

Legal Events

Date Code Title Description
AS Assignment

Owner name: ABLYNX N.V., BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SAUNDERS, MICHAEL JOHN SCOTT;BLANCHETOT, CHRISTOPHE;ROMMELAERE, HEIDI;AND OTHERS;SIGNING DATES FROM 20100902 TO 20100909;REEL/FRAME:025054/0583

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION